Molecular mechanisms of enhanced expression of the chemokine interleukin 8 (CXCL8) in cystic fibrosis (CF) airway epithelial cells by Poghosyan, Anna
Poghosyan, Anna (2014) Molecular mechanisms of 
enhanced expression of the chemokine interleukin 8 
(CXCL8) in cystic fibrosis (CF) airway epithelial cells. 
PhD thesis, University of Nottingham. 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/27801/1/Anna%20Poghosyan.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
· Copyright and all moral rights to the version of the paper presented here belong to 
the individual author(s) and/or other copyright owners.
· To the extent reasonable and practicable the material made available in Nottingham 
ePrints has been checked for eligibility before being made available.
· Copies of full items can be used for personal research or study, educational, or not-
for-profit purposes without prior permission or charge provided that the authors, title 
and full bibliographic details are credited, a hyperlink and/or URL is given for the 
original metadata page and the content is not changed in any way.
· Quotations or similar reproductions must be sufficiently acknowledged.
Please see our full end user licence at: 
http://eprints.nottingham.ac.uk/end_user_agreement.pdf 
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
1Molecular mechanisms of enhanced expression
of the chemokine Interleukin 8 (CXCL8) in cystic
fibrosis (CF) airway epithelial cells
Anna Poghosyan, BM (Hons)
Thesis submitted to the University of Nottingham for the
degree of Doctor of Philosophy
November 2014
2ABSTRACT
Cystic fibrosis (CF) is a fatal disease caused by a mutation of the CFTR gene and
severe inflammation of the lungs. The inflammatory process is characterised by
increased production of the potent neutrophil-attracting chemokine interleukin 8
(CXCL8), but the mechanism responsible is poorly understood. We tested the
hypothesis that altered epigenetic regulation is responsible for the basal and
cytokine-induced CXCL8 upregulation in CF airway epithelial cells. We found that
CXCL8 protein levels and mRNA expression were higher in CF as compared to
normal cells both basally and following cytokine stimulation. The difference in the
expression was independent of increased mRNA stability or increased transcription
factor activation and/or expression in CF cells. We found increased basal, but not
cytokine-induced transcription factor binding to the CXCL8 promoter in a chromatin
environment in CF cells in comparison with normal cells, increased histone H3
lysine 4 trimethylation, hypomethylation of CpG sites and increased binding of
BRD3 and BRD4 to the CXCL8 promoter. Disruption of BRD4 association with
chromatin using the selective BET bromodomain inhibitor JQ1 decreased CXCL8
protein release from CF cells to the levels observed in normal cells. Our
observations suggest that epigenetic alterations are responsible for the
upregulation of CXCL8 in CF and could become potential targets in the development
of new therapeutic strategies.
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1 INTRODUCTION
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1.1 Overview of cystic fibrosis
1.1.1 Aetiology
Cystic fibrosis (CF) is a life-shortening inherited disease occurring in people of all
ethnic and racial backgrounds, but mostly widespread among the Caucasians. CF
affects 1 in 3500 newborn babies in the USA (CFF, 2012) and 1 in 2000-3000 live
newborns in the European Union (WHO, 2010). The median predicted age of
survival of patients with CF has risen progressively with improvements in
treatment.
CF is an autosomal recessive disorder caused by mutations in a gene encoding the
1480-residue cystic fibrosis transmembrane conductance regulator (CFTR) protein.
The CFTR gene is located on the long arm of chromosome 7 at q31.2. It contains
approximately 170 000 base pairs and comprises 27 coding exons. The molecular
weight of the CFTR protein is 170 kDa and the transcript is 6.5 kb (Kerem et al.,
1989, NIH, Zielenski J, 1995, Bartling, 2009, Home and Reference, 2013). To date,
1939 mutations of the CFTR gene have been identified (Database, 2001). CFTR is
expressed in epithelial cells of several organs including the skin, lungs, liver,
pancreas, sweat glands, salivary glands, kidney, digestive and reproductive tracts
(Guo et al. 2009, Cozens et al., 1994, Chmiel and Davis, 2003).
The CFTR protein is a phosphorylation-dependent cyclic adenosine monophosphate
(cAMP)-controlled adenosine triphosphate (ATP)-gated chloride (Cl-) channel
located at the apical membrane of secretory epithelial cells and exocrine glands
(Terheggen-Lagro et al., 2005, Sheppard and Welsh, 1999, Xu et al., 2003). CFTR
functions both as an ion channel and a regulator of ion transport by suppressing
16
sodium (Na+) permeability across epithelial apical surfaces and activating non-CFTR
Cl- channels. CFTR also possesses the ability to regulate other membrane proteins
(Kunzelmann, 2003): the best studied and documented is the negative regulation of
the amiloride-sensitive epithelial Na+ channel (ENaC). ENaCs are primarily
expressed in the airways and alveolar epithelium: they are the major regulators of
electrolyte and water exchange in the airways (Catalán et al., 2010, Rubenstein et
al., 2011). Several studies have shown that lack of CFTR in CF airways results in an
increased open probability (Po) and amplified conductance of Na
+ due to
dysfunction or absence of negatively regulated ENaCs and, consequently, increased
levels of basal Na+ absorption (Berdiev et al., 2009, Nagel et al., 2001).
CFTR dysfunction disrupts transepithelial ion transport and results in increased
water reabsorption, reduced airway surface liquid (ASL) volume and impaired ciliary
clearance followed by development of chronic lung disease (Kunzelmann and Mall,
2003, Welsh et al., 1995, Boucher, 2007). There is growing evidence that CFTR is
involved in the regulation of other membrane proteins responsible for several ion
transporters such as non-CFTR Cl-, Cl-, Na+, potassium (K+), ATP and glutathione
channels, and the Cl-/HCO3
- exchanger (Bear et al., 1992, Carroll et al., 2005).
1.1.2 Symptoms and diagnosis
CF is equally diagnosed in males and females (Nick et al., 2010, CFF, 2011). Average
survival depends on the nature and progression of the lung disease, and correlates
with CFTR genotype and mutation type. Patients with mutations causing a milder
lung disease have significantly better survival.
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CFTR deficiency leads to the development of broad-spectrum hallmark CF
symptoms: they include elevated sweat chloride levels, thick and dehydrated
airway mucus production resulting in bronchial obstruction and persistent lung
infection, chronic sinusitis and nasal polyp formation, pancreatic insufficiency, bile
duct and intestinal obstruction, and urogenital abnormalities causing infertility in
men (Carroll et al., 2005). Although, CF has multiple clinical manifestations, lung
disease is the most serious complication resulting in 90% of the morbidity and
mortality in CF patients (CFF, 2011, Bartling, 2009). Despite enormous progress in
the field of CF pathophysiology and treatment since the discovery of CFTR gene in
1989 (Kerem et al., 1989), the median life expectancy remains short estimated at
41.1 in 2012 (CFF, 2012) compared to 31.3 at the beginning of the 21st century
(FitzSimmons, 1998).
Lung disease in CF is best characterised as a perpetuating circle of bronchial
obstruction, permanent bacterial colonisation leading to excessive inflammation
and resulting in airway remodelling followed by respiratory failure and death
(Katkin, 2014, Ratjen and Döring, 2003). Several studies have reported that the
lungs of newborns developing CF are sterile in utero with only minor enlargement
of tracheal submucosal glands within first few months of their life (Meyerholz et al.,
2012, De Rose, 2002). Shortly after birth, the airways and bronchoalveolar (BAL)
fluid of CF newborns display signs of bacterial colonisation characterised by
increased levels of Interleukin 8 (CXCL8), neutrophil elastase (NE) and profound
neutrophil infiltration compared to control subjects (Peterson-Carmichael et al.,
2009, Armstrong et al., 2005). Post-mortem examination of these infants reveals
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abnormal mucus secretion, existing inflammation and increased levels of pro-
inflammatory cytokines (Nixon et al., 2002, Armstrong et al., 1997). These findings
suggest that CFTR-deficient airways are prone to plugging with thick mucus in its
turn leading to bronchial obstruction and chronic bacterial infection characterised
by excessive inflammation eventually resulting in airway remodelling, scarring, and
fibrosis crowned with respiratory failure and ultimate death.
In 1996, the US Cystic Fibrosis Foundation developed criteria for the diagnosis of CF
(Farrell et al., 2008) that have been revised later on (Dequeker et al., 2008, Ooi et
al., 2012). Currently, a diagnosis of CF is suggested based on a presence of at least
two major clinical symptoms such as:
x an abnormal sweat test with Cl- concentration over 60mM/L with borderline
levels of 30-59 mM/L (CFTR.INFO, 2014),
x family history accompanied by genetic confirmation of the existence of one or
more characteristic mutations,
x at least, two distinctive clinical symptoms such as chronic sinopulmonary
disease, gastrointestinal and nutritional abnormalities, salt loss syndromes and/or
genital abnormalities,
x basic and ancillary testing including exocrine pancreatic function tests and
imaging, respiratory tract culture for CF-associated pathogens (especially P.
aeruginosa), genital evaluation in males, pulmonary function testing,
bronchoalveolar lavage, high-resolution chest CT, nasal potential difference (NPD)
testing and exclusionary testing for ciliary dyskinesia and immune deficiency
confirming CF diagnosis.
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Despite the existence of several diagnostic tests, a precise and reliable CF diagnostic
method still does not exist. 2-10% of all CF diagnoses are atypical cases not
detectable by the current gold standard CF diagnostic techniques such as
quantitative pilocarpine iontophoresis and NPD test (Mishra et al., 2005, Wang and
Freedman, 2002).
1.1.3 Therapy
The Cystic Fibrosis Foundation (CFF) guidelines suggest aggressive treatment of
pulmonary exacerbations (defined as a progressive decline of lung function with
episodes of acute deterioration of respiratory symptoms) with intravenous
antibiotics aiming to control severe inflammation in the lungs, to improve
pulmonary outcomes and extend life expectancy (Flume et al., 2009, Conese et al.,
2009).
Once a pulmonary exacerbation is diagnosed, current treatment includes
antibacterial drugs against P. aeruginosa activity, other anti-inflammatory
medicines such as corticosteroids and non-steroid anti-inflammatory drugs
(Narasimhan and Cohen, 2011, Hoiby, 2011), airway clearance techniques,
improved nutrition (Milla, 2007) and relief of various symptoms (Donaldson et al.,
2006). Although aggressive approaches using continuous courses of high-dose
antibiotics every three months are designed to avoid permanent pulmonary
damage, this regimen can lead to the development of drug resistance.
Furthermore, while antibiotics can improve lung function and delay tissue
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remodelling, developing resistance restricts the long-term use of these medicines
(Konstan and Davis, 2002, CFF, 2009).
Double lung or heart-lung transplantation is considered as a treatment option for
patients with progressive and/or end-stage lung disease. Despite the fact that
modern techniques have lowered post-transplant mortality levels to 5%, infection
and graft rejection still remain major problems in patients undergoing lung
transplantation (Chan et al., 2006, Hirche, 2014). An ultimate cure for CF would be a
restoration of CFTR function via transfecting cells with the wild type CFTR gene.
Although some progress has been achieved in the field of gene therapy, it is still in
its developmental stage and is not widely used in CF patients (Conese et al., 2009,
Mallory, 1996).
Recently, development of potentiator molecules restoring CFTR protein function
has been acknowledged to successfully improve the outcomes of lung exacerbation
in patients with CF. Several clinical studies in patients 6 years and older with CF
have reported, that Ivacaftor (VX-770), a newly developed compound, possesses
the ability to improve CFTRs channel function and consequently improve Cl-
transport (Van Goor et al., 2009) as well as to potentiate the open-channel
probability of the CFTR protein (Ramsey et al., 2011).
To date, it is the only known effective medication, and yet the safety and long-term
effects of the drug are to be evaluated in larger scale clinical trials, phase III
completed studies have reported successful use of this molecule associated with
significantly improved pulmonary lung function (FEV1), decline in the frequency of
exacerbations, decrease in sweat chloride levels (Flume et al., 2012) as well as
21
improved weight and walking distance in patients with CF who have G551D-CFTR
mutation (Harrison et al., 2013, Condren and Bradshaw, 2013, Bobadilla et al.,
2002). It would seem likely that other drugs targeting specific CF genotypes will be
developed in the future.
1.2 Inflammation in cystic fibrosis
1.2.1 CFTR deficiency and lung pathology
Several hypotheses have been developed to associate the loss of CFTR with changes
in CF airways structure, physiology and increased susceptibility to bacterial
infection.
One, proposed by Smith in 1996 and confirmed by Zabner in 1998, is a salt-
defensins (high salt) hypothesis. The core statement of this theory is that CFTR
protein is considered to function mostly as an anion channel: lack or absence of
functional CFTR results in disproportionate accumulation of Na+  ?A? ? ? ? ŵD EĂů Z
and Cl- ions in airway surface liquid (ASL) as a result of altered Cl- conductance
(Smith et al., 1996, Zabner et al., 1998). These changes consequently alter
functioning of innate defensive mechanisms inactivating salt-sensitive antibacterial
ƉĞƉƚŝĚĞƐ ĂŶĚ ɴ ?ĚĞĨĞŶƐŝŶƐ  ? ĂŶĚ  ? ? dŚĞ ĂĐƚŝǀŝƚǇ ŽĨ ƚŚĞƐĞ ƐĂůƚ ?ƐĞŶƐŝƚŝǀĞ ƉƌŽƚĞŝŶƐ ŝƐ
significantly reduced in the ASL of CF patients due to ion disbalance (Smith et al.,
1996) allowing increased bacterial colonisation on the airway surfaces of CF
patients (De Rose, 2002)( Figure 1-1).
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Figure 1-1. The high salt/defensins hypothesis. In healthy lungs, ASL has low salt levels maintained by a
combination of surface tension and impermeant anions. In CF lungs, salt is poorly absorbed resulting in
extremely salty ASL. The most important features of this model are impaired CFTR Cl

conductance and
development of hypertonic salt absorption due to a thin surface layer and residual water trapping. No any
specific role for the inhibition of ENaCs by CFTR is observed (Wine, 1999).
This hypothesis was challenged by Matsui who suggested that changes in the CF
lungs are due to CF airway epithelium absorbing isotonic fluid at accelerated rates
compared to control cell lines rather than a result of differences in Na+ and Cl- levels
and/or altered osmolality (Matsui et al., 1998). These findings were confirmed by
another research group that highlighted the role of CFTR as a regulator of other
channels, namely ENaCs. Loss of CFTR, negatively regulating ENaCs, results in an
increased Na+ absorption, excessive Cl- flow via shunt pathways and transcellular
water absorption leading to a reduction in ASL volume. These changes result in
further impairment of mucociliary clearance and development of thick and dry
mucus promoting airway infection by CF-associated pathogens (De Rose, 2002,
O'Sullivan and Freedman, 2009, Matsui et al., 1998) (Figure 1-2).
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Figure 1-2. The low volume hypothesis. ASL of healthy subjects contains salt levels almost equal to plasma. In
CF lungs, lack of ENaCs inhibition due to impaired CFTR function leads to abnormally elevated isotonic fluid
absorption depleting ASL and resulting in reduced mucociliary clearance. The main characteristics of this model
are Cl

channel shunt pathway(s) and inhibition of ENaC via CFTR (Wine, 1999).
Another hypothesis, linking CFTR deficiency and amplified bacterial susceptibility in
CF, is a cell-receptor theory suggesting that acidification (Poschet et al., 2001) or
alkalisation (Imundo et al., 1995) of organelles is responsible for increased
susceptibility to P. aeruginosa via amplification of asialoglycolipid (aGM1) molecules
on the cell surface serving as receptors for bacteria (Poschet et al., 2001, Imundo et
al., 1995). An alternative hypothesis considers the CFTR as a receptor for P.
aeruginosa indicating that whilst accurately functioning CFTR assimilates and
destroys the bacteria, the mutated gene is not able to bind the pathogen allowing
growth and multiplication of the latter in the lumen of CF airways (Pier et al., 1996).
However, although all the above mentioned hypotheses are debatable, it is
inarguable, that lung disease in CF is characterised by progressive and
uncontrollable inflammatory response to bacterial and other stimuli accompanied
by neutrophil influx and pro-inflammatory cytokines release (Ratjen and Döring,
2003).
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1.2.2 Bacterial presence in the lungs
Several studies have shown that soon after birth, CF patients become infected with
bacteria and develop severe lung inflammation. A variety of microorganisms such
as Staphylococcus aureus (S.aureus), Haemophilus influenzae (H.influenza),
Pseudomonas aeruginosa (P.aeruginosa) and Burkholderia cepacia complex (BCC)
can colonise the endobronchial lumen of patients with CF (Harrison, 2007, Lyczak et
al., 2002, Coutinho et al., 2011). CF patients are characterised by S. aureus and H.
influenzae early in life followed by replacement with P.aeruginosa in adolescence or
adulthood. After initial colonisation with non-mucoid strains, untreated patients
become chronically infected with alginate-coated mucoid strains of P.aeruginosa
(Callaghan and Mcclean, 2011, Delhaes et al., 2012, Bragonzi et al., 2005).
Transformation into this type as well as impaired mucociliary bacterial clearance
alongside with secreted toxins makes the eradication of P.aeruginosa difficult. This
pathogen causes long-term impairment of lung function via a release of numerous
tissue-damaging mediators such as proteases, neutrophil elastase (NE), and other
agents resulting in a decline in lung function and a worse prognosis (Nichols et al.,
2008). Though the exact mechanisms of increased susceptibility to P.aeruginosa in
CF are unclear, there is increasing evidence that altered CFTR function, increased
number of asialylated pseudomonal receptors on the cell surface and compromised
mucociliary clearance may be involved (Lyczak et al., 2002, Starner and McCray,
2005).
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The epidemiology of pulmonary infection has changed during the past few years
and now encompasses newly emerging pathogens such as Stenotrophomonas
maltophilia, Achromobacter xylosoxidans, Aspergillus spp, Klebsiella spp and non-
tuberculous mycobacteria. The identification of new pathogens and increased
complexity of the bacterial environment changing the manifestation and course of
CF can be in part explained by advances in medical care, continuous research, and
improved management (Lambiase et al., 2006).
1.3 Inflammatory response
1.3.1 Overview of an inflammatory process
Inflammation is a non-specific immune response developing in reply to injury
(Ferrero-Miliani et al., 2007). This protective process is normally initiated by cells
such as macrophages, dendritic cells, histiocytes, Kupffer cells and mastocytes.
These cells present receptors named pattern recognition receptors (PRRs) on their
surfaces that recognise particles shared by pathogens but different from the host
molecules called pathogen-associated molecular patterns (PAMPs). Upon
activation, cells release inflammatory mediators altering blood vessel permeability
and allowing leukocytes (mostly neutrophils) migration along a chemotactic
gradient. The inflammation is potentiated by cell-derived mediators and activated
biochemical cascade systems (Cotran et al., 1998, Abdel-Azim, 2011, Ricciotti and
FitzGerald, 2011). Pro-inflammatory mediators such as lysosomal enzymes,
ŚŝƐƚĂŵŝŶĞ ? ŝŶƚĞƌĨĞƌŽŶ  ?/&E Z ?ɶ ? ŝŶƚĞƌůĞƵŬŝŶ  ?  ?y> ? Z ? ůĞƵŬŽƚƌŝĞŶĞ  ? ? ŶŝƚƌŝĐ ŽǆŝĚĞ ?
ƉƌŽƐƚĂŐůĂŶĚŝŶƐ ?ƚƵŵŽƌŶĞĐƌŽƐŝƐĨĂĐƚŽƌ ?dE& Z ?ɲĂŶĚy> ?ĂƌĞƌĞƐƉŽŶƐŝďůĞĨŽƌĐůŝŶŝĐĂů
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symptoms and pathophysiological changes. Chemokines such as CXCL8 are
responsible for activation, recruitment and chemotaxis of neutrophils, their
migration across the epithelium and further production of cytokines (Eming et al.,
2007, Rottner et al., 2009).
In healthy subjects, the inflammatory process is self-limiting due to the short half-
life of released mediators quickly degrading in the inflammatory focus. Once the
stimulus has been removed, the inflammation resolves (Cotran et al., 1998,
Soehnlein and Lindbom, 2010) through several mechanisms including production
and release of anti-inflammatory cytokines such as transforming growth factor
(TGF) ß (Ashcroft, 1999, Soehnlein and Lindbom, 2010), CXCL10 (Sato et al., 1999,
Asadullah et al., 2003, Ouyang et al., 2011) and anti-inflammatory lipoxins (Serhan,
2008, Soehnlein and Lindbom, 2010). Downregulation of pro-inflammatory
mediators such as leukotrienes and upregulation of anti-inflammatory molecules
including CXCL1 receptor agonist or soluble tumour necrosis factor receptor (TNFR)
(Eming et al., 2007) along with apoptosis of pro-inflammatory cells (Greenhalgh,
1998, Aggarwal et al., 2014) also contribute to resolution. Desensitisation and
downregulation of receptors and cleavage of chemokines via matrix
metalloproteinases (MMPs) 8 and 9 (McQuibban et al., 2000) are other mechanisms
contributing to the resolution of inflammation (Figure 1-3).
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Figure 1-3. Inflammation in non-CF airways. In healthy subjects bacterial invasion results in activation of
protective immunological mechanisms in the airways: macrophages, neutrophils and other competent cells
migrate to the inflammatory focus and release pro-inflammatory mediators. This is followed by active gene
transcription and increased expression of anti-inflammatory and decreased production of pro-inflammatory
cytokines with further resolution of the process through cough and mucociliary clearance (adapted from
http://www.cfgenetherapy.org.uk/cysticfibrosis/causes.html).
1.3.2 Inflammatory chemokines
Chemokines (chemotactic cytokines) are a family of small (8-15 kDa) proteins
sharing common structural and functional motifs which traffic leukocytes to areas
of injury. Chemokines are divided into four subfamilies: CXC, CC, CX3C and XC based
on the number and position of four conserved cysteine residues in the N-terminal
end of the protein (Zlotnik and Yoshie, 2000, Russo et al., 2014). To date, around 50
chemokines and 18 chemokine receptors have been identified (Steinke and Borish,
2006, Colobran et al., 2007, Balkwill, 2004).
The majority of chemokines perform their functions via binding of their N-terminal
region (Deshmane et al., 2009) to G-protein coupled receptors present on different
cells including leukocytes and endothelial cells (Murphy, 1994, Mélik-Parsadaniantz
and Rostène, 2008). This reaction initiates various intracellular processes activating
different signalling pathways and corresponding physiological effects. An additional
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complexity is achieved as cells express receptors for several chemokines and are a
target for several mediators with overlapping effects (Murdoch and Finn, 2000,
Viola and Luster, 2008).
Chemokines play a pivotal role in the immune response due to their ability to
sample antigen and recruit/direct leukocytes to the site of injury or infection by
trans-endothelial migration (Van Coillie et al., 1999, Zlotnik and Yoshie, 2000,
Speyer and Ward, 2011). Chemokines also play a role in host immune responses,
homeostasis, T cell development, angiogenesis, wound healing, and immune
surveillance (Zlotnik and Yoshie, 2000, Steinke and Borish, 2006, Speyer and Ward,
2011).
Chemokines are classified as inducible (inflammatory) or constitutive (homeostatic).
Inducible chemokines are induced by bacterial products, growth factors such as
TGF-ß, pro-inflammatory mediators such as IL-1 and several pathophysiologic
conditions both independently and in cooperation with other stimuli (Brat et al.,
2005). In contrast, constitutive chemokines are expressed in the absence of
infection or damage (Colobran et al., 2007).
1.4 CXCL8 and its role in CF inflammation
1.4.1 Excessive inflammation in CF
Inflammation is the major driver of airway pathology in CF and is characterised by
excessive influx of polymorphonuclear neutrophils (PMNs), macrophages and
monocytes. Lung secretions as well as sputum obtained from patients with CF have
ůĂƌŐĞ ĐŽŶĐĞŶƚƌĂƚŝŽŶƐ ŽĨ dE& ?ɲ ? /> ? ? ? /> ? ? ? y> ? ĂŶĚ ŽƚŚĞƌ ƉƌŽ ?ŝŶĨůĂŵŵĂƚŽƌǇ
29
mediators (Cohen-Cymberknoh et al., 2013, Elizur et al., 2008). BAL fluid and
sputum of CF patients already have higher levels of CXCL8 compared to non-CF
subjects by the age of 6-7 months (Flume and Van Devanter, 2012). Furthermore,
infants with CF have disproportionate expression of pro-inflammatory cytokines
including CXCL8 in response to bacterial overload (Noah et al., 1997, Starner and
McCray, 2005, Heijerman, 2005, Chmiel and Davis, 2003), but also in the absence of
lung infection (Khan et al., 1995a, Verhaeghe et al., 2007a, Cohen and Prince,
2012).
Endogenous activation of CF airways together with excessive bacterial overload and
increased number of aGM1 receptors are thought to be responsible for the
distinctive inflammatory response in CF (DiMango et al., 1998, McClean and
Callaghan, 2009). CF airways are infiltrated with neutrophils that excessively
ƉƌŽĚƵĐĞ ƉƌŽ ?ŝŶŇĂŵŵĂƚŽƌǇ ŵĞĚŝĂƚŽƌƐ ĂŶĚ ƌĞĂĐƚŝǀĞ ŽǆǇŐĞŶ ƐƉĞĐŝĞƐ  ?ZK^ Z ĐĂƵƐŝŶŐ
damage. Decomposition of neutrophils is the major source of the deoxyribonucleic
acid (DNA) that makes the sputum of CF patients viscous and difficult to
expectorate (De Rose, 2002, Livraghi and Randell, 2007). Altered inflammation is
worsened by electrolyte misbalance and dehydration maintaining and amplifying
bronchoconstriction and impairing airway clearance. Collectively these studies
suggest that disproportionate and persistent inflammation is a key component of
the CF lung pathology. Furthermore, there is evidence that it is initiated and
governed by constitutive alterations in the regulation of cytokine production by
airway epithelial cells (De Rose, 2002, Cohen-Cymberknoh et al., 2013).
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Accumulation of mediators and imbalance of pro- and anti-inflammatory cytokines
contribute to further damage (Corvol et al., 2003). Neutrophils are a source of
prostaglandin E2 (PGE2) that has an anti-inflammatory effect through lowering
levels of endothelial adhesion and chemotaxis (Nakanishi and Rosenberg, 2013). CF
lungs are also deficient in IL-10, a major anti-inflammatory cytokine, and nitric oxide
(NO) leading to an activation of pro-inflammatory signalling pathways (Saadane et
al., 2005, Nakanishi and Rosenberg, 2013) resulting in lung injury (Cohen-
Cymberknoh et al., 2013, Serhan, 2008, Sagel et al., 2007, Corvol et al., 2003)
(Figure 1-4).
Figure 1-4. Inflammation in CF airways. In CF lungs, impairment of local defensive mechanisms in conjunction
with ASL pathology results in bacterial overload leading to continuous neutrophil recruitment with excessive
release of pro-inflammatory cytokines and potent chemoattractant CXCL8. Failure of protective mechanisms
including lack of IL-10, local defensins, electrolyte misbalance and compromised mucociliary clearance results in
a development of a vicious circle of inflammation and lung damage (adapted from
http://www.cfgenetherapy.org.uk/cysticfibrosis/causes.html).
1.4.2 CXCL8 and other pathologies
1.4.2.1 CXCL8 and asthma
Several studies have reported increased CXCL8 levels in BAL fluid and sputum
obtained from asthmatic patients implicating the importance of this chemokine in
the pathogenesis of bronchial asthma (Norzila et al., 2000, Yalcin et al., 2012).
IL-8
Antimicrobial substances
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Biopsies of bronchial mucosa obtained from patients with mild and asymptomatic
asthma have demonstrated increased secretion of MCP-1, RANTES, IL-5 resulting in
eosinophils recruitment to the airways and submucosal infiltration with activated
lymphocytes and eosinophils resulting in development of fibrosis and oedema.
These changes lead to an enhanced activation and release of leukotrienes and
eosinophilic proteins further damaging airway epithelium and promoting bronchial
hyper responsiveness. Several studies have demonstrated increased levels of
eosinophils, macrophages and overexpression of pro-inflammatory cytokines such
ĂƐ y> ? ? dE& ?ɲ ? /> ? ? ? /&E ?ɶ ƉƌŽŵŽƚŝŶŐ ůŽĐĂů ŝŶĨůĂŵŵĂƚŝŽŶ  ?ĚĐŽĐŬ ĂŶĚ ĂƌĂŵŽƌŝ ?
2001). Studies using CXCR2-deficient mice have showed increased levels of IgE and
CXCL8 in serum suggesting selective inhibition of IL-4-induced IgE production by
CXCL8 with an establishment of a negative feedback for IgE expression (Mukaida,
2003). Although further research has demonstrated an association between
excessive inflammation in the airways of asthmatic patients and severity of the
disease (Pukelsheim et al., 2010), the exact mechanisms and role of CXCL8 in the
pathogenesis of bronchial asthma are not clear yet.
1.4.2.2 CXCL8 and COPD
COPD is another inflammatory lung disease that has been characterised by an
increased expression of CXCL8: BAL fluid, sputum and plasma of COPD patients
have been reported to have higher levels of CXCL8 and CXCL6 compared to normal
controls (Hacievliyagil et al., 2013, Chan et al., 2010, Sin and Man, 2008, Culpitt et
al., 2003). Greater CXCL8 protein secretion has been linked to an increased mRNA
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expression (de Boer et al., 2000) and associated with higher basal CXCL8 production
from airway epithelial cells of COPD patients (Profita et al., 2003, Schulz et al.,
 ? ? ? ? Z ? KǆŝĚĂƚŝǀĞ ƐƚƌĞƐƐ ĞǆŝƐƚŝŶŐ ŝŶ ƚŚĞ ĂŝƌǁĂǇƐ ƌĞƐƵůƚƐ ŝŶ ĂŶ ĂĐƚŝǀĂƚŝŽŶ ŽĨ E& ?ʃ ?
mediated signalling and synthesis of pro-inflammatory cytokines promoting
neutrophil influx and stimulating transcription of CXCL8 and other chemokines
ŝŶĐůƵĚŝŶŐ /> ? ? ? dE& ?ɲ ? ĂŶĚ DDW ? ? ƉƌŽƚĞĂƐĞ  ?sĂŶ ĞĚĞŶ ĂŶĚ ^ŝŶ ?  ? ? ? ? Z ? ǆĐĞƐƐŝǀĞ
inflammation characterised by increased levels of macrophages, T-lymphocytes,
and neutrophils in the bronchial lumen (Barnes and Cosio, 2006, Barnes, 2013)
promote thickening of a bronchial wall and increased smooth muscle tone,
remodelling of small airways, and destruction of lung parenchyma as result of loss
of elastic structures due to protease/antiprotease imbalance (Roche et al., 2011).
These changes result in a development and establishment of vicious circle: the level
of lung inflammation directly correlates with disease severity (Chan et al., 2010).
1.4.2.3 CXCL8 and IPF
Several in vivo and in vitro studies have reported increased CXCL8 production by
alveolar macrophages and higher levels of this chemokine in serum and BAL fluid of
patients with IPF demonstrating a direct correlation between level of inflammation
and disease severity. The inflammatory stage in IPF is characterised by an increased
influx of monocytes, neutrophils, T-lymphocytes and eosinophils to the lungs
secreting high levels of CXCL8, CCL2 and CCL5 (Razzaque and Taguchi, 2003). BAL
fluid of patients with IPF has been reported to contain enhanced levels of CXCL8
and lower levels of CXCL10 as compared to normal controls. It has been suggested
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that these cytokines regulate angiogenesis in IPF as CXCL8 possesses potent
angiogenic properties as opposed to angiostatic activity of CXCL10 (Schwiebert,
2005). Administration of anti-mouse CXCR2 antibodies to bleomycin-induced IPF
mice has resulted in reduced angiogenesis, but not neutrophil infiltration, whereas
an inhibition of CXCL10 transcription has repressed angiogenesis process, but not
neutrophil migration (Mukaida, 2003). The impaired balance between CXCL8 and
CXCL10 results in an excessive accumulation of matrix proteins, destruction of the
alveolar wall, loss of airway elasticity and development of severe angiogenesis and
decreased pulmonary function that are hallmarks of IPF (Mukaida, 2003,
Schwiebert, 2005).
1.4.2.4 CXCL8 and cancer
Enhanced CXCL8 production by tumour cells has been reported in several animal
models of various cancer types (Li et al., 2005). BAL fluid of patients with bronchial
carcinoma has demonstrated increased levels of neutrophils and CXCL8 and IL-6
correlating with poor outcome (Mukaida, 2003). Existing knowledge suggests an
increased expression of CXCR1 and CXCR2 receptors on cancer cells, endothelial
cells, neutrophils/tumour-associated macrophages (Waugh and Wilson, 2008) and
in in vivo models of breast cancer (Singh et al., 2013, Russo et al., 2014). CXCL8 is
thought to be involved in tumour progression via recruitment and activation of
macrophages producing growth factors, cytokines CXCL1, CXCL2, CXCL5, CXCL6,
CXCL8 and CXCL7 promoting migration of tumour-associated leukocytes and
endothelial cells. Some in vivo studies using animal models of non-small lung and
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gastric cancer have suggested a direct correlation between CXCL8 transcription and
level of neovascularisation in tumour tissues via increased expression of metastasis-
related genes, such as MMPs (Mukaida, 2003). Blocking CXCL8 activity with a
monoclonal antibody in murine cancer models has led to a reduction in tumour
growth (Mian et al., 2003, Qazi et al., 2011). Further research in androgen-
independent prostate cancer and melanoma cells has proposed a direct correlation
between CXCL8 levels and tumorogenicity and metastatic potential in in vivo
models. The ability of CXCL8 to upregulate MMP2 results in increased collagenase
activity and increased tumour cell invasiveness in in vitro models (Schwiebert,
2005). Although some progress has been made, the exact role of CXCL8 in cell
differentiation, neovascularisation, fibrosis and metastasis in cancer still remain
elusive.
1.4.3 CXCL8 structure
CXCL8 is secreted from leukocytes and other granulocytes, T cells, fibroblasts,
airway smooth muscle cells, endothelial and epithelial cells (Russo et al., 2014, Brat
ĞƚĂů ? ? ? ? ? ? Z ?/ƚŝƐŝŶĚƵĐĞĚďǇdE& ?ɲ ?/&E ?ɶ ?ŽƚŚĞƌĐŚĞŵ ŬŝŶĞƐŝŶĐůƵĚŝŶŐ/> ? ? ?ďĂĐƚĞƌŝĂů
flagella and the lipopolysaccharide (LPS) component of the bacterial wall, and
viruses (Hoffmann et al., 2002, Shi et al., 2004, Venza et al., 2009).
CXCL8 acts on two heterotrimeric G protein-coupled surface receptors, CXCR1 and
CXCR2 (Nasser et al., 2009) expressed on the surfaces of leukocytes (mostly
granulocytes) and endothelial cells. CXCL8 receptors share 78% homology, but
differences in the N-terminal domains result in different binding peculiarities (Russo
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et al., 2014). Whereas CXCR1 binds CXCL6 and CXCL8, CXCL1, 2, 3, 5, 6, 7 and 8 have
higher affinity towards CXCR2 (Balkwill, 2004). The classical chemotactic CXCL8
response implicates involvement and activation of pertussis toxin-sensitive Gɲŝ-
proteins (Thelen, 2001, Campbell et al., 2013), while non-classical CXCL8 response
involves stimulation of pertussis-insensitive Gɲ-proteins (Schraufstatter et al., 2001,
Campbell et al., 2013).
1.4.4 CXCL8 functions
CXCL8 has a range of biological functions including promotion of directed
chemotaxis in target cells and their migration to the site of inflammation (Qazi et
al., 2011). The sequence of physiological reactions prerequisite for migration and
phagocytosis includes an increase in intracellular calcium (Ca2+) levels, exocytosis,
release of a variety of lysosomal enzymes from activated neutrophils, and the
respiratory burst (Brat et al., 2005). The latter is vital in allowing phagocytes to
degrade bacteria through the swift release of ROS from immune cells including
neutrophils and monocytes coming into contact with bacterial particles. CXCL8 can
also promote neutrophil adhesion to endothelial cells and their trans-endothelial
migration (Mukaida, 2003, Qazi et al., 2011) as well as neutrophil activation (Qazi et
al., 2011) and histamine liberation from human basophils (Brat et al., 2005).
CXCL8 is also involved in the regulation of ion transport, activation and proliferation
of cells including epithelial cells, phagocytosis, angiogenesis and tumorigenesis
(Rossi and Zlotnik, 2000, Brat et al., 2005). Collectively, all these properties and
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functions indicate that CXCL8 is a key component of the inflammatory response
CXCL8 transcription and regulation.
1.4.5 CXCL8 transcription and regulation
Gene expression is tightly regulated by well-established mechanisms resulting in
the transcription of target genes in response to stimulation by specific signal
transduction pathways that can either activate or silence gene expression (Venters
and Pugh, 2009). The majority of genes are regulated at the transcriptional level by
synchronised binding of transcription factors (TFs) to cis-acting DNA elements in the
promoter region of the relevant gene. Gene expression is mediated via a
coordinated binding of different TFs rather than by sole presence or absence of a
single TF (Hoffmann et al., 2002). CXCL8 expression is also regulated post-
transcriptionally by stabilisation of mRNA transcripts (via the p38 mitogen-activated
protein kinase (MAPK) pathway); stationary mRNA levels are usually comparative to
CXCL8 secretion (Hoffmann et al., 2002, Li et al., 2002, Shi et al., 2004).
Sequencing analysis of the CXCL8 promoter region has shown that the 5-flanking
region encompassing an area from -425 to -70 (Hoffmann et al., 2002, Mukaida,
2003) relative to the transcription start site comprises binding sites for various TFs
ŝŶĐůƵĚŝŶŐ d ?ĞŶŚĂŶĐĞƌ ďŝŶĚŝŶŐ ƉƌŽƚĞŝŶ  ? ?W Zɴ ?ŶƵĐůĞĂƌ ĨĂĐƚŽƌ  ?E& Z ?Ů ?
activator protein (AP)-1, and octamer (Oct)-1 binding proteins (Campbell et al.,
2013, Brat et al., 2005, John et al., 2010)( Figure 1-5).
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Figure 1-5. Schematic representation of the human CXCL8 promoter region. The CXCL8 gene promoter
ĐŽŶƚĂŝŶƐďŝŶĚŝŶŐƐŝƚĞƐĨŽƌ ?Wɴ ?E& ?Ů ?ĂŶĚW ? ?ůŽĐĂƚĞĚŝŶĐůŽƐĞƉƌŽǆŝŵŝƚǇƚŽĞĂĐŚŽƚŚĞƌ ?ZŝĐŚŵŽŶĚ ?  ? ? ? Z ?
^ǇŶĐŚƌŽŶŝƐĞĚ ďŝŶĚŝŶŐ ŽĨ E& ?Ů ? W ? ? ? ĂŶĚ  ?WƘ ŝƐƌĞƋƵŝƌĞĚ ĨŽƌ ƚŚĞ ŝŶƚĞŐƌĂƚĞĚ
effect and ultimate activation of CXCL8 transcription upon induction by
inflammatory stimuli (John et al., 2009, Verhaeghe et al., 2007b, Hoffmann et al.,
2002). Though all three factors are involved in the regulation and transcription of
CXCL8, studies using transient transfections in cancer cell lines have demonstrated
ƚŚĂƚy> ?ĞǆƉƌĞƐƐŝŽŶŝƐE& ?Ů ?ĚƌŝǀĞŶ ?ůƚŚŽƵŐŚĚŝĨĨĞƌĞŶƚŵĞŵďĞƌƐŽĨƚŚĞŮ ?ZĞů
family have different DNA-binding affinity, it is RelA that influences CXCL8 gene
ƚƌĂŶƐĐƌŝƉƚŝŽŶ ?:ŽŚŶĞƚĂů ? ? ? ? ? ? ?ŚĞŶĞƚĂů ? ? ? ? ? ?Z E& ?ʃƚŚĞŶĐĂƵƐĞƐƌĞĐƌƵŝƚŵĞŶƚŽĨ
a large co-activator complex incorporating histone acetyltransferase (HAT) proteins
such as cAMP response element binding protein (CREB) binding protein (CBP) and
p300/CBP (PCAF), transcriptional intermediary factor-2 (TIF-2), p160 family
members and steroid receptor coactivator-1 (SRC-1) (Jenkins et al., 2001, Adcock et
al., 2006). Histone acetylation and/or DNA methylation can also influence CXCL8
transcription (Muselet-Charlier et al., 2007, Bartling and Drumm, 2009).
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1.5 E& ?ʃ
1.5.1.1 E& ?ʃƌŽůĞĂŶĚĨƵŶĐƚŝŽŶƐ
Studies in immortalised cell lines, patient samples and animal models have shown
ƚŚĂƚ ůƵŶŐ ŝŶĨůĂŵŵĂƚŝŽŶ ŝŶ & ŝƐ ĂƐƐŽĐŝĂƚĞĚ ǁŝƚŚ ŝŶĐƌĞĂƐĞĚ E& ?Ů ƐŝŐŶĂůůŝŶŐ ǁŚŝĐŚ
contributes to the excessive CXCL8 expression (Saadane et al., 2005, Knorre et al.,
2002, Joseph et al., 2005).
E& ?Ů ŝƐ ĂŶ ŝŶĚƵĐŝďůĞ ƉŽƚĞŶƚ ƚƌĂŶƐĐƌŝƉƚŝŽŶĂů ĂĐƚŝǀĂƚŽƌ ŽĨ Ă ǀĂƐƚ ŶƵŵďĞƌ ŽĨ ŐĞŶĞƐ
involved in the regulation of stress-induced, inflammation and immunological
ƌĞƐƉŽŶƐĞƐ ?'ĂůůĂŐŚĞƌĞƚĂů ? ? ? ? ? ? Z ?E& ?ŮŝƐĂĐƚŝǀĂƚĞĚďǇ>W^ ?ŝŶĨůĂŵŵĂƚŽƌǇĐǇƚŽŬŝŶĞƐ
ŝŶĐůƵĚŝŶŐdE& ?ɲĂŶĚ/> ? ?Ƙ ?ŐƌŽǁƚŚĨĂĐƚŽƌƐ ? ůǇŵƉŚŽŬŝŶĞƐ ?ŽǆŝĚĂŶƚ ?ĨƌĞĞƌĂĚŝĐĂůƐ ?Žƌ
T-cell activation, viral infections, inhaled particles and UV radiation (Pomerantz and
ĂůƚŝŵŽƌĞ ? ? ? ? ? Z ?E& ?ŮŝƐĐŽŶƐƚŝƚƵƚŝǀĞůǇĞǆƉƌĞƐƐĞĚŝŶ ǀĞƌĂůĐĞůůƐƉůĂǇŝŶŐĂŬĞǇƌŽůĞ
in gene control and regulation (Barnes, 2006, DiMango et al., 1998).
1.5.1.2 E& ?ŮƐƚƌƵĐƚƵƌĞĂŶĚƌĞŐƵůĂƚŝŽŶ
E& ?Ů ŝƐĂŚĞƚĞƌŽĚŝŵĞƌŝĐƉƌŽƚĞŝŶďĞůŽŶŐŝŶŐ ƚŽ ƚŚĞE& ?Ů ?ZĞůƉƌŽƚĞŝŶĨĂŵŝůǇĂŶĚ ŝƐ
ĐŽŵƉŽƐĞĚ ŽĨ ǀĂƌŝŽƵƐ ĐŽŵďŝŶĂƚŝŽŶƐ ŽĨ ŵĞŵďĞƌƐ ŽĨ ƚŚĞ ZĞů ĨĂŵŝůǇ ? dŚĞ E& ?Ů ?ZĞů
family is characterised by the presence of the Rel homology domain (RHD)
responsible for the DNA binding, nuclear localisation, and protein dimerisation and
a 300-amino acid N-terminal region (Hoesel and Schmid, 2013, Huxford and Ghosh,
2009). The N-terminal region encompasses the DNA-binding domain, whilst the C-
terminal contains the dimerisation domain of the RHD and nuclear localization
ƐŝŐŶĂů  ?E>^ Z ƌĞƐƉŽŶƐŝďůĞ ĨŽƌ ƚŚĞ ƚƌĂŶƐůŽĐĂƚŝŽŶ ŽĨ ĂĐƚŝǀĞ E& ?Ů ĐŽŵƉůĞǆĞƐ ƚŽ ƚŚĞ
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nucleus. These proteins are responsible for the regulation of cytokines and other
modulators of the host immune response (Hoesel and Schmid, 2013, Hayden et al.,
2006).
dŚĞŵĂŵŵĂůŝĂŶE& ?ŮĨĂŵŝůǇĐŽŶƐŝƐƚƐŽĨƉ ? ? ?ZĞů Z ?ZĞů ?Đ ?ZĞů ?Ɖ ? ? ?Ɖ ? ? ? ?E& ?ʃ ? Z
ĂŶĚƉ ? ? ?Ɖ ? ? ? ?E& ?ʃ ? ZƉƌŽƚĞŝŶƐĂŶĚĐĂŶďĞĚŝǀŝĚĞĚŝŶƚŽƚǁŽŐƌŽƵƉƐ ?W ? ? ?ZĞůĂŶĚ
c-Rel contain powerful transactivation domains (TDs) and are rich in serine, acidic
and hydrophobic amino acids necessary for transactivation activity. The second
group comprising p50 and p52 proteins do not possess TDs, and, thus, cannot
function as independent transcriptional catalysts (Heissmeyer et al., 2001, Hoesel
ĂŶĚ ^ĐŚŵŝĚ ?  ? ? ? ? Z ? E& ?Ů ŝƐ ĐŽŵƉŽƐĞĚ ŽĨ ŚŽŵŽ ? ĂŶĚ ŚĞƚĞƌŽĚŝŵĞƌƐ ŽĨ ƚŚĞ ĨŝǀĞ
members which possess different DNA binding characteristics (Gilmore, 2006).
dŚĞĂĐƚŝǀĞĨŽƌŵŽĨŚƵŵĂŶE& ?ŮƌĞƉƌĞƐĞŶƚƐĂĚŝŵĞƌĐŽŵƉŽƐĞĚŽĨƚǁŽEďŝŶĚŝŶŐ
ƐƵďƵŶŝƚƐ PĂ ? ? ?ŬĂƐƵďƵŶŝƚ ?ŝŶŝƚŝĂůůǇŬŶŽǁŶĂƐƉ ? ?ĂŶĚƚŚĞŶƌĞŶĂŵĞĚE& ?Ů ? Z ?ĂŶĚĂ
65-kDa subunit (previously called p65 and now titled RelA) (Hayden et al., 2006,
,ƵǆĨŽƌĚ ĂŶĚ 'ŚŽƐŚ ?  ? ? ? ? Z ? ĐƚŝǀŝƚǇ ŽĨ ƚŚĞ E& ?ʃ ŚĞƚĞƌŽĚŝŵĞƌ ĚĞƉĞŶĚƐ ŽŶ ƚŚĞ
ĐŽŽƌĚŝŶĂƚĞĚ ĨƵŶĐƚŝŽŶŝŶŐ ŽĨ ƚŚĞ ĐŽŵƉŽŶĞŶƚƐ ĂŶĚ ĂŶǇ ŵŝŶŽƌ ĐŚĂŶŐĞƐ ĂůƚĞƌ E& ?ʃ
activity. The p65 subunit is responsible for the expressed transcriptional activation
of genes, while p50 serves as a regulator of trans-activated p65 subunit increasing
ŝƚƐ ?E ?ďŝŶĚŝŶŐĂĨĨŝŶŝƚǇ ?ĂůĚǁŝŶ ? ? ? ? ? ?KĞĐŬŝŶŐŚĂƵƐĂŶĚ'ŚŽƐŚ ? ? ? ? ? Z ?dŚĞE& ?Ů
dimer binds to DNA sequences of the consensus S'-GGGPuNNPyPyCC-3'(S) via p65
interacting directly with the basal transcription apparatus (Schmitz and Baeuerle,
1991, Ruben et al., 1992). Whilst overexpression of p65 leads to a constitutive
activation, excessive expression of p50 results in the production of a constitutive
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DNA-binding protein with no or low trans-activating potential (Nakamura et al.,
2002, Guan et al., 2005).
NF-dB exists in 2 forms: one in the cytoplasm of non-stimulated cells which requires
dissociation from mediators for its activation, and another in the nucleus, which
ĚŽĞƐ ŶŽƚ ŶĞĞĚ ĂŶǇ ĨĂĐƚŽƌƐ ĨŽƌ ŝƚƐ E ďŝŶĚŝŶŐ ĂĐƚŝǀŝƚǇ ? /Ŷ ŝŶƚĂĐƚ ĐĞůůƐ ? E& ?Ů ŝƐ
ƌĞƚĂŝŶĞĚŝŶƚŚĞĐǇƚŽƉůĂƐŵŝŶĂĐŽŵƉůĞǆǁŝƚŚŝŶŚŝďŝƚŽƌǇĂŶŬǇƌŝŶƌĞƉĞĂƚ ?ĐŽŶƚĂŝŶŝŶŐ/Ů
proteins (Grimm and Baeuerle, 1993, Gilmore, 2006). Although this family has
ƐĞǀĞƌĂů ŵĞŵďĞƌƐ  ?/Ůɲ ? /ŮƘ ? /Ůɶ ? /Ůɸ ? /Ůɺ ? Đů ?  ? ĂŶĚ ƚŚĞ ƌŽƐŽƉŚŝůĂ ĂĐƚƵƐ
ƉƌŽƚĞŝŶ Z ? ŵŽƐƚ ŵĂŵŵĂůŝĂŶ ĐĞůůƐ ĐŽŶƚĂŝŶ /Ůɲ ĂŶĚ /ŮƘ ƉƌŽƚĞŝŶƐ  ?ƌĞŶǌĂŶĂ ?
Seisdedos et al., 1997, Bergqvist et al., 2008). These proteins vary in their affinity
ĨŽƌ ƐƉĞĐŝĨŝĐ ZĞů ?E& ?Ů ĐŽŵƉůĞǆĞƐ ĂŶĚ ƌĞŐƵůĂƚŽƌǇ ŵĞĐŚĂŶŝƐŵƐ ĂŶĚ ŚĂǀĞ ƚŝƐƐƵĞ ?
specific distribution (Baldwin, 1996).
dŚĞŵĂŝŶƌŽůĞŽĨƚŚĞ/ŮĨĂŵŝůǇŵĞŵďĞƌƐŝƐƚŽƉƌĞǀĞŶƚƚŚĞŶƵĐůĞĂƌƚƌĂŶƐůŽĐĂƚŝŽŶŽĨ
E& ?Ů ǀŝĂ ŵƵůƚŝƉůĞ ĐŽŶƚĂĐƚƐ ǁŝƚŚ ƚŚĞ E& ?Ů ŚĞƚĞƌŽĚŝŵĞƌ ? ĂŶĚ ? ƚŚĞƌĞďǇ ?
ĚŽǁŶƌĞŐƵůĂƚŝŶŐŮ ?ĚĞƉĞŶĚĞŶƚŐĞŶĞĞǆƉƌĞƐƐŝŽŶŝŶƚŚĞŶƵĐůĞƵƐ ?'ŝůŵŽƌĞ ? ? ? ? ? Z ?dŚĞ
ďĞƐƚƐƚƵĚŝĞĚE& ?Ů ?/ŮŝŶƚĞƌĂĐƚŝŽŶŝƐĂƐƐŽĐŝĂƚŝŽŶŽĨE& ?ŮƉ ? ? ?Ɖ ? ?ĚŝŵĞƌǁŝƚŚ/Ůɲ
ŝŶŚŝďŝƚŽƌǇƉƌŽƚĞŝŶ ?/ŶƵŶƐƚŝŵƵůĂƚĞĚĐĞůůƐ ?ƚŚĞE& ?ŮĚŝŵĞƌŝƐƐƚŽƌĞĚŝŶƚŚĞĐǇƚŽƐŽůǀŝĂ
ŶŽŶ ?ĐŽǀĂůĞŶƚ ŝŶƚĞƌĂĐƚŝŽŶƐ ǁŝƚŚ /Ůɲ  ?ůĂĞĐŬĞ Ğƚ Ăů ? ?  ? ? ? ? Z ? hƉŽŶ ƐƚŝŵƵůĂƚŝŽŶ ? /Ů
ƉƌŽƚĞŝŶƐ ? ĂƐƐŽĐŝĂƚĞĚ ǁŝƚŚ E& ?Ů ? ƵŶĚĞƌŐŽ ƚĂƌŐĞƚĞĚ ƉŚŽƐƉŚŽƌǇůĂƚŝŽŶ ĂŶĚ
ƵďŝƋƵŝƚŝŶĂƚŝŽŶ ? dŚĞ E& ?Ů ?/Ů ĐŽŵƉůĞǆ ĚŝƐĂƐƐŽĐŝĂƚĞƐ ƌĞůĞĂƐŝŶŐ E& ?Ů ĂƐ Ă
homodimer exposing its nuclear localisation sequence and allowing nuclear
ƚƌĂŶƐůŽĐĂƚŝŽŶ ŽĨ E& ?Ů  ?&ĞƌƌĞŝƌŽ ĂŶĚ <ŽŵŝǀĞƐ ?  ? ? ? ? Z ? dŚĞ ĐŽŵƉŽŶĞŶƚƐ ŽĨ ƚŚĞ E& ?
Ů ?/ŮɲĐŽŵƉůĞǆĞĂƐŝůǇĚŝƐƐŽĐŝĂƚĞĂŶĚƌĞ ?ĂƐƐŽĐŝĂƚĞ ?ƐŝŐŶŝĨǇŝŶŐƚŚĂƚŝŶŚŝďŝƚŝŽŶďǇ/Ů
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inhibitory protein is reversible (Hoffmann and Baltimore, 2006, Trask, 2012). Thus,
ƚŚĞ E& ?Ů ?/Ůɲ ĐŽŵƉůĞǆ ĐŽŶƚŝŶƵŽƵƐůǇ ƐŚƵƚƚůĞƐ ďĞƚǁĞĞŶ ƚŚĞ ŶƵĐůĞƵƐ ĂŶĚ ƚŚĞ
cytoplasm, but due to prevalence of the nuclear export over the import rate, the
complex mainly remains in the cytoplasm (Hoffmann and Baltimore, 2006).
1.5.1.3 E& ?ŮĂĐƚŝǀĂƚŝŽŶĂŶĚƚĂƌŐĞƚŐĞŶĞƌĞŐƵůĂƚŝŽŶ
KŶĐĞ ŝŶ ƚŚĞ ŶƵĐůĞƵƐ ? ƚŚĞ Ɖ ? ? ƐƵďƵŶŝƚ ďŝŶĚƐ ƚŽ ƚŚĞ Ů ƐŝƚĞƐ ŝŶ ƚŚĞ ƚĂƌŐĞƚ ŐĞŶĞ
promoter either independently or in a complex with other (Moreno et al., 2010,
&ĞƌƌĞŝƌŽĂŶĚ<ŽŵŝǀĞƐ ?  ? ? ? ? Z ?E& ?Ů ŝŶŝƚŝĂƚĞƐƚĂƌŐĞƚŐĞŶ ƚƌĂŶƐĐƌŝƉƚŝŽŶƚŚƌŽƵŐŚƚŚĞ
ĂĐƚŝǀĂƚŝŽŶ ŽĨ Ă ŚŝŐŚ ŵŽůĞĐƵůĂƌ ǁĞŝŐŚƚ ĐŽŵƉůĞǆ ĐŽŶƚĂŝŶŝŶŐ Ă ƐĞƌŝŶĞ ?ƐƉĞĐŝĨŝĐ /Ů
ŬŝŶĂƐĞ ?/<< Z ?dŚĞƌĞĂƌĞƚŚƌĞĞŬŶŽǁŶƐƵďƵŶŝƚƐŽĨ/<< ?/<<ɲ ?/<<ƘĂŶĚ/<<ɶ ?/<<ɲĂŶĚ
/<<Ƙ ĂƌĞ ĂƐƐŽĐŝĂƚĞĚ ĐĂƚĂůǇƚŝĐ ŬŝŶĂƐĞ ƐƵďƵŶŝƚƐ ĂŶĚ /<<ɶ  ?ĂŬĂ EDK Z ŝƐ Ă ƉƌŝŶĐŝƉĂů
ƐƵďƵŶŝƚ ŝĚĞŶƚŝĨǇŝŶŐ ĂŶĚ ŐŽǀĞƌŶŝŶŐ ƵƉƐƚƌĞĂŵ ƐŝŐŶĂůƐ ? ůĂƐƐŝĐĂů Žƌ ĐĂŶŽŶŝĐĂů E& ?Ů
pathway includes activation of the IKK complex via phosphorylation of two specific
ƐĞƌŝŶĞƐŶĞĂƌ ƚŚĞE ?ƚĞƌŵŝŶƵƐŽĨ /ŮɲďǇ /<<ƘƚŚĂƚ ƌĞƐƵůƚƐ ŝŶ ƚŚĞƵďŝƋƵŝƚŝŶĂƚŝŽŶĂŶĚ
degradation of IkBa by the 26S proteasome. During the non-canonical (alternative)
pathway, activation of the p100/RelB complex takes place via phosphorylation of
ƚŚĞ ?ƚĞƌŵŝŶĂůƌĞŐŝŽŶŽĨƉ ? ? ?ďǇĂŶ/<<ɲŚŽŵŽĚŝŵĞƌƚŚĂƚĐŽŶƐĞƋƵĞŶƚůǇůĞĂĚƐƚŽƚŚĞ
ƵďŝƋƵŝƚŝŶĂƚŝŽŶ ĂŶĚ ĚĞŐƌĂĚĂƚŝŽŶ ŽĨ Ɖ ? ? ? /Ů ?ůŝŬĞ  ?ƚĞƌŵŝŶĂů ƐĞƋƵĞŶĐĞƐ ƚŽ ĐƌĞĂƚĞ
Ɖ ? ? ?ZĞů ?/ŶďŽƚŚĐĂƐĞƐ ?ƚŚĞƵŶƌĞǀĞĂůĞĚE& ?ŮĐŽŵƉůĞǆƚƌĂŶƐůŽĐĂƚĞƐƚŽƚŚĞŶƵĐůĞƵƐ
and activates target gene transcription (Figure 1-6). The classical pathway includes
ĂĐƚŝǀĂƚŝŽŶ ĂŶĚ ƌĞŐƵůĂƚŝŽŶ ŽĨ E& ?Ů ?ŝŶĚƵĐĞĚ ƚĂƌŐĞƚ ŐĞŶĞƐ ƚŚƌŽƵŐŚ ƉĞŶĞƚƌĂƚŝŽŶ ŽĨ
ŶĞǁůǇ ?ƐǇŶƚŚĞƐŝƐĞĚ/ŮɲŝŶƚŽĂŶƵĐůĞƵƐ ?ƌĞŵŽǀĂůŽĨE& ?ŮĨƌŽŵEĂŶĚƌĞůŽĐĂƚŝŽŶ
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ŽĨ E& ?Ů ?/Ůɲ ĐŽŵƉůĞǆ ƚŽ ƚŚĞ ĐǇƚŽƉůĂƐŵ ƚŽ ƌĞĐŽǀĞƌ ƚŚĞ ŝŶŝƚŝĂů ĚŽƌŵĂŶƚ ƐƚĂƚƵƐ
(Pomerantz and Baltimore, 2002, O'Dea and Hoffmann, 2010, Gilmore, 2006,
Ferreiro and Komives, 2010).
&ŝŐƵƌĞ  ? ? ? ? ĂŶŽŶŝĐĂů  ?ůĞĨƚ ? ĂŶĚ ŶŽŶ ?ĐĂŶŽŶŝĐĂů  ?ƌŝŐŚƚ ? ƉĂƚŚǁĂǇƐ ĨŽƌ ƚŚĞ ĂĐƚŝǀĂƚŝŽŶ ŽĨ E& ?ʃ  ?WŽŵĞƌĂŶƚǌĂŶĚ
Baltimore, 2002).
,ŽǁĞǀĞƌ ?ƌĞŐƵůĂƚŝŽŶŽĨƚŚĞE& ?ŮƉĂƚŚǁĂǇŝƐĐŽŵƉůĞǆĂŶĚĐĂŶďĞŵŽĚŝĨŝĞĚďǇŽƚŚĞƌ
mechanisms such as DNA methylation and/or histone acetylation, methylation,
phosphorylation, oxidation/reduction, and prolyl isomerisation. Some studies have
shown that ligand binding, its phosphorylation, and integration with regulatory
subunits can considerably affect DNA binding capacity and/or transcriptional
ĂĐƚŝǀŝƚǇŽĨE& ?Ů ?ŵĞĚŝĂƚĞĚŐĞŶĞƐ ?DŽƌĞŶŽĞƚĂů ? ? ? ? ? ? Z ?&ŝŶĂůůǇ ?ƉƌŽƚĞŝŶƐŝŶǀŽůǀĞĚŝŶ
ƚŚĞ E& ?Ů ƐŝŐŶĂůůŝŶŐ ƉĂƚŚǁĂǇ ĂŶĚ ƉƌŽƚĞŝŶ ?ƉƌŽƚĞŝŶ ŝŶƚĞƌĂĐƚŝŽŶƐ ǁŝƚŚ ŶŽŶ ?E& ?Ů
proteins such as p300 (Yu et al., 2004), HDACs (Chen et al., 2001) and TFIIB (Xia et
al., 2004), make the regulation process even more complex.
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1.5.2 Other transcription factors involved in CXCL8 transcription
ůƚŚŽƵŐŚ E& ?Ů ŝƐ Ă ǀŝƚĂů ƌĞŐƵůĂƚŽƌ ŽĨ ŝŶĨůĂŵŵĂƚŽƌǇ ĐǇƚŽŬŝŶĞƐ ĂŶĚ y> ? ŝŶ
ƉĂƌƚŝĐƵůĂƌŝŶĂůůĐĞůůƚǇƉĞƐ ?,ŽĨĨŵĂŶŶĞƚĂů ? ? ? ? ? ? Z ŝƚ ŝƐƵŶůŝŬĞůǇ ?ƚŚĂƚE& ?ŮĂůŽŶĞŝƐ
able to cause excessive CXCL8 transcription in CF. Several studies have suggested,
that CXCL8 is under multifactorial control and synchronised coordination by
 ?WƘ ?ĂŶĚW ? ?ĂůŽŶŐǁŝƚŚE& ?Ů ŝƐƌĞƋƵŝƌĞĚ  ?ůĂƵĞƚ ů ? ?  ? ? ? ? ?,ŽĨĨŵĂŶŶĞƚĂů ? ?
2002, Li et al., 2002).
1.5.2.1 C/EBPß and its role in CXCL8 regulation
C/EBPß or CCAAT/enhancer-binding protein ß is a protein belonging to the C/EBP-
related family of nuclear TFs also called bZIP proteins (Ramji and Foka, 2002, Gene
Entrez, 2012). The most prominent characteristic of this class of proteins is their
ability to bind the CCAAT nucleotide consensus sequence and prompt either
transcriptional activation or repression of target genes (Cloutier et al., 2009). The
 ?WĨĂŵŝůǇĐŽŵƉƌŝƐĞƐƐŝǆƉƌŽƚĞŝŶƐ ?Wɲ ? ?WƘ ? ?Wɶ ? ?Wɷ ? ?Wɸ ?ĂŶĚ
 ?Wɺ ?ůůĐŽŶƚĂŝŶĂĨƵŶĐƚŝŽŶĂůůǇƌĞůĂƚĞĚůĞƵĐŝŶĞǌŝƉƉĞƌĚŝŵĞƌŝǌĂƚŝŽŶĚŽŵĂŝŶ ?> ZĂƚ
the C-terminus in addition to a shared highly conserved basic region (BR) facilitating
ƚŚĞƐĞƋƵĞŶĐĞ ?ƐƉĞĐŝĨŝĐEďŝŶĚŝŶŐ ?dŚĞE ?ƚĞƌŵŝŶƵƐŽĨ ?Wɲ ? ?Wɴ ? ?WɷĂŶĚ
 ?WɸĂůƐŽĞŶĐŽŵƉĂƐƐĞƐƚƌĂŶƐĂĐƚŝǀĂƚŝŽŶĚŽŵĂŝŶƐ ?dƐ ZĂŶĚĂƌĞŐƵůĂƚŽƌǇĚŽŵĂŝŶ
(RD). Members of the C/EBP family can form homo- and heterodimers with each
other and/or with other TFs. The dimerisation is indispensable for C/EBP proteins to
bind to specific DNA palindromic sequence (Johnson, 2005, Cloutier et al., 2009).
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C/EBP proteins have wide tissue distribution and can be found in hepatocytes,
adipocytes, hematopoietic cells, spleen, kidney, brain, and some other organs.
These multifunctional proteins are vital components of numerous cellular processes
including regulation of cellular proliferation, growth and differentiation, liver
regeneration, metabolism and immune reactions. Experiments in mice have shown
that C/EBPß is crucial for the regular functioning of macrophages and their ability to
ĚŝĨĨĞƌĞŶƚŝĂƚĞĂŶĚĞǆĞĐƵƚĞƚŚĞŝƌďŝŽůŽŐŝĐĂůĨƵŶĐƚŝŽŶƐ ?ZƵĨĨĞůůĞƚĂů ? ? ? ? ? ? Z ? ?WɴŚĂƐ
been reported to be involved in the anti-inflammatory response, glial and neuronal
cell functioning, and neurotrophic factor expression (Ramji and Foka, 2002).
dŚĞ ŵĂũŽƌŝƚǇ ŽĨ ƚŚĞ  ?W ĨĂŵŝůǇ ƉƌŽƚĞŝŶƐ ? ĞǆĐĞƉƚ  ?Wɶ ƚŚĂƚ ůĂĐŬƐ Ă ĨƵŶĐƚŝŽŶĂů
TAD, can initiate target gene transcription via activation of TADs through
cooperation with elements of the basal transcriptional machinery. C/EBP proteins
are regulated at multiple levels governed by hormones, mitogens, and cytokines.
,ŝƐƚŽŶĞ ŵŽĚŝĨŝĐĂƚŝŽŶƐ ĂŶĚ ?Žƌ E ŵĞƚŚǇůĂƚŝŽŶ ĐĂŶ ŝŶĨůƵĞŶĐĞ  ?Wɴ ƐŝŐŶĂůůŝŶŐ
including DNA binding, transcriptional activity, protein-protein interactions and
ŝŶƚƌĂĐĞůůƵůĂƌ ůŽĐĂůŝƐĂƚŝŽŶ ? /Ŷ ĂŶ ƵŶƐƚŝŵƵůĂƚĞĚ ĐĞůů ?  ?Wɴ ŝƐ ƌĞƚĂŝŶĞĚ ŝŶ ƚŚĞ
cytoplasm in a repressed condition via dimensional inhibition of TADs by regulatory
domains. Upon activation, phosphorylation of the inhibitory domains results in
termination of the repressive effect and leads to an increase in transcriptional
ĂĐƚŝǀĂƚŝŽŶ ŽĨ  ?Wɴ ĂŶĚ ĞŶŚĂŶĐĞĚ E ďŝŶĚŝŶŐ ĨŽůůŽǁĞĚ ďǇ ĞŝƚŚĞƌ ĂĐƚŝǀĂƚŝŽŶ Žƌ
inhibition of gene activity (Ramji and Foka, 2002).
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C/EBPß is involved in the regulation of immune and inflammatory genes. Its
binding sequences are found in the regulatory regions of a number of pro-
ŝŶĨůĂŵŵĂƚŽƌǇ ĐǇƚŽŬŝŶĞƐƐƵĐŚ ĂƐ /> ? ?Ƙ ? y> ? ? dE& ?ɲĂŶĚ /> ? ?  ?'ĞŶĞ ŶƚƌĞǌ ?  ? ? ? ? Z ?
There is a direct physical association of the bZIP region of C/EBP proteins with the
Ɖ ? ?ŚŽŵŽůŽŐǇĚŽŵĂŝŶŽĨE& ?Ů ?dŚĞĐƌŽƐƐ ?ĐŽƵƉůŝŶŐŽĨƚŚĞƐĞƉƌŽƚĞŝŶƐƌĞƐƵůƚƐ ŝŶĂŶ
interaction between distinct TF families and modulation of target gene expression.
&ƵƌƚŚĞƌŵŽƌĞ ? ĞǆĐĞƐƐ E& ?Ů ŵŝŐŚƚ ƉŚǇƐŝĐĂůůǇ ŝŶƚĞƌĂĐƚ ǁŝƚŚ  ?W ďŽƵŶĚ ƚŽ ŝƚƐ ƐŝƚĞ
and synergistically activate it. Alternatively, it has been suggested that excess C/EBP
ĐŽƵůĚŝŶŚŝďŝƚE& ?ŮďŝŶĚŝŶŐƚŽŝƚƐďŝŶĚŝŶŐƐŝƚĞ ?dŚĞƐĞĚĂƚĂƐƵŐŐĞƐƚƚŚĂƚĂůƚŚŽƵŐŚE& ?
ŮŚĂƐĂĐƌƵĐŝĂůƌŽůĞŝŶy> ?ƌĞŐƵůĂƚŝŽŶ ?ŝƚƐĂĐƚŝǀ ƚǇĐĂŶďĞŵŽĚŝĨŝĞĚďǇ ?W ?WĂǌ ?
Priel et al., 2011).
E& ?Ů ĂŶĚ  ?W ĨĂŵŝůǇ ŵĞŵďĞƌƐ ĂƌĞ ĨƵŶĐƚŝŽŶĂůůǇ ĂŶĚ ƉŚǇƐŝĐĂůůǇ ŝŶƚĞƌůŝŶŬĞĚ  ?WĂǌ ?
Priel et al., 2011). Binding of representatives from both families to cis-DNA
elements in the CXCL8 promoter and subsequent physical protein-protein
interactions regulate CXCL8 gene expression (Wang et al., 2009a, Dooher et al.,
2011). These findings suggest that C/EBP is an important TF for CXCL8 gene
ĞǆƉƌĞƐƐŝŽŶĂŶĚŝƐŝŶƚĞƌůŝŶŬĞĚďŽƚŚĨƵŶĐƚŝŽŶĂůůǇĂŶĚƉŚǇƐŝĐĂůůǇǁŝƚŚE& ?Ů ?
1.5.2.2 AP-1 and its role in CXCL8 regulation
AP-1 or activator protein-1 is another protein involved in CXCL8 transcription. It
belongs to the AP-1 protein family commonly referred to as "immediate-early
genes" swiftly induced in response to extracellular stimuli such as pro-inflammatory
cytokines, growth factors and bacterial and viral infection (Hess et al., 2004b).
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These proteins are responsible for the regulation of the genes accountable for cell
proliferation and differentiation, tumorigenic transformation, apoptosis, pulmonary
defense, and inflammatory and immune responses (Reddy and Mossman, 2002,
Jochum et al., 2001).
AP-1 is a TF composed of proteins belonging to various families, namely Fos (c-Fos,
FosB, Fra1, and Fra2), Jun (c-Jun, JunB, and JunD), Maf (c-Maf, MafB, MafA,
MafG/F/K and Nrl) and activating transcription factor-1 (ATF) (ATF2, LRF1/ATF3, B-
ATF, JDP1, JDP2), which form numerous homo- and heterodimers through their
leucine zipper regions (Hess et al., 2004b, Rajasekaran et al., 2012). AP-1 homo- or
heterodimers generally contain Jun-Jun or Jun-Fos TFs that belong to the basic
region-leucine zipper (bZIP) group. AP-1 members can also form heterodimers with
other related bZIP families of proteins such as ATFs, C/EBPs, Nrf/Mafs, and helix-
loop-helix ZIP proteins including upstream stimulatory factors (USFs) (Chinenov and
Kerppola, 2001, Fujioka et al., 2004). Jun-Fos dimers are more stable with greater
DNA binding affinity than Jun-Jun homodimers (Reddy and Mossman, 2002). They
are involved in the regulation of a range of genes engaged in epithelial injury and
repair, and differentiation (Chinenov and Kerppola, 2001, Zenz et al., 2008).
Regulation of AP-1 is complex and can be influenced by interactions of AP-1
components with other TFs in multifactorial complexes (Shaulian and Karin, 2001,
Khanjani et al., 2012) and via changes in the transcription of genes encoding AP-1
subunits, post-translational processing and turnover of newly synthesized AP-1
subunits (Hess et al., 2004b, Wagner, 2001).Upon stimulation, phosphorylation of
AP-1 occurs via activation of the MAPK family (Hazzalin and Mahadevan, 2002) that,
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in turn, phosphorylates Jun via activation of the Jun N-terminal kinase (JNK) cascade
(Muselet-Charlier et al., 2007). Once activated by the MAPK cascade, JNK proteins
translocate to the nucleus and phosphorylate Jun at serine 63 and 73 within its N-
terminal TAD. Though progress has been made in the field of Jun activation and
regulation, the enzymes responsible for Fos activation have not been identified yet
(Hess et al., 2004a).
AP-1-dependent gene expression is tightly controlled by interaction between
subunits within AP-1 as well as via complex formation between AP-1 and other non-
/W ƉƌŽƚĞŝŶƐ ƐƵĐŚ ĂƐ ŶƵĐůĞĂƌ ĨĂĐƚŽƌ ŽĨ ĂĐƚŝǀĂƚĞĚ d  ?E&d Z ĐĞůůƐ ? E& ?Ů ? ĂŶĚ dd ?
binding protein (TBP) (Chinenov and Kerppola, 2001). Furthermore, post-
translational modifications such as phosphorylation, acetylation and/or methylation
of each component have an important impact on the regulation of AP-1 activity
 ?>ĞĞ Ğƚ Ăů ? ?  ? ? ? ? ? ĂƌŶĞƐ Ğƚ Ăů ? ?  ? ? ? ? Z ? E& ?Ů ĂŶĚW ?  ĐĂŶ ŵƵƚƵĂůůǇ ŚĞŝŐŚƚĞŶ ƚŚĞ
response induced by either of the TFs resulting in a greater inflammatory response
(John et al., 2009, Hoffmann et al., 2002). Due to an overlap in the signalling
ƉĂƚŚǁĂǇƐ  ?<ŚĂůĂĨ Ğƚ Ăů ? ?  ? ? ? ? Z ? ƐǇŶĐŚƌŽŶŝƐĞĚ ďŝŶĚŝŶŐ ŽĨ ďŽƚŚ W ? ? ĂŶĚ E& ?Ů
alongside C/EBP to the CXCL8 promoter suggests contribution of three TFs to the
transcriptional activation of CXCL8 in CF (Mukaida et al., 1990, Adcock and
Caramori, 2001, Muselet-Charlier et al., 2007, Raia et al., 2005). Despite some
progress in the understanding of AP-1 role in the CXCL8 expression, the exact role
of this TF in CF lung inflammation is not clear yet.
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1.6 Epigenetic regulation of gene transcription
1.6.1 Concept of epigenetics and epigenetic modifications
The term "epigenetics" was introduced around 60 years ago, but only recently
chromatin remodelling and inherited changes have been considered influential
factors in the control of gene expression (Holliday, 1987). Epigenetic regulation is
essential for cell diversity generation, and retention of constancy and continuity of
cell expression profiles (Adcock et al., 2006).
Epigenetics is a scientific term used for the inherited changes in gene expression
and activity without alteration in DNA sequence (Adcock et al., 2006, Cheung and
Lau, 2005) closely controlled by DNA methylation, RNA-associated silencing and
chromatin modifications which are often interlinked (Egger et al., 2004, Wilson,
2008, Cheung and Lau, 2005, Urnov and Wolffe, 2001). Abberant alterations in the
activities of any of the components lead to abnormal gene transcripiton resulting in
a development of an "epigenetic disease" (Cheung and Lau, 2005, Egger et al.,
2004). Epigenetic modificaions, apart from DNA methylation and histone tail
modifications, also include transient alterations such as histone acetylation and
phosphorylation (Bird, 2007, Ospelt et al., 2011).
Epigenetic alterations of activity and/or expression of chromatin remodelling
enzymes in cancer and inflammatory airways diseases including CF have been
identified emphasising their importance in the development of these pathologies
(Adcock et al., 2006, Cheung and Lau, 2005). Thereby, better understanding of
epigenetic molecular mechanisms can lead to the development of new drugs to
cure severe age-limiting diseases such as CF.
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1.6.2 Chromatin remodelling
In mammalian cells, genomic DNA is tightly compressed into chromatin with
categorised levels of hierarchy. The basic 7-fold compaction unit of chromatin, a
146-base pair DNA segment firmly wrapped around eight core histone (H) proteins,
two of H2A, H2B, H3 and H4, is called the nucleosome (Cheung and Lau, 2005,
Shilatifard, 2006) (Figure 1-7). Nucleosomal DNA can be further compacted via
association with the linker H1 and other supplementary non-histone proteins
(Cheung and Lau, 2005, Urnov and Wolffe, 2001). Whilst, formerly, histones were
considered as inert and static structural elements, they are now recognised as
essential and dynamic components of the transcriptional machinery (Strahl and
Allis, 2000). Nucleosomes continuously pack and unpack the chromosomal DNA
exposing it from an inaccessible condensed condition to accessible open chromatin
allowing the DNA to be compactly packaged, correctly replicated and organised into
daughter cells (Urnov and Wolffe, 2001).
The N-terminal tails of histone molecules protrude through and beyond the DNA
coil representing accessible targets for post-translational modifications of selective
amino acids (Firestein et al., 2013, Shilatifard, 2006). Lysine (K) residues acetylated
at the tails of histone H3 and histone H4 enable coupling of other co-activators such
as chromatin modifying enzymes and RNA Polymerase (Pol) II (Urnov and Wolffe,
2001, Roth et al., 2001).
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Figure 1-7. The structure of the nucleosome. A 146-base pair DNA segment wrapped around eight core
histones (Firestein et al., 2013).
In a non-dividing cell, chromatin is present in two functional states: transcriptionally
active euchromatin or inactive heterochromatin (Kouzarides, 2007, Cheung and
Lau, 2005). Heterochromatin is a highly packaged condensed form of DNA
remaining unchanged during the interphase, inaccessible to TFs and/or chromatin-
associated proteins. It is essential in the regulation of chromosomal stability and
prevention of mutations and translocations (Talbert and Henikoff, 2006). As
opposed to heterochromatin, euchromatin represents a loosened state occurring
by the end of mitosis. The genomic regions of euchromatin are flexible and contain
transcriptionally active and inactive genes, whilst heterochromatin mostly contains
repetitive sequences and silenced genes (Adcock et al., 2006).
Gene transcription is initiated when the chromatin structure is open allowing RNA
Pol II and basal transcription complexes to interact with DNA and commence
transcription. Activated TFs and chromatin-associated proteins bind to specific DNA
recognition sequences and further recruit large co-activator proteins such as CBP,
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p300, PCAF and other complexes to the site of gene promoter (Urnov and Wolffe,
2001).
1.6.3 Epigenetic modifications
The molecular mechanisms such as DNA methylation and post-translational
modifications of histones such as acetylation, methylation, ubiquitination,
sumoylation, and phosphorylation have been implicated in the epigenetic control of
the genome (Egger et al., 2004). Histone modifications can occur at several sites,
and, thus, can act as signalling bases integrating different pathways to stimulate
nuclear responses resulting in a target gene activation or repression (Cheung et al.,
2000, Bannister and Kouzarides, 2005). Combinations of different epigenetic
alterations serve as epigenetic marks reflecting gene activity and chromatin status
(Kouzarides, 2007) constituting a complex "histone code" (Ospelt et al., 2011).
1.6.3.1 Histone acetylation
Acetylation is a reversible modification of lysine (K) residues within the N-terminal
tail and/or within the folded core of histones (Grunstein, 1997, Kouzarides, 2007).
The positively charged K residues are tightly bound to the negatively charged DNA
shaping a closed chromatin structure impenetrable for TFs. Acetylation reduces the
affinity between DNA and histones via modification of the charge of K residues,
resulting in the decondensation of chromatin and allowing active transcription
(Carrozza et al., 2003, Peterson and Laniel, 2004, Ruthenburg et al., 2007). Histone
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acetylation has been associated with euchromatin (Kouzarides, 2007), and
implicated in metabolism regulation (Guan and Xiong, 2011), DNA recognition and
repair (Celic et al., 2006), proteinprotein interactions and protein stability
(Kouzarides, 2000). The "histone code" suggests that covalent histone modifications
serve as epigenetic markers for gene expression (Strahl and Allis, 2000).
Acetylation is associated with gene activation, whilst lack or absence of acetylation
is linked to a transcriptional repression (Kuo and Allis, 1998, Waterborg, 2002).
Mutation of certain K residues results in an inability of yeast cells to acetylate the
histone H4 tail leading to altered GAL1 gene transcription (Durrin et al., 1991).
Another study has reported that treatment of mammalian cells with a histone
deacetylase (HDAC) inhibitor trichostatin A leads to active transcription of target
genes (Yoshida et al., 1995, Lee et al., 2006). Increased histone acetylation has been
reported in cancer and different inflammatory diseases (Adcock et al., 2006).
Furthermore, it has been recognised to regulate protein-protein interaction and
generate a recognition site for bromodomain (BRD) containing proteins and other
chromatin remodelling enzymes and co-factors (Filippakopoulos et al., 2010).
1.6.3.2 Histone acetyltransferases and deacetylases
Histone acetylation is carried out by a family of "writer" enzymes named histone
acetyltransferases (HATs) that catalyse the transfer of an acetyl group from acetyl-
CoA to the lysine 1-amino group on the N-terminal tails of histones (Carrozza et al.,
2003). HATs are involved in almost all biologically important cellular processes as
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well as DNA repair and replication (Carrozza et al., 2003, Kouzarides, 2000, Yang
and Seto, 2007) (Figure 1-8).
Figure 1-8. Schematic representation of the involvement of reversible lysine acetylation in numerous cellular
processes. The letter A refers to an acetylation and for each process representative proteins are presented
(Yang and Seto, 2007).
HATs are divided into 5 groups based on sequence homology, structural
characteristics and functions. The first group, Gcn5-related N-acetyltransferase
(GNAT) family, includes Gcn5, PCAF, HAT1, Elp3, Hpa2, Hpa3, ATF-2, and Nut1
proteins containing a BRD: they have been reported to acetylate K residues on
histones H2B, H3, and H4 (Carrozza et al., 2003). The second groups, MYST family,
encompasses MOZ, Ybf2 (Sas3), Sas2, and Esa1, MOF, MORF, and HBO1 HATs.
These proteins acetylate K residues on histones H2A, H3, and H4 and play an
important role in transcriptional activation, DNA repair, and gene silencing (Takechi
and Nakayama, 1999, Avvakumov and Cote, 2007). The third group includes
p300/CBP HATs: these enzymes have greater HAT domains compared to GNAT and
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MYST families (Marmorstein, 2001), a BRD and three other cysteine/histidine-rich
domains modulating interactions with other proteins. P300/CBP display no
sequence homology with other HATs and are involved in the transcriptional
activation. These HATs have been reported to equally acetylate all four core
histones (Roth et al., 2001, Wang, 2009). The fourth group is the SRC family or
nuclear receptor co-activators; it includes SRC-1, ACTR (RAC3, AIB1 and TRAM-1),
TIF-2 and SRC-3. These enzymes include general TF HATs and have been reported to
strongly bind histone H4 and be responsible for its modifications. The firth group
comprises all other proteins possessing HAT activity and includes TAFII250, TFIIIC
(p220, p110 and p90), Rtt109 and CLOCK (Carrozza et al., 2003). Several studies
have demonstrated that transcriptional co-activator proteins might also function as
molecular switches regulating gene transcription and possess intrinsic HAT activity
(Spiegelman and Heinrich, 2004, Roth et al., 2001).
The majority of HATs exist as elements of multicomponent complexes recognising
specific modifications of histone tails, directing transcriptional complexes to the
gene promoter and modifying target gene transcription (Carrozza et al., 2003,
Kouzarides, 2007, Adcock et al., 2006). Acetylation of four core histones differs:
whilst H2A and H2B are commonly acetylated at K5 and K12 and K15 respectively,
H3 is acetylated mostly at K9, K14, K18, K23, and K56. Histone H4 is characterised
by modifications at K5, K8, K12, and K16 (Kouzarides, 2007).
Lysine acetylation is a reversible process regulated by epigenetic "erasers" named
histone deacetylases (HDACs). HDACs remove acetyl groups from histone tails and
facilitate chromatin condensation and gene silencing (Carrozza et al., 2003). The
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superfamily of HDACs is divided into 4 groups based on DNA sequence homology,
subcellular localisation, substrates and binding patters as well as regulatory
mechanisms. The first group encompasses HDAC1, HDAC2, HDAC3, and HDAC8
which are located in the nucleus, except membrane-associated HDAC3 that can be
found both in the nucleus and cytoplasm. The second group is clustered in IIA
including HDAC4, HDAC5, HDAC7 and HDAC9, and IIB comprising HDAC6 and
HDAC10. Whilst IIA group HDACs are able to shuttle between the nucleus and
cytoplasm (de Ruijter et al., 2003, Longworth and Laimins, 2006), HDACs belonging
to the IIB group are predominantly located in the cytoplasm. HDAC6 is known to be
involved in important biological processes via forming complexes with other
proteins (Valenzuela-Fernández et al., 2008). The third group consists of
mammalian sirtuins (SIRT1-SIRT7) and Sir2 in the yeast S. cerevisiae, and the fourth
family includes HDAC11 located both in the nucleus and cytoplasm (Yang and Seto,
2007).
HDACs are involved in a variety of signalling pathways and cellular processes such
as signal transduction, cell cycle and the development of a number of human
diseases including cancer and chronic myeloid leukaemia (KEGG, 2014). Studies
performed in animal models have demonstrated that absence or deficiency of
HDAC1 results in an alteration of the transcription of a specific subset of genes
suggesting that HDAC1 might serve as a transcriptional activator (Zupkovitz et al.,
2006). Both HATs and HDACs are responsible for the modification of DNA-binding
proteins (histones and TFs), non-nuclear proteins (tubulin) and nuclear import
factors (Sterner et al., 1979, L'Hernault and Rosenbaum, 1985, Bannister et al.,
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 ? ? ? ? ? <ŽƵǌĂƌŝĚĞƐ ?  ? ? ? ? Z ? W ? ? E& ?ʃ ŝƐ ƚŚŽƵŐŚƚ ƚŽ ďĞ ƌĞŐƵůĂƚĞĚ ǀŝĂ ĂĐĞƚǇůĂƚŝŽŶ ďǇ
PCAF and deacetylation by HDAC3 and HDAC6 (Hasselgren, 2007, Ospelt et al.,
2011).
HDACs are regulated by differentially interacting with other non-histone proteins
and co-repressor molecules that heighten the repressive effect and ensure greater
specificity (de Ruijter et al., 2003). Their effect and functions are controlled by
localisation, protein-protein interactions, and post-translational modifications
(Adcock et al., 2006). Although some progress has been made in the identification
of the acetylation effect on chromatin assembly and the role of HATs and HDACs in
the acetylation process, the exact mechanisms remain unclear.
1.6.3.3 Bromodomains and their role in gene transcription
Recently, the bromodomains and extra-terminal (BET) family of proteins have
gained increasing attention. These proteins are evolutionary well preserved
ƉƌŽƚĞŝŶ ?ŝŶƚĞƌĂĐƚŝŽŶ ŵŽĚƵůĞƐ ĂŶĚ ƚŚĞ ƉƌŝŶĐŝƉĂů ƌĞĂĚĞƌƐ ŽĨ ɸ ?E ?ĂĐĞƚǇů ůǇƐŝŶĞ  ?<ac)
marks (Kouzarides, 2000, Chen et al., 1999, Belkina et al., 2013b). To date, around
61 human BRDs and 40 human BET proteins have been identified (Filippakopoulos
et al., 2010). BRDs are present in numerous chromatin-associated proteins such as
HATs (GCN5, PCAF) (Nagy and Tora, 2007b), ATP-dependent chromatin-remodelling
complexes (BAZ1B) (Trotter and Archer, 2008), helicases (SMARCA) (Filippakopoulos
et al., 2010, Sanchez and Zhou, 2009), methyltransferases (MLL, ASH1L) (Malik and
Bhaumik, 2010), transcriptional co-activators (TRIM/TIF1, TAFs) (Jacobson et al.,
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2000) and mediators (TAF1), nuclear-scaffolding proteins (PB1) and the BET protein
family (Muller et al., 2011b).
The human BET family is a group of dual BRD-containing proteins comprising four
members: BRD2, BRD3, BRD4 and the testis-specific isoform, BRD-T, proteins (Rhee
et al., 1998, Wang et al., 2009b). BRD2, BRD3 and BRD4 are implicated in cell-cycle
control (Dey et al., 2003, Mochizuki et al., 2008, Sinha et al., 2005), cell growth (Dey
et al., 2000, Maruyama et al., 2002, Houzelstein et al., 2002), transcription
elongation (Brès et al., 2008, Yang et al., 2005, Jang et al., 2005), embryogenesis
and neurogenesis (Gyuris et al., 2009). Studies in animal models have reported that
deletion of BRD2 or BRD4 in mice is fatal; BRD4+/ mice develop severe
developmental defects (Houzelstein et al., 2002, Shang et al., 2009). BRD2 acts as a
co-activator or co-repressor of transcription in a promoter- and tissue-specific
manner (Gyuris et al., 2009). Simulatenous dysfunction of BRD3 and BRD4 is
associated with the development of different types of cancer highlighting these
proteins as potential targets for drug development (Filippakopoulos et al., 2012).
Analysis of 30 BRD containing proteins has shown that these proteins recognise a
combination of epigenetic modifications rather than a single acetylated site
(Filippakopoulos et al., 2010). They further recruit chromatin remodelling enzymes
to distinct epigenetic modifications forming an active platform for co-activator
complexes to assure a high level of specificity (Muller et al., 2011b, Kouzarides,
2007).
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Studies in mice have demonstrated BRD2, BRD3 and BRD4 involvement in the
ƚƌĂŶƐĐƌŝƉƚŝŽŶĂů ĐŽŶƚƌŽů ŽĨ y> ? ? dE& ?ɲ ? DW ? ? ĂŶĚŬĞƌĂƚŝŶŽĐǇƚĞ ĐŚĞŵŽĂƚƚƌĂĐƚĂŶƚ
(KC) which is a mouse CXCL8 ortholog (Belkina et al., 2013b). Furthermore, recent
ƐƚƵĚŝĞƐŚĂǀĞƐŚŽǁŶƚŚĂƚ/> ? ?ɴ ?ŝŶĚƵĐĞĚy> ?ĞǆƉƌĞƐƐŝŽŶŝŶĂŝƌǁĂǇĞƉŝƚŚĞůŝĂůĐĞůůƐŝƐ
ŵĞĚŝĂƚĞĚ ǀŝĂ ŝŶĐƌĞĂƐĞĚ ĂƐƐŽĐŝĂƚŝŽŶ ŽĨ Ɖ ? ? E& ?ʃ ĂŶĚ Z ? ǁŝƚŚ ƚŚĞ y> ?
ƉƌŽŵŽƚĞƌ ĂƐ ǁĞůů ĂƐ ŝŶĐƌĞĂƐĞĚĂĐĞƚǇůĂƚŝŽŶ ŽĨ ŚŝƐƚŽŶĞ , ? Ăƚ ƚŚĞ E& ?ʃ ďŝŶĚŝŶŐ ƐŝƚĞ
(Khan et al., 2014). Although the ability of BRD containing proteins and BET proteins
to regulate transcription of pro-inflammatory cytokines has been studied, the exact
role is not fully understood.
1.6.3.4 Histone methylation
Histone methylation occurs via transfer of methyl groups from S-Adenosyl
methionine onto lysine (K) or arginine (R) residues of histones H3 and/or H4
resulting in either gene activation or repression depending on the target amino
acid, extent of methylation and presence/absence of epigenetic modifications in
the proximity (Greer and Shi, 2012). Histone methylation is an important process
for cell mitosis, gene expression and genomic stability, genetic imprinting, cell
maturation and cell lineage development (Sawan and Herceg, 2010). To date,
methylation of approximately 17 K and 7 R residues has been identified (Bannister
and Kouzarides, 2005).
Histone methylation is catalysed by histone methyltransferases (HMTs) covalently
methylating Ks and Rs within histone tails. These enzymes are clustered in two
major groups: K-specific and R-specific. K methylation occurs in mono-, di- or tri-
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methylation form, whereas R methylation is more likely to be in a mono- or di-form.
An additional complexity of R methylation is achieved via symmetrical or
asymmetrical positioning of the methylated residues (Bannister and Kouzarides,
2005). K-specific HMTs can be further divided into SET and non-SET-domain
containing proteins based on the presence or absence of a Suppressor of
variegation-Enhancer of zeste-Trithorax (SET)-domain catalysing the methylation of
the K residues on core histones (Sawan and Herceg, 2010).
Methylation marks are recognised by two families of domains in HMTs: PhD finger
domains and the Royal family which includes chromo, tudor and malignant brain
tumour (MBT) domains (Berger, 2007, Kouzarides, 2007). The domain type
determines HMTs affinity for histones, the ability to recognise the particular
methylation marks and catalyse the reaction with binding co-factors
(Mosammaparast and Shi, 2010). Thus, the PHD finger recognises trimethylated
H3K4 mark, whilst the chromo domain of the Royal family has greater affinity for
methylated H3K9 (H3K9me) (Jenuwein and Allis, 2001, Kouzarides, 2007).
Methylated marks alone or in combination with other epigenetic modifications such
as acetylation create a complex platform functioning as a recognition pattern for
the chromatin remodelling either initiating active transcription or silencing it
(Bhaumik et al., 2007, Arrowsmith et al., 2012).
Active regions of chromatin are associated with distinct histone methylation
modifications. Methylation of histone H3 at the positions of K4, K36 and K79 of the
5' controlling region has been observed in transcriptionally active genes (Bannister
and Kouzarides, 2005, Wang and Zhu, 2008). Similarly, H3K4me3 is a characteristic
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mark of an actively transcribed gene (Pray-Grant et al., 2005). In contrast,
methylation of K9 and K27 on histone H3 and K20 on histone H4 are marks of gene
silencing and heterochromatin formation (Strahl and Allis, 2000, Bannister and
Kouzarides, 2005). Di- or trimethylation of H3K9 and H3K27me3 lead to
transcriptional repression via recruitment of repressive complexes to the target
gene promoter (Kouzarides, 2007, Shilatifard, 2006, Berger, 2007).
Arginine methylation is mostly a positive transcriptional regulator catalysed via
arginine methyltransferases (PRMTs). The most well-studied PRMT is co-activator-
associated PRMT1 (CARM1), that methylates R17 and R26 on histone H3, and
PRMT2 that has affinity for H4R3 (Davie and Dent, 2002, Bhaumik et al., 2007). Both
of these proteins have been associated with active transcription: CARM1 can act in
conjunction with p300 HAT to heighten gene transcription (Daujat et al., 2002). As
yet, no R demethylases have been identified (Ehrenhofer-Murray, 2004).
Similarly to acetylation, histone methylation is a reversible process. The removal of
methyl groups from histones is catalysed by histone demethylases (HDMs) that are
implicated in the regulation of cell development and gene transcription (Cloos et
al., 2008). These enzymes are categorised in two groups: the Jumonji (JmjC) family
of 2-oxoglutarate dependent HDMs or flavin adenine dinucleotide (FAD)-dependent
ĂŵŝŶĞ ŽǆŝĚĂƐĞƐ >^ ?  ?ůǇƐŝŶĞ ?ƐƉĞĐŝĨŝĐ ,D Z ĂŶĚ Ă &Ğ ?// Z ĂŶĚ ɲ ?ŬĞƚŽŐůƵƚĂƌĂƚĞ ?
dependent dioxygenase LSD2 (Klose and Zhang, 2007). It is thought that HDMs have
substrate specificity for H3K4, H3K9, H3K27 and H3K36: members of LSD1 group
specifically target mono- and di-methylated H3K4 and H3K9 (Berger, 2007, Bhaumik
et al., 2007). Recognition of epigenetic signatures by HDMs results in the formation
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of large complexes with other co-activator/repressor proteins such as HDACs, HMTs
and nuclear receptors enhancing each others activities and altering gene
transcription (Kouzarides, 2007).
1.6.3.5 DNA methylation
DNA methylation is a stable epigenetic modification involved in the continuous
conservation of some genomic regions (Cheung et al., 2000), stabilisation and
maintenance of genomic integrity (Jiang et al., 2004) and expression of tissue
specific genes (Ospelt et al., 2011). Dysfunction of this epigenetic modification is
present in nearly all types of cancer (Jaenisch and Bird, 2003): studies have
demonstrated that loss of methylation in oncogenes and/or abnormal
hypermethylation in tumor suppressor genes results in cancer growth and
metastasis (Ospelt et al., 2011).
DNA methylation is the covalent transfer of a methyl group from S-adenosyl-L-
methionine to cytosines in cytosine-guanine (CG) dinucleotides (CpG sites) catalised
by methyltransferases (Ospelt et al., 2011, Cheung and Lau, 2005). In the
mammalian genome, around 40% of genes have CpG sites located upstream of their
transcriptional start site: 70-80% of these sites are methylated (Bird, 2002, Jiang et
al., 2004). Extensive methylation at the regulatory region of the gene results in
target gene silencing and alters the DNA-binding affinity of TFs and other regulatory
co-factors recruited to the gene promoter (Deng et al., 2001, Ospelt et al., 2011).
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DNA methylation is catalysed by DNA methyltransferases (DNMTs). This family of
enzymes is divided in four main groups. DNMT1 is responsible for the maintenance
of methylation patterns during DNA replication; deletion of DNMT1 in animal
models results in death of mice embryos. DNMT2 (TRDMT1) is homologous to other
DNMTs, but has limited activity methylating cytosine-38 in transfer RNA rather than
DNA. DNMT3a and DNMT3b are involved in de novo DNA methylation and
generation of new methylation patterns early in development (Goll et al., 2006).
The DNA sequence itself, conformation or secondary structure including specific
RNAs targeting homologous regions and specific chromatin proteins, histone
modifications and higher-order chromatin structures alone or in combination can
serve as potential triggers for the DNA methylation (Freitag and Selker, 2005).
DNA methylation is associated with chromatin condensation and gene silencing
(Klose and Bird, 2006, Jones and Liang, 2009). Increased DNA methylation leads to
the direct suppression of DNA binding affinity and inability of TFs and regulatory co-
activators to bind the gene promoter. Subsequent recruitment of methyl CpG
binding proteins (MBPs) to methylated CpG islands in association with HDACs and
HMTs form repressor complexes leading to chromatin condensation (Salozhin et al.,
2005, Fuks, 2005) and transcriptional silencing (Jaenisch and Bird, 2003).
1.6.3.6 Other histone modifications
Histone phosphorylation is an important mechanism in the cell cycle (Roth and Allis,
1992) and has been implicated in DNA replication control and gene transcription
regulation (Happel and Doenecke, 2009). Phosphorylation of histone H1 is involved
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in chromatin condensation and decondensation via changes in the affinity for
chromatin (Bradbury et al., 1974, Zheng et al., 2010). Phosphorylation of histone H3
Ăƚ ƐĞƌŝŶĞ  ? ? ƌĞŐƵůĂƚĞƐ ƚƌĂŶƐĐƌŝƉƚŝŽŶ ŽĨ E& ?Ů ?ŵĞĚŝĂƚĞĚ ĂŶĚ  SŝŵŵĞĚŝĂƚĞ ?ĞĂƌůǇ ?
genes such as Fos and Jun (Prigent and Dimitrov, 2003, Strahl and Allis, 2000).
Further research has acknowledged that transcription of these genes may be
regulated cooperatively in conjunction with other epigenetic modifications such as
acetylation (Strahl and Allis, 2000).
Another epigenetic modification, ubiquitination, is sequentially catalysed by three
E1-activating, E2-conjugating and E3-ligating enzymes resulting in either a
repressive or activating effect subject to the site modified (Bhaumik et al., 2007).
Monoubiquitination of histone H2A at K119 is a repressive mark, whilst
ubiquitination of H2B at K120 is associated with both transcription activation and
gene silencing (Berger, 2007, Kouzarides, 2007, Weake and Workman, 2008,
Bhaumik et al., 2007). Furthermore, ubiquitination of histones H2A and H2B is
interlinked and can have contrary effects: H3K4 methylation as a consequence of
H2B ubiquitination is inhibited by H2A ubiquitination (Weake and Workman, 2008).
Sumoylation has been implicated in different biological processes including protein
stability, nuclear-cytosolic transport and transcriptional regulation (Gill, 2005,
Peters and Schübeler, 2005). Addition of a nearly 100 amino acid long Small
Ubiquitin-related MOdifier protein (SUMO) (Shiio and Eisenman, 2003) results in
the recruitment of chromatin-modifying enzymes such as HDACs and HP1 protein
(Klose and Zhang, 2007). Studies in yeast have described sumoylation of all four
core histones: sumoylation of K6/7 and K16/17 on histone H2B, K126 on histone
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H2A and all four K tails in the N-terminus of histone H4 correlates with
transcriptional repression (Peters and Schübeler, 2005).
1.6.4 Epigenetic regulation of the CXCL8 gene
To date, the exact mechanisms of epigenetic regulation of individual genes
including CXCL8 have not been fully understood. One study demonstrated that IL-
 ?Ƙ ?ŝŶĚƵĐĞĚE& ?ŮƉ ? ?ďŝŶĚŝŶŐƚŽƚŚĞy> ?ƉƌŽŵŽƚĞƌƌĞƐƵůƚƐŝŶƚŚĞƌĞĐƌƵŝƚŵĞŶƚŽĨ
co-activators and chromatin remodelling enzymes such as p300 and CBP resulting in
ŚŝƐƚŽŶĞ , ? ĂĐĞƚǇůĂƚŝŽŶ ĂƌŽƵŶĚ ƚŚĞ E& ?Ů ƐŝƚĞ  ?ĂƌƚůŝŶŐ ?  ? ? ? ? Z ? dŚĞƐĞ ĐŚĂŶŐĞƐ
ĨƵƌƚŚĞƌ ƌĞĐƌƵŝƚ ഺƌĞĂĚĞƌƐ ? ŽĨ ĂĐĞƚǇůĂƚĞĚ ůǇƐŝŶĞ ƌĞƐŝĚƵĞƐ ƐƵĐŚ ĂƐ Z ĐŽŶƚĂŝŶŝŶŐ
proteins leading to an increased binding of C/EBP and AP-1 TFs and chromatin
remodelling, open chromatin structure and enhanced CXCL8 transcription. Another
study has reported similar observations in human airway smooth muscle cells
derived from asthmatic patients confirming increased binding of p300, CBP and
PCAF to the CXCL8 promoter as a result of increased histone H3 acetylation
ĨŽůůŽǁŝŶŐ dE& ?ɲ ƐƚŝŵƵůĂƚŝŽŶ  ?:ŽŚŶ Ğƚ Ăů ? ?  ? ? ? ? Z ? ƐƚƵĚǇ ĐŽŶĚƵĐƚĞĚ ŝŶ ďƌŽŶĐŚŝĂů
ĞƉŝƚŚĞůŝĂů ĐĞůůƐ ŝŶǀĞƐƚŝŐĂƚŝŶŐ /> ? ?ɴ ?ŝŶĚƵĐĞĚ y> ?ƚƌĂŶƐĐƌŝƉƚŝŽŶ ŚĂƐ ƐŝŵŝůĂƌůǇ
detected pan-acetylation of histone H3 but not H4 associated with increased
ďŝŶĚŝŶŐŽĨZ ?ĂŶĚE& ?ŮƉ ? ? ?<ŚĂŶĞƚĂů ? ? ? ? ? ? Z ?
While some progress has been made in the field of cytokine-mediated epigenetic
regulation of CXCL8 transcription, the distinct mechanisms of CXCL8 expression in
CF have not been fully explored. Thus, it would be interesting to determine
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epigenetic modifications affecting cytokine-induced CXCL8 transcription in CF
human airway epithelial cells.
1.6.5 Disease epigenetics
In the last few decades, research has highlighted the fundamental role of epigenetic
regulation, particularly DNA methylation and histone modifications, in the
development and/or progression of cancer, inflammation and metabolic disorders
(Sigalotti et al., 2007, Bhaumik et al., 2007, Strahl and Allis, 2000, Klose and Bird,
2006).
Epigenetic modifications at early stages of tumorigenesis alter different signalling
pathways involved in cell cycle control, apoptosis, metastasis, angiogenesis and
immune recognition (Sigalotti et al., 2007). DNA hypermethylation associated with
ƚƌĂŶƐĐƌŝƉƚŝŽŶĂůƐŝůĞŶĐŝŶŐŽĨƐŽŵĞƚƵŵŽƵƌƌĞƉƌĞƐƐŽƌŐĞŶĞƐĂƐĂƌĞƐƵůƚŽĨഺŚŽƚƐƉŽƚ ?
mutations in the CpG islands of their promoters has been reported in some
aggressive types of cancer (Berger, 2007). Furthermore, studies have acknowledged
simultaneous presence of global DNA methylation and individual gene
hypermethylation suggesting co-existence of different and sometimes incompatible
epigenetic alterations (Weber et al., 2005).
Histone modifications have also been reported to be present at the promoters of
individual genes in human tumours. Breast and liver cancer have been
characterised by genome-wide loss of H4K20 methylation (Fraga et al., 2005) as
well as loss of H3K4 trimethylation (Bhaumik et al., 2007). Increased H3K9
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methylation alongside altered H3K27 methylation resulting in gene silencing have
been identified as epigenetic signatures of certain forms of cancer (Nguyen et al.,
2002, Valk-Lingbeek et al., 2004). Overexpression of chromatin-remodelling
enzymes such as HMTs has been reported in some cancers: enhanced transcription
of EZH2 which is a H3K27 HMT is associated with silencing of onco suppressor genes
in breast and prostate cancer (Valk-Lingbeek et al., 2004). Furthermore, increased
levels of G9a, the H3K9 HMT, have been described in liver cancer as a hallmark of
malignant phenotype (Kondo et al., 2008, Kondo et al., 2007).
Studies conducted in cancer have reported altered acetylation patterns as a result
of a misbalance in the HAT/HDAC equilibrium leading to target gene repression
(Halkidou et al., 2004, Song et al., 2005). Lack of H4K16 acetylation is one of the
characteristic features of cancer transformation and progression (Fraga et al.,
2005). Modifications of HATs and HAT-related genes such as CBP and p300 have
been reported to be significantly altered in leukemia (Yang, 2004).
1.6.6 Epigenetics of CF
CF is characterised by profound inflammation in the lungs along with increased
transcription of pro-inflammatory cytokines including CXCL8 (Bhattacharyya et al.,
2010). Although deficiency of CFTR gene and/or continuous presence of P.
aeruginosa in the lungs are believed to be responsible for the lung inflammation
and altered cytokine profile in CF, little is known about the molecular mechanisms
underlying enhanced CXCL8 expression. Altered epigenetic mechanisms regulating
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vital cellular processes have been recognised as potential reasons accountable for
the altered CXCL8 transcription in CF.
Histone acetylation has been implicated in the altered transcriptional regulation of
y> ? ŝŶ & P &dZ ?ĚĞĨŝĐŝĞŶƚ ĐĞůůƐ ĂƌĞ ĐŚĂƌĂĐƚĞƌŝƐĞĚ ďǇ ŐƌĞĂƚĞƌ ůĞǀĞůƐ ŽĨ E& ?ʃ ĂŶĚ
increased acetylation of histone H4 at the CXCL8 promoter. Furthermore, whilst no
changes in the activity and/or expression of chromatin remodelling enzymes such
as p300 and/or CBP and HDAC1 have been identified, an intrinsic alteration in
HAT/HDAC balance with a particular decrease in HDAC2 protein transcription and
activity have been described in CF human airway epithelial cells (Bartling, 2009).
WŽƐƚ ?ƚƌĂŶƐůĂƚŝŽŶĂů ŵŽĚŝĨŝĐĂƚŝŽŶƐ ĂƌĞ ƌĞƐƚŽƌĂďůĞ ďǇŶĞǁ ഺĞƉŝŐĞŶĞƚŝĐ ĚƌƵŐƐ ? ƐƵĐŚ ĂƐ
inhibitors of HATs, DNMTs and HDACs and inhibitors of BRD proteins. Though they
are still in the developmental stage, data, derived from studies using in vivo
myeloma models, indicate successful application of these drugs and their
antiproliferative effect (Delmore et al., 2011). BRD inhibitors have also been applied
in the treatment of inflammatory conditions: JQ1 decreased the inflammatory
ƌĞƐƉŽŶƐĞŝŶĂŶŝŵĂůŵŽĚĞůƐǀŝĂĚŽǁŶƌĞŐƵůĂƚŝŽŶŽĨƚŚĞƚƌĂŶƐĐƌŝƉƚŝŽŶŽĨE& ?ʃ ?ĚƌŝǀĞŶ
ŐĞŶĞƐ ?dŚŝƐŝŶŚŝďŝƚŽƌĐĂŶĂďůĂƚĞ>W^ ?ŝŶĚƵĐĞĚ/> ? ?ĂŶĚdE& ?ɲƚƌĂŶƐĐƌŝƉƚŝŽŶin vitro as
ǁĞůůĂƐƚŽďůƵŶƚƚŚĞഺĐǇƚŽŬŝŶĞƐƚŽƌŵ഼ ŝŶĞŶĚŽƚŽǆĞŵŝĐŵŝĐĞ  ?ĞůŬŝŶĂĞƚĂů ? ?  ? ? ? ?Ă Z ?
Another drug, GSK1210151A (I-BET 151), has successfully been implicated in the
treatment of haematological and solid malignancies in both in vitro and in vivo
models (Dawson et al., 2011). Collectively, these studies suggest that BET protein
inhibitors can be considered as new targets for the development of new epigenetic
drugs for the large number of diseases caused by aberrant histone acetylation.
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1.7 Summary
CF is a fatal disease caused by a mutation of CFTR gene and characterised by
intensive inflammation in the airways with increased levels of CXCL8 and other pro-
inflammatory cytokines. A vicious cycle of continuous inflammation and permanent
bacterial colonisation results in irreversible fibrosis, loss of lung function and
respiratory failure.
CXCL8 is a powerful pro-inflammatory chemokine, which plays a key role in the
pathogenesis of the inflammation in CF. Airway epithelial cells play a fundamental
role in the initiation and maintenance of the inflammatory process. Although
increased CXCL8 secretion by airway epithelial cells has been described in CF, the
exact molecular mechanisms are not completely understood. Work from our group
in other airway and parenchymal lung diseases such as idiopathic pulmonary
fibrosis (IPF) and asthma has suggested that structural lung cells may be
reprogrammed epigenetically proposing that epigenetic processes might have a
potential role in the regulation of CXCL8 release from airway epithelial cells in CF.
The purpose of the studies in this thesis was to study these processes in greater
depth than previously to gain a greater understanding of the molecular
mechanisms involved, and to identify the potential targets for therapeutic
intervention.
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2 HYPOTHESIS AND AIMS
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CXCL8 plays an important role in the pathogenesis of CF. Previous studies suggest
that CXCL8 release is increased in airway epithelial cells derived from CF patients or
engineered CF cell lines in vitro suggesting a fundamental relation between CFTR
function and CXCL8, independent of the CF airway microenvironment. Previous
ƐƚƵĚŝĞƐŚĂǀĞƐƵŐŐĞƐƚĞĚƚŚĂƚƚŚŝƐŵĂǇďĞƉĂƌƚŝĂůůǇůŝŶŬĞĚƚŽE& ?ŮĂĐƚŝǀĂƚŝŽŶ ?ďƵƚƚŚĞ
exact mechanisms are unclear.
Here we tested the hypothesis, that altered epigenetic regulation of transcription is
the key factor increasing CXCL8 production basally and in response to pro-
inflammatory cytokines in CF airway epithelial cells.
The specific aims were:
 ? ? dŽ ĐŽŶĨŝƌŵ ƚŚĂƚ /> ? ?ɴ ĐĂŶ ŝŶĚƵĐĞ y> ? ƉƌŽƚĞŝŶ ƐĞĐƌĞƚŝŽŶ ĨƌŽŵ ŶŽƌŵĂů ĂŶĚ &
airway epithelial cells.
 ? ? dŽ ǀĞƌŝĨǇ ƚŚĂƚ y> ? ƉƌŽĚƵĐƚŝŽŶ ŝƐ ŝŶĐƌĞĂƐĞĚ ŝŶ& ĐĞůůƐ ďĂƐĂůůǇ ĂŶĚ ĂĨƚĞƌ /> ? ?ɴ
stimulation.
3. To compare the activation and binding pattern of transcription factors to the
CXCL8 promoter in normal and CF airway epithelial cells.
4. To analyse the transcriptional mechanisms responsible for the enhanced CXCL8
expression in CF cells.
5. To explore the epigenetic mechanisms regulating the CXCL8 promoter both
basally and after stimulation with IL-1ß in normal cells and to determine if they are
dysregulated in CF cells.
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3 MATERIALS AND METHODS
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This chapter provides an outline of general methods used in this thesis with a
comprehensive description of cells employed. Full details of all primer sequences,
reagents, and buffers are listed in 9.3 of Appendix.
3.1 Cell lines
Two sets of immortalised human bronchial epithelial cells were used for the
experiments:
- IB3-1 cells derived from a CF patient with a compound heterozygous
ŵƵƚĂƚŝŽŶ  ?ȴ&508/W1282X) in the CFTR gene, and S9 cells (IB3-1 cells, stably
transfected with complimentary DNA (cDNA) encoding CFTR protein by the adeno-
associated virus type 2 inverted terminal repeat) (Zeitlin et al., 1991, Flotte et al.,
1993). IB3-1 and S9 cells were a generous gift from Prof. Pamela L. Zeitlin (Johns
Hopkins University, Baltimore, MD). Both cell lines were cultured to passage 15 and
41 respectively in LHC-8 without gentamicin (1X) medium supplemented with 10%
heat-inactivated foetal calf serum (FCS), 100U/mL penicillin, 100µg/mL
streptomycin, and 2.5µg/mL amphotericin B.
- CFBE41o- cells derived from a CF patient with homozygous mutation
ȴ ? ? ? ?ȴ ? ? ? ? ĂŶĚ ǁŝůĚ ƚǇƉĞ ŚƵŵĂŶ ĂŝƌǁĂǇ ĞƉŝƚŚĞůŝĂů ĐĞůůƐ  ?ƉĂƌĞŶƚĂů & ? ?Ž ? ĐĞůůƐ ?
stably transfected with cDNA encoding wild type CFTR protein by lentiviral-based
transduction). These cell lines were a generous gift from Prof. Bruce Stanton
(Dartmouth University, NH). CFBE41o- and wild type cells were cultured to passage
22 and 21 respectively in Minimum Essential Medium Eagle (MEM) medium
supplemented with 10% FCS, 100U/mL penicillin, 100µg/mL streptomycin,
2.5µg/mL amphotericin B, and 10µg/mL of puromycin.
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For future reference IB3-1 and S9 cells will be referred as IB3-1 normal and IB3-1 CF
cells, and CFBE41o- and wild type human airway epithelial cells as CFBE41o- normal
and CFBE41o- CF cells.
3.1.1 Cell culture
All cell lines were grown in a humidified incubator at 37°C under 5% CO2 and 20%
O2.Once the required 80-90% confluence was achieved, cells were growth arrested
in serum free medium for 24 hours prior to experiments with further replacement
with serum free medium with or without stimuli as per experimental design.
3.1.2 Cell counting
Cells were cultured in T150 or T225cm2 flasks until 90% confluent, washed once
with PBS and trypsinised. After centrifugation at 1000rpm for 5 minutes, the pellet
was resuspended in 10mL of medium containing serum, and the number of cells in
the cell suspension was determined using a Neubauer haemocytometer and a light
microscope: 10µl of the solution was pipetted under the cover slip on the
haemocytometer and the cells were observed under the microscope using the x40
magnification lens. The number of cells was counted in each of the 4 large squares
in the corners of the grid. Cells lying on the top and left margins of the grid were
counted and clusters of cells were counted as one. The total number of cells
counted was divided by 4, and finally multiplied by x104 to obtain the number of
cells per 1mL. To determine the total number of cells in the suspension, the last
number was multiplied by the total volume.
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3.1.3 Cell freezing
To create frozen stocks, trypsinised and pelleted cells were resuspended in a
solution containing 90% FCS and 10% dimethyl sulfoxide (DMSO) to achieve 3x106
cell/mL density. The suspension was aliquoted in 1mL cryovials and placed in a -
80°C freezer overnight in a Nunc Cryo 1°C Freezing Container (Mr. Frosty)
containing 100% isopropyl alcohol. The following day the cells were transferred to
liquid nitrogen and stored until required.
3.2 Human CXCL8 enzyme-linked immunosorbent assay (ELISA)
The human CXCL8/IL-8 DuoSet ELISA kit (R&D Systems, UK) was used to determine
the human CXCL8 protein concentration in culture medium. Cells were grown in 24
well plates until confluent, serum deprived for 24 hours prior to experiments, and
treated with a stimulant for the required time. Supernatants were collected and
stored at -20°C until assayed according to the manufacturers instructions.
Briefly, 96 well plates were pre-coated with 50 or 100µl (half and full surface area
wells respectively) of a capture antibody per well (720µl/mL of mouse anti-human
CXCL8 when reconstituted with 1mL of sterile phosphate buffered saline (PBS)), and
incubated overnight at room temperature. The following day the plates were
washed at least three times with a washing buffer (0.05% Tween-20 in 1L of PBS),
and blocked with 150 or 300µl of a block buffer per well (1% bovine serum albumin
(BSA) in PBS) for at least an hour. Subsequently, the plates were washed three
times and incubated with 50 or 100µl of non-diluted and 1:5 or 1:10 diluted
supernatants (in triplicate) and standards (in duplicate) for at least 2 hours at room
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temperature. 100ng/mL of recombinant human CXCL8 when reconstituted with
0.5mL distilled water was used as a standard. An eight point standard curve (0,
31.25, 62.5, 125, 250, 500, 1000, 2000pg/mL) was prepared by serial two fold
dilutions in reagent diluent (0.1g BSA and 50µl 0.05% Tween-20 in 100mL tris
buffered saline).
Following the incubation, the plates were washed at least three times with a wash
buffer, and incubated for another two hours with 50 or 100µl of detection antibody
per well (3.6µg/mL of biotinylated goat anti-human CXCL8 when reconstituted with
1mL of reagent diluent). Then, the plates were washed again, and 50 or 100µl of
streptavidin, conjugated to horseradish-peroxidase (Streptavidin-HRP) diluted in
reagent diluent, were added per well with further incubation of 30 minutes away
from the direct light. Plates were washed again and incubated with 50 or 100µl of a
substrate solution (a 1:1 mixture of colour reagent A (H2O2) and colour reagent B
(Tetramethylbenzidine)) per well for 20 minutes away from the direct light.
The reaction was terminated by adding 25 or 50µl of stop solution (2N sulphuric
acid (H2SO4))), and the colour intensity was measured using a plate reader (Omega
Fluostar, BMG Labtech, UK) at an optical density of 450nm and reference
wavelength of 570nm. CXCL8 concentrations in samples were calculated by creating
a four parameter logarithmic standard curve fit generated by Omega V2.10R4
software; a multiplication by a relevant dilution factor was applied to calculate the
concentration of diluted samples. Readings were expressed as pg/mL and
normalised against total cellular protein amount; the final data were presented as
pg/mL/µg.
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3.3 Bicinchoninic acid (BCA) protein assay
Colorimetric bicinchoninic acid (BCA) protein assay was used to determine protein
concentration in the experimental samples using kits supplied by Pierce, UK
according to the manufacturers instructions.
Having removed the supernatants to be assayed by ELISA, cells were washed with
PBS once, lysed with a lysis buffer (100µl of TritonTM X-100 diluted in 1mL of
double-distilled water) and either stored at -80°C until required or processed
immediately. 25µl of samples diluted 1:5 when required (in triplicate) alongside
standards (in duplicate) were added to 96 well plates. Known concentrations of BSA
were used to create a nine point standard curve (0, 25, 125, 250, 500, 750, 1000,
1500, 2000µg/mL) by means of serial dilutions in the lysis buffer. Reagent B (4%
cupric sulphate) and Reagent A (containing sodium carbonate, sodium bicarbonate,
bicinchoninic acid and sodium tartrate in 0.1 sodium hydroxide) were mixed in a
50:1 ratio to create the working reagent. 200µl of the working reagent was added
per well followed by incubation at 37°C for 30 minutes. Samples were left to cool to
room temperature, and the absorbance measured at a 590nm wavelength using a
plate reader. The best-fit standard curve was generated by Omega V2.10R4
software; a multiplication by the relevant dilution factor was applied to calculate
the protein concentrations of diluted samples.
3.4 Real-time polymerase chain reaction (qPCR)
Real-time polymerase chain reaction (qPCR) is a technique used to assess
qualitative gene expression within a cell through measuring messenger RNA
(mRNA) levels by creating cDNA transcripts from RNA. It is a multistage process
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including total RNA extraction from the cells followed by reverse transcription into
cDNA and qPCR analysis using gene specific primers.
3.4.1 Total RNA isolation
Total RNA was isolated using NucleoSpin RNA II kit (Macherey-Nagel, Germany)
according to the manufacturers instructions. Cells were grown in 6 well plates until
confluent, growth arrested for 24 hours prior to experiments and treated with a
stimulant as described in the experimental design.
After removing media, cells were lysed in 350µl of lysis buffer RA1 supplemented
with 10µl/mL ß-mercaptoethanol. Cell lysates were loaded onto a NucleoSpin® Filter
ĐŽůƵŵŶ ĐŽŶƚĂŝŶŝŶŐ Ă ƐŝůŝĐĂ ŵĞŵďƌĂŶĞ ŝŶ  ? ? ?ʅů ŽĨ  ? ?A? ĞƚŚĂŶŽů ĂŶĚ ĐĞŶƚƌŝĨƵŐĞĚ Ăƚ
11000xg for 30 seconds. Subsequently, having discarded the eluate, 350µl of
membrane desalting buffer (MDB) was added to each tube followed by
centrifugation at 11000xg for 1 minute. Next, 95µl of recombinant
deoxyribonuclease (rDNase) reaction mixture (10µl of reconstituted rDNase in 90µl
of a reaction buffer for rDNase) was directly applied onto the center of the silica
membrane of each column, followed by 15 minutes incubation at room
temperature. Then, silica membranes were washed with 200µl of wash buffer
RAW2 and centrifuged at 11000xg for 30 seconds. The first wash was followed by a
second one with 600µl of buffer RA3 and subsequent centrifugation at 11000xg for
30 seconds. The supernatants were discarded, samples washed a final time with
250µl of buffer RA3, and centrifuged for 2 minutes at 11000xg. The columns were
then placed into a nuclease-free collection tube, and centrifuged at 11000xg for 2
minutes to ensure all ethanol residue was removed from the column. Finally, RNA
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was eluted in 40µl of nuclease-free water (supplied with a kit) by centrifugation at
11000xg for 1 minute with further storage at -80°C until required.
3.4.2 Reverse transcription
Reverse transcription (RT) was used to synthesise cDNA from an RNA template
using a reverse transcriptase enzyme.
For each reaction, 1µl of extracted RNA was heated for 5 minutes at 72°C in 13.7µl
of a master mix 1 containing 200µg/mL oligodeoxythymidylic acid (OligoDT) primer,
10mM of deoxynucleoside triphosphates (dNTPs) mix, and 5.7µl of nuclease-free
water in a thermo cycler (Bio-Rad, PTC 100, UK). After 5 minutes incubation on ice,
RNA was reverse transcribed in 25µl of master mix 2 containing 132 units of
Moloney murine leukemia virus reverse transcriptase (M-MLV RT), 26.4 units of
recombinant RNasin ribonuclease (RNAase) inhibitor, 5µl of 1xM-MLV RT buffer,
and nuclease-free water at 42°C for 90 minutes in a thermal cycler. Resulting cDNA
samples were stored at -20°C until required or used for the quantitative qPCR
immediately.
3.4.3 Quantitative real-time polymerase chain reaction (qPCR)
Quantitative real-time polymerase chain reaction (qPCR) was used to amplify a
specific region of CXCL8 DNA using a fluorescence detecting thermal cycler.
1µl of reverse transcribed cDNA was subjected to qPCR in a master mix containing
10µl of SYBR® Premix Ex TaqΡ II (Tli RNase H Plus), and 0.4µl (40nM) of human
CXCL8 forward and reverse primers; the final volume was adjusted to 20µl with
nuclease-free water. Human CXCL8 expression was determined using an
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Mx3000P®QPCR System thermal cycler (Stratagene, California, USA) (primer
sequences and cycling conditions are described in 9.5 of the Appendix). All samples
were assayed in triplicate and successful amplification of a single product was
confirmed by presence of a single dissociation peak in melting curve analysis. CXCL8
ĞǆƉƌĞƐƐŝŽŶǁĂƐŶŽƌŵĂůŝƐĞĚƚŽɴ2-microglobulin expression; data were presented as
relative expression compared to control non-treated samples.
3.5 Transfections
CXCL8 promoter activity and identification of TFs that influence CXCL8 promoter
activity were determined by transient transfection of luciferase reporter constructs.
Plasmids were grown on ampicillin selective LB agar plates at 37°C in a humidified
atmosphere overnight. The following day, the largest single colony was selected
and grown in ampicillin selective LB broth for further 24 hours at 37°C in an
ExcellaΡ E24/E24R temperature-controlled benchtop shaker (New Brunswick
Scientific, UK). Plasmid DNA was isolated and purified using a plasmid purification
midi kit (Qiagen, UK) according to the manufacturers instructions.
A wild type CXCL8 promoter-driven luciferase construct (-162/+44), and constructs
ĐŽŶƚĂŝŶŝŶŐ ŵƵƚĂƚŝŽŶƐ ŝŶ ƚŚĞ ďŝŶĚŝŶŐ ƐŝƚĞƐ ĨŽƌ W ? ? ?  ?Wɴ Žƌ E& ?Ů ŝŶ ƚŚĞ y> ?
promoter region were a kind gift of Dr. A. R. Braiser (Department of Medicine, Sealy
Center for Molecular Science, Galveston, TX). Cells were seeded in 24 well plates at
50000 cells per well density, grown to 60% of confluence and serum deprived for 16
hours prior to experiments. Master mixes containing 0.8µg of wild type or mutant
CXCL8 promoter constructs DNA, 0.8µg pRL-SV40 plasmid containing Renilla
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luciferase gene as an internal control, and LipofectamineΡ 2000 transfection
reagent at a 1:2 DNA:LF2000 ratio were made in antibiotic and serum free medium
and incubated at room temperature for 15 minutes to form complexes. After
aspirating growth media, 100µl of media containing DNA: transfection reagent
complexes was added to specific wells and incubated for 3 hours. Then, cells were
ƐƚŝŵƵůĂƚĞĚǁŝƚŚ ?ŶŐ ?ŵ>/> ? ?ɴĨŽƌ ?ŚŽƵƌƐŽƌůĞĨƚƵŶƐƚŝŵƵůĂƚĞĚǁŝƚŚŽƵƚĐŚĂŶŐŝŶŐƚŚĞ
media at 37°C in a humidified atmosphere. After stimulation, cells were washed in
PBS, lysed in 100µl of 1x passive lysis buffer (supplied with the kit), and stored at -
80°C until required. Firefly and Renilla luciferase activities were measured using a
Dual-Luciferase reporterTM assay system kit (Promega, UK) first by adding 50µl of
luciferase assay reagent II (LAR II) to the samples. This step was followed by Renilla
luciferase activity quantification through addition of 50µl of Stop&Glo® reagent to
the same sample on a plate reader (Omega Fluostar, BMG Labtech, UK). Data were
normalised by dividing Firefly readings by Renilla and expressed as a ratio of Firefly:
Renilla (fold change over control).
3.6 Cell viability and proliferation assay
The toxicity of drug compounds used during the study was determined using a
colorimetric assay identifying the reduction of a yellow 3-(4, 5-dimethythiazol-2-yl)-
2, 5-diphenyl tetrazolium bromide (MTT) reagent.
Cells were grown as per the experimental design; at the end of the experiment,
media was removed, and 250µl of 1mg/mL 3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide, diluted in serum free medium was added per well.
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Samples were incubated at 37°C for 30 minutes, the medium was removed and
plates left to air dry overnight. The following day, 250µl of DMSO was added to
each well to solubilise purple-colored tetrazolium crystals, and 100µl of each
sample was loaded in 96 well plates in duplicate.
The color intensity in the experimental samples was measured using a plate reader
(Omega Fluostar, BMG Labtech, UK) at an optical density of 550nm. The color
change was directly proportional to the levels of viable cells; data were expressed
as percent viability relative to control.
3.7 Chromatin immunoprecipitation (ChIP)
ChIP was used to identify histone modifications and transcription factor binding to
the CXCL8 promoter. The assay can be divided into 4 major phases: cell fixation,
sonication, immunoprecipitation and qPCR analysis. The assay was performed using
the ChIP-IT® Express kit (Active Motif, UK) according to the manufacturers
instructions.
3.7.1 Cell fixation
Cells were grown in T225cm2 flasks, serum deprived for 24 hours when confluent,
ĂŶĚ ĞŝƚŚĞƌ ŝŶĐƵďĂƚĞĚ ǁŝƚŚ  ?ŶŐ ?ŵ> /> ? ?ɴ ĨŽƌ  ? ?  ? ? ? ? ĂŶĚ  ? ŚŽƵƌƐ Žƌ ůĞĨƚ ŝŶ ĨƌĞƐŚ
serum free medium without any treatment to be used as control samples. Cells
were fixed in 20mL of fixative solution (1% formaldehyde solution in serum free
media to preserve DNA/protein interactions) for 10 minutes on a shaking platform
at room temperature. Next, the cells were washed with 10mL of ice-cold PBS and
incubated in 10mL 1x glycine stop solution for a further 5 minutes on a shaking
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platform at room temperature. This step was followed by another wash with 10mL
of ice-cold PBS. Then, cells were scraped in 2mL of PBS containing 5µl/mL 100mM
phenylmethylsulfonyl fluoride (PMSF) and centrifuged for 10 minutes at 720rcf at
4°C. The supernatants were discarded and 1µl of 100mM PMSF and proteinase
inhibitor cocktail (PIC) added to the cell pellet. The pellets were either processed
the same day or stored at -80°C until required.
3.7.2 Sonication
On the day of sonication, cells were lysed in 2mL (IB3-1 CF) or 3mL (IB3 normal) 1x
lysis buffer (supplied with the kit) supplemented with 10µl and 15µl of PMSF and
PIC respectively on ice for 30 minutes. The cells were pelleted by centrifugation at
2400rcf for 10 minutes at 4°C, the supernatants discarded, and the pellet
resuspended in 1mL shearing buffer (supplied with the kit) supplemented by 5µl of
PMSF and PIC each. The total volume was divided into 333µl aliquots for sonication.
Sonication was performed using an EpiShearΡ Multi-Sample sonicator (Active
Motif, UK). Cycles of 59 seconds of sonication were followed by 59 seconds of rest
for 15 minutes at 35% of power; the total duration was 15 minutes. Aliquots of the
same time points were combined together and centrifuged at 13000rpm at 4°C for
10 minutes. The samples were either processed the same day or stored at -80°C
until required. 25µg of chromatin was isolated to be processed as control Input
DNA later on.
3.7.3 Immunoprecipitation
For ChIP reactions 25µg of chromatin was incubated in siliconised tubes overnight
on a roller at 4°C in 200µl solution containing 25µl of protein G magnetic beads,
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20µl of ChIP buffer 1 (supplied with the kit), 2µl of PIC, 3-5µg of antibody of interest
or IgG antibody or normal rabbit/goat serum used as a negative control (as
determined by titration experiments for each antibody), and nuclease-free water.
The next day, the magnetic beads were washed once with 800µl of ChIP buffer 1
and twice with ChIP buffer 2. The immunoprecipitated complexes were eluted in
50µl of elution buffer by 15 minutes incubation on a roller at room temperature.
Then, crosslinks were reversed by incubation in 50µl reverse cross-linking buffer at
95°C for 15 minutes. Immunoprecipitated samples and Input DNA were further
incubated with 2µl of proteinase K at 37°C for 1 hour to remove remaining protein.
Input DNA was processed in 100µl solution containing 25µg of chromatin, 5mM
NaCl and ChIP buffer 2. To terminate the reactions, 2µl of proteinase K stop
solution was added.
Input DNA underwent further purification by incubation at 37°C for 30 minutes with
1µl RNase A. Subsequently, 200µl of nuclease-free water and 300µl of
phenol/chloroform were added to Input DNA samples followed by vortexing and
centrifugation at 13000rpm for 5 minutes. Afterwards, the aqueous part located on
the top was transferred to a new eppendorf tube, and 750µl of 100% ethanol, 35µl
of 3M sodium acetate (pH=5.2) and 1µl of glycogen (20mg/mL) were added to the
samples. The samples were vortexed and left at 70°C overnight. The following day,
the samples were centrifuged at 13000rpm for 10 minutes, and supernatants
discarded. The samples were further washed with 500µl of 70% ethanol and
pelleted at 13000rpm for 10 minutes. The pellet was left to air dry, and
resuspended in 500µl of nuclease-free water.
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3.7.4 QPCR
4µl of samples including Input DNA were subject to qPCR in 20µl of a master mix
containing 12.5µl of SYBR® Premix Ex TaqΡ II (Tli RNase H Plus), 50nM of human
CXCL8 promoter forward and reverse primers and nuclease-free water. Human
CXCL8 promoter levels were determined using a thermal cycler, the details of
primer sequences and cycling conditions (John et al., 2009) are provided in the 9.5
of Appendix.
Successful amplification of a single product was confirmed by the presence of a
single dissociation peak in melting curve analysis. ChIP assay was considered as
successful when CXCL8 promoter DNA levels in the experimental samples incubated
with antibodies of interest were lower compared to samples incubated with IgG
antibody used as a negative control. CXCL8 promoter DNA levels were normalised
to the Input DNA; data were presented as relative association with the CXCL8
promoter compared to control non-treated samples.
3.8 Co-Immunoprecipitation (Co-IP)
Co-Immunoprecipitation (Co-IP) is a method designed to study protein/protein
interactions within a cell by precipitation of a target protein and identification of
any bound interacting proteins using specific antibodies.
3.8.1 Isolation of nuclear and cytoplasmic proteins
Isolation of nuclear proteins for Co-IP was performed using Nuclear Extract kit
(Active Motif, UK) according to the manufacturers instructions.
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Briefly, cells were grown in T225cm2 flasks until confluent, growth arrested 24
ŚŽƵƌƐƉƌŝŽƌĂŶĞǆƉĞƌŝŵĞŶƚĂŶĚŝŶĐƵďĂƚĞĚŝŶŵĞĚŝĂǁŝƚŚŽƌǁŝƚŚŽƵƚ ?ŶŐ ?ŵ>/> ? ?ɴĂƐ
per the experimental design. Following stimulation, cells were washed with 5mL
ice-cold PBS supplemented with phosphatase and deacetylase inhibitors, scraped in
3mL of the same solution and transferred to pre-chilled 15mL conical tubes. Cells
were centrifuged at 1500rpm for 5 minutes at 4°C, supernatants discarded, and
pellets resuspended in 500µl complete hypotonic buffer supplemented with
phosphatase and deacetylases inhibitors, PIC and PMSF. This was followed by 15
minutes incubation on ice and addition of 25µl detergent. Then, cell suspensions
were centrifuged at 14000xg for 30 seconds at 4°C, and supernatants containing
cytoplasmic fractions discarded.
The remaining nuclear pellets were resuspended in 100µl complete digestion buffer
supplemented with phosphatase and deacetylases inhibitors, PIC, and PMSF. This
step was followed by addition of 0.5µl enzymatic shearing cocktail and vortexed
gently for 2 seconds. Suspensions were then incubated in a water bath for 10
minutes at 37°C and vortexed every 2-3 minutes during the incubation. To stop the
reactions, 2µl of 0.5M ethylenediaminetetraacetic acid (EDTA) was added and
samples were gently vortexed at the lowest setting for 2 seconds. This was followed
by 5 minutes incubation on ice and centrifugation at 14000xg for 10 minutes at 4°C.
Resulting supernatants were transferred to a fresh microcentrifuge tube and stored
at -80°C until required or processed immediately.
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3.8.2 Co-immunoprecipitation (Co-IP)
250µg of nuclear extract was incubated with either 5µg of antibody of interest or
IgG used as a negative control and complete Co-IP/Wash buffer in a total volume of
500µl for 4 hours at 4°C on an end-to-end rotator. Subsequently, antibody/extract
complexes were centrifuged at 4000rpm for 30 seconds at 4°C and further
incubated with 25µl of Protein G magnetic beads for 1 hour at 4°C on an end-to-end
rotator. Following 30 seconds centrifugation at 4000rpm at 4°C, the supernatants
were discarded and pellets washed in 500µl complete Co-IP/Wash buffer four
times. Then, each bead pellet was resuspended in 20µl of 2x Reducing buffer,
vortexed and stored at -20°C until required or run in western blotting immediately.
BCA assay was performed to quantify total protein in the cell lysates before
proceeding further.
3.8.3 Western blotting
To identify specific proteins within samples, western blotting, a semi-quantitative
technique using gel electrophoresis to separate proteins according to their
molecular weight, was used.
3.8.3.1 Protein sample preparation
20µl of nuclear extract samples isolated as described in 3.8.1 were denatured at
100°C for 15 minutes on a heated block and run on sodium dodecyl sulphate
polyacrylamide gel electrophoresis (SDS-PAGE).
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3.8.3.2 Sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
Proteins within the cell sample were separated by SDS-PAGE. The gel casting system
(Protean 3, Bio-Rad, UK) was set up according to the manufacturers instructions. A
10% resolving gel was prepared and poured into the gel casting system (for the
recipe see 9.4 of Appendix); the gel was allowed to set for 40 minutes at room
temperature. Once set, a stacking gel was prepared and poured on top of the
resolving gel (for the recipe see 9.4 of Appendix); a comb was inserted and the gel
was allowed to set at room temperature for 30 minutes. Having removed the comb,
the apparatus was carefully placed in the tank and filled with 1x running buffer (for
the recipe see 9.4 of Appendix). The first lane was loaded with 5µl of RainbowTM
coloured protein marker and 20µl of samples and relevant controls were loaded
into the subsequent wells. Due to a large number of samples, they were split in 3
gels. The samples were subjected to electrophoresis at 150V constant voltage for
approximately 1 hour.
3.8.3.3 Protein transfer
Proteins were transferred from the gel to the polyvinylidene difluoride (PVDF)
ImmunblottTM membrane (Bio-Rad, UK) in a Transblott apparatus (Bio-Rad, UK). A
piece of PVDF membrane was soaked in 100% methanol for 30 seconds and then
washed in 1x transfer buffer. Subsequently, two pieces of filter paper, two sponges,
the PVDF membrane and the gel were soaked in 1x transfer buffer (for recipe see
9.4 of Appendix) for 5 minutes on a rocker. Next, one of the sponges was laid on to
the transfer cassette, followed by filter paper and then the PDVF membrane. The
gel was placed on top of the membrane and carefully laid on to the cassette
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between two pieces of filter paper and two sponges. The transfer cassette was
placed in the transfer tank filled with 1x transfer buffer (for recipe see 9.4 of
Appendix) and the system run at 100V for approximately 90 minutes on ice. Once
the transfer was completed, the membrane was removed and washed twice for 5
minutes in 1x TBS-T buffer (for recipe see 9.4 of the Appendix).
3.8.3.4 Protein detection
The membrane was incubated in a blocking buffer (1x TBS-T containing 5% non-fat
milk) at room temperature for 1 hour to reduce the non-specific binding of
antibodies. The membrane was then washed three times 10 minutes each in 1x
TBS-T; and incubated with the primary antibody of interest diluted in 5% non-fat
milk at the correct ratio on a rotator at 4°C overnight. The following day, the
membrane was washed three times 10 minutes each in 1x TBS-T on a rocker and
incubated in the secondary antibody diluted at 1:2000 in 5% non-fat milk on a
rocker for 1 hour at room temperature. Once completed, another three washes 10
minutes each were applied to the membrane and the membrane was blotted dry.
Equal volumes of ECLTM Western blotting detection kit (GE Healthcare Life Sciences,
UK) reagents were mixed in 1:1 ratio and poured over the membrane surface and
left to incubate for 2 minutes. Then the membrane was blotted dry to remove the
excess of ECLTM detection reagent and placed face down in a plastic wallet. The
membrane then was developed in a dark room using hyper film ECLTM (GE
Healthcare Life Sciences, UK); presence of a single strong band at the relevant size
was identified using the RainbowTM protein molecular weight markers (GE
healthcare, UK).
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3.9 Bisulphite sequencing
Pyrosequencing was used to identify the methylation levels of CpG sites within the
CXCL8 promoter region. This method allows sequencing of a single strand of DNA by
synthesising the complementary strand alongside and determining the base added
at each step. It is a complex technique consisting of genomic DNA extraction,
bisulphite conversion followed by PCR of the converted DNA and pyrosequencing.
3.9.1 Genomic DNA extraction
Cells were grown to confluence in T75cm2 flasks, serum deprived 24 hours prior to
ĂŶǇ ĞǆƉĞƌŝŵĞŶƚ ? ĂŶĚ ĞŝƚŚĞƌ ƚƌĞĂƚĞĚ ǁŝƚŚ  ?ŶŐ ?ŵ> /> ? ?ɴ ĨŽƌ  ? ŚŽƵƌƐ Žƌ ůĞĨƚ
unstimulated. Cells were washed with sterile PBS, scraped and centrifuged at
1000rpm for 5 minutes. Genomic DNA was isolated using the QIAamp DNA blood
mini kit (50) (Qiagen, UK) according to the manufacturers instructions.
ƌŝĞĨůǇ ? ĐĞůů ƉĞůůĞƚƐ ǁĞƌĞ ƌĞƐƵƐƉĞŶĚĞĚ ŝŶ  ? ? ?ʅů ŽĨƐƚĞƌŝůĞ W^ ƐƵƉƉůĞŵĞŶƚĞĚ ǁŝƚŚ
 ? ?ʅůŽĨƉƌŽƚĞĂƐĞ ?ĂŶĚůǇƐĞĚŝŶ ? ? ?ʅůůǇƐŝƐďƵĨĨĞƌ>ĨŽůůŽǁĞĚďǇƉƵůƐĞ ?ǀŽƌƚĞǆŝŶŐĨŽƌ
 ? ? ƐĞĐŽŶĚƐ ĂŶĚ  ? ? ŵŝŶƵƚĞƐ ŝŶĐƵďĂƚŝŽŶ Ăƚ  ? ? ? ? ^ƵďƐĞƋƵĞŶƚůǇ ?  ? ? ?ʅů ŽĨ  ? ? ?A?
ethanol was added to the samples and mixed by pulse-vortexing for 15 seconds.
The mixture was carefully applied to the QIAamp mini spin column, and centrifuged
Ăƚ  ? ? ? ?ǆŐĨŽƌ  ?ŵŝŶƵƚĞ ?dŚĞŶ ?ƐĂŵƉůĞƐǁĞƌĞǁĂƐŚĞĚǁŝƚŚ  ? ? ?ʅůǁĂƐŚďƵĨĨĞƌt ?
ĂŶĚĐĞŶƚƌŝĨƵŐĞĚĂƚ ? ? ? ?ǆŐĨŽƌ ?ŵŝŶƵƚĞ ?^ĂŵƉůĞƐƵŶĚĞƌǁĞŶƚĂŶŽƚŚĞƌǁĂƐŚŝŶ ? ? ?ʅů
wash buffer AW2 and centrifugation at 20000xg for 3 minutes and 1 minute
ĂĚĚŝƚŝŽŶĂůůǇ ?'ĞŶŽŵŝĐEǁĂƐĞůƵƚĞĚŝŶ ? ? ?ʅůĞůƵƚŝŽŶďƵĨĨĞƌďǇŝŶĐƵďĂƚŝŽŶĨŽƌ ?
minutes at room temperature, and centrifugation at 6000xg for 1 minute.
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3.9.2 Bisulphite conversion
 ?ʅŐ ŽĨ ŐĞŶŽŵŝĐ E ǁĂƐ ďŝƐƵůƉŚŝƚĞ ĐŽŶǀĞƌƚĞĚ ƵƐŝŶŐ ƚŚĞ ƉŝdĞĐƚ® Bisulfite kit
(Qiagen, UK) in accordance with the manufacturers protocol.
EƐŽůƵƚŝŽŶƵŶĚĞƌǁĞŶƚďŝƐƵůƉŚŝƚĞĐŽŶǀĞƌƐŝŽŶŝŶ ? ? ?ʅůŽĨĂŵĂƐƚĞƌŵŝǆĐŽŶƚĂŝŶŝŶŐ
 ? ?ʅů ďŝƐƵůƉŚŝƚĞ ŵŝǆ ?  ? ?ʅů E ƉƌŽƚĞĐƚ ďƵĨĨĞƌ ĂŶĚ ŶƵĐůĞĂƐĞ ?ĨƌĞĞ ǁĂƚĞƌ ƵƐŝŶŐ Ă
thermal cycler (for cycling conditions see 9.5 of Appendix). When completed,
ďŝƐƵůƉŚŝƚĞĐŽŶǀĞƌƚĞĚEƵŶĚĞƌǁĞŶƚĨƵƌƚŚĞƌĐůĞĂŶƵƉďǇĂĚĚŝƚŝŽŶŽĨ ? ? ?ʅůůŽĂĚŝŶŐ
buffer BL with consequent vortexing and brief centrifugation. The mixture was
transferred to EpiTect spin columns and centrifuged at 20000xg for 1 minute. Then,
ƚŚĞƐĂŵƉůĞƐǁĞƌĞǁĂƐŚĞĚǁŝƚŚ ? ? ?ʅůǁĂƐŚďƵĨĨĞƌtĂŶĚĐĞŶƚƌŝĨƵŐĞĚĂƚ  ? ? ? ? ?ǆŐ
ĨŽƌ  ? ŵŝŶƵƚĞ ?  ? ? ?ʅů ĚĞƐƵůĨŽŶĂƚŝŽŶ ďƵĨĨĞƌ  ǁĂƐ ĂĚĚĞ  ƚŽ ĞĂĐŚ ƐƉŝŶ ĐŽůƵŵŶ ĂŶĚ
incubated for 15 minutes at room temperature with subsequent centrifugation at
ŵĂǆŝŵƵŵ ƐƉĞĞĚ ĨŽƌ  ?ŵŝŶƵƚĞ ? E ƐĂŵƉůĞƐ ǁĞƌĞ ǁĂƐŚĞĚ ƚǁŝĐĞ ǁŝƚŚ  ? ? ?ʅů ǁĂƐŚ
buffer BW and centrifuged at the maximum speed for 1 minute. Samples were
ŝŶĐƵďĂƚĞĚŽŶĂŚĞĂƚŝŶŐďůŽĐŬĂƚ  ? ? ?ĨŽƌ  ?ŵŝŶƵƚĞƐ ?&ŝŶĂůůǇ ?  ? ?ʅůĞůƵƚŝŽŶďƵĨĨĞƌ
was dispensed into the center of each column, and purified DNA samples were
centrifuged at 15000xg for 1 minute.
3.9.3 PCR of bisulphite converted DNA
Eluted and purified DNA was subjected to PCR (Bio-Rad, PTC 100, UK) to amplify
regions of interest within the CXCL8 promoter using primers designed by the
WǇƌŽDĂƌŬ ĂƐƐĂǇ ĚĞƐŝŐŶ ƐŽĨƚǁĂƌĞ ?EƚĞŵƉůĂƚĞƐ ǁĞƌĞĂŵƉůŝĨŝĞĚ ŝŶ  ? ?ʅů ƌĞĂĐƚŝŽŶƐ
containing 1x CoralLoad PCR buffer, 200µM of dNTPs, 0.2µM of primer A and
primer B, 2.5 units/reaction of HotStarTaq Plus DNA polymerase, and nuclease-free
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ǁĂƚĞƌ ?ĨŽƌĐǇĐůŝŶŐĐŽŶĚŝƚŝŽŶƐƐĞĞ ? ? ?ŽĨƉƉĞŶĚŝǆ Z ?KŶĐĞĂĐĐŽŵƉůŝƐŚĞĚ ? ? ?ʅůŽĨWZ
products were run on 2% agarose gel at 100V for 30 minutes using Bio-Rad
PowerPac 300 supply (Bio-Rad, UK). Presence of a single strong band at the relevant
size was considered as successful, and samples underwent further pyrosequencing.
3.9.4 Pyrosequencing
5-20µl of biotinylated PCR products were immobilised on streptavidin-coated
sepharose beads in a master mix containing 1µl agarose beads, 40µl binding buffer
and nuclease-free water with total volume of 80µl. The reactions containing PCR
products were dispersed into PCR strips, sealed and agitated constantly for at least
5-10 minutes at 1400rpm using a thermo-shaker (Grant-bio PCMT, UK). Primers
used for sequencing were designed by PyroMark assay design software (for primer
sequences see 9.5 of Appendix). 25µl 0.3µM primers diluted in annealing buffer
were added to required wells of a PyroMark Q24 plate.
Immediately after immobilisation, the PCR and the PyroMark Q24 plates were
placed on the PyroMark Q24 work station. Vacuum was applied and filters were
lowered into the PCR plate for 15 seconds to capture the beads containing
immobilised template. The filter probes with samples were washed in 50mL of 70%
ethanol for 5 seconds, then in 40mL of denaturation solution for 5 seconds, and
finally in 50mL of 1x wash buffer for 10 seconds. Then, beads were released in the
PyroMark Q24 plate containing sequencing primers, the filter probes were washed
in 50mL of nuclease-free water for 10 seconds twice and left to be drained of the
residual liquid. Subsequently the PyroMark Q24 plate was heated at 80°C for 2
minutes, and allowed to cool for at least 5 minutes before being processed. A
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PyroMark Q24 cartridge was filled with enzyme and substrate mixtures and dNTPs;
required volumes as well as a run design were calculated using PyroMark Q24 2.0.6
software. Data were expressed as a percentage of CpG sites methylated in the
CXCL8 promoter region.
3.10 Statistics
The data were presented as mean ± SEM (standard error of the mean). Analysis for
statistical significance was performed using one-way ANOVA and unpaired
Students t-test and GraphPad Prism software versions 5.0 and 6.0. A p value <0.05
was considered as statistically significant.
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4 DIFFERENCES IN EXPRESSION AND PRODUCTION OF CXCL8
IN CF AND NON-CF AIRWAY EPITHELIAL CELLS
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4.1 Introduction
CF is characterised by severe inflammation affecting the lungs from infancy
(Armstrong et al., 2005, Nixon et al., 2002). Several studies have shown that the
CFTR defect results in bacterial overload and enhanced inflammation characterised
by a continuous influx of immunocompetent cells and altered expression of pro-
inflammatory mediators in the airways (Elizur et al., 2008, Cloutier et al., 2009).
Although progress has been made in understanding how the basic defect in CF
leads to the lung pathology, there are still many unanswered questions.
The bronchoalveolar lavage (BAL) fluid of CF patients contains increased quantities
ŽĨƉƌŽ ?ŝŶĨůĂŵŵĂƚŽƌǇŵĞĚŝĂƚŽƌƐƐƵĐŚĂƐy> ? ?/> ? ? ?/>   ?ĂŶĚdE& ?ɲŝŶĞĂƌůǇŝŶĨĂŶĐǇ
prior to any symptoms of altered lung function and/or signs of bacterial presence
(Ranganathan et al., 2011, Stecenko et al., 2001). Furthermore, studies using animal
models have showed that the BAL fluid of CFTR-deficient mice contains increased
levels of inflammatory mediators which correlate with higher mortality rates
compared to control mice (Heeckeren et al., 1997).
CXCL8 is a powerful neutrophil chemoattractant which coordinates the
inflammatory response in CF airways. It is produced by several cell types including
bronchial epithelial cells (Strieter, 2002). While little CXCL8 is expressed basally, it is
induced by a range of stimuli including pro-inflammatory mediators such as IL-1ß
(Bonfield et al., 1995, Cao et al., 2005). The molecular mechanisms responsible for
the increased CXCL8 expression in CFTR-deficient cells are still not fully understood.
In this chapter, we performed largely confirmatory experiments to verify that IL-1ß
would enhance CXCL8 release via an increase in CXCL8 mRNA levels in two different
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CF cell lines. This was a necessary prelude to performing mechanistic studies in later
chapters.
4.2 Aims
The aims of this chapter were to determine:
 whether CXCL8 secretion is increased in two different CFTR-deficient cell
lines compared to normal cells both basally and after stimulation with IL-1ß;
 whether CXCL8 mRNA expression is increased in CFTR-deficient cell lines
compared to normal cells both basally and after stimulation with IL-1ß;
 whether mRNA stability experiments show any evidence of altered post-
transcriptional regulation.
4.3 Methods
4.3.1 Concentration response and time course experiments
To detect the amount of secreted CXCL8, IB3-1 normal, IB3-1 CF, CFBE41o- normal
and CFBE41o- CF cells were cultured until confluent in 24 well plates. 24 hours prior
to each experiment, cells were serum starved in 1mL serum free medium;
subsequently, medium was replaced with fresh medium containing specified
concentrations of IL-1ß. For concentration response experiments supernatants
were collected after 24 hours; for time course experiments stimulated and
unstimulated supernatants were collected at the time points stated. CXCL8 levels
were measured either immediately by ELISA or stored at -80°C until required.
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Concentrations were normalised against the amount of total cellular protein as
described in 3.3 of Chapter 3 Materials and Methods.
4.3.2 CXCL8 mRNA expression
dŽ ŝĚĞŶƚŝĨǇ ƚŚĞ ĞĨĨĞĐƚ ŽĨ /> ? ?ɴ ŽŶ y> ? ĞǆƉƌĞƐƐŝŽŶ ? ĐĞůůƐ ǁĞƌĞ ŐƌŽǁŶ ŝŶ  ? ǁĞůů
plates. Confluent cells were serum starved for 24 hours before the experiments,
ĂŶĚŵĞĚŝĂǁĂƐƌĞƉůĂĐĞĚǁŝƚŚƐĞƌƵŵĨƌĞĞŵĞĚŝĂǁŝƚŚŽƌǁŝƚŚŽƵƚ ?ŶŐ ?ŵ>/> ? ?ɴĨŽƌ ? ?
2, 4, 6, 8, and 24 hours. Total RNA was extracted and stored at 80°C until required.
CXCL8 mRNA was quantified by qPCR as described in 3.4.3 of Chapter 3 Materials
and Methods. Data were normalised to ß2-microglobulin which was used as a
housekeeping gene.
4.3.3 CXCL8 mRNA stability experiments
To determine mRNA stability, confluent and growth arrested cells were incubated
with 5µg/mL of transcription inhibitor Actinomycin D for 0, 1, 2, 4, 8, and 24 hours.
Total RNA was collected at each time point, extracted and quantified for CXCL8
mRNA by qPCR as described in 3.4.3 of Chapter 3 Materials and Methods. Data
were normalised to ß2-microglobulin used as a housekeeping gene.
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4.4 Results
4.4.1 IL-1ß stimulates increased CXCL8 protein production from CF
airway epithelial cells
We determined the ability of normal and CF airway epithelial cells to express CXCL8
ĂŶĚƚŚĞĞĨĨĞĐƚŽĨ/> ? ?ƘŽŶy> ?ƐĞĐƌĞƚŝŽŶ ?/> ? ?ɴǁĂƐĐŚŽƐĞŶĂƐĂƐƚŝŵƵůƵƐĚƵĞƚŽŝƚƐ
potent pro-inflammatory properties and implications in the pathophysiology of CF.
All four (two normal and two CF) cell lines were stimulated with IL-1ß at
concentrations of 0.1, 1, 2, 5, and 10ng/mL for 24 hours. Basal CXCL8 expression
was observed in all experiments, and stimulation with IL-1ß significantly increased
CXCL8 expression at the concentration 0.1ng/mL and above (Figure 4-1).
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Figure 4-1. Concentration response of IL-1ß on CXCL8 expression from normal and CF airway epithelial cells.
CFBE41o- normal and CFBE41o- CF (A) and IB3-1 normal and IB3-1 CF (B) cell lines, confluent and growth-
arrested 24 hours prior to an experiment, were incubated with increasing concentrations of IL-1ß for 24 hours.
CXCL8 protein levels were measured by ELISA, and values normalised to total amount of cellular protein. Each
bar represents means ± SEM from triplicate determinants of at least 3 independent experiments. Student t-test
was used for the analysis, *
, #
p value <0.05, **
, ##
p<0.01, ***
, ###
p<0.001 and ****p<0.0001 (
*
indicates the
difference between unstimulated and IL-1ß-induced samples within the same cell line,
#
is the difference
between normal and CF cells).
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Following the concentration response experiments, time course experiments were
performed to determine the optimal time point for IL-1ß-induced CXCL8
production. 1ng/mL IL-1ß induced CXCL8 expression in a time-dependent manner
with the greatest increase at 24h (Figure 4-2).
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Figure 4-2. Time course of IL-1ß-induced CXCL8 expression in normal and CF airway epithelial cells. CFBE41o-
normal and CFBE41o- CF (A) and IB3-1 normal and IB3-1 CF (B) cell lines, confluent and growth-arrested 24
hours prior an experiment, were incubated with 1ng/mL of IL-1ß over 24 hours. CXCL8 protein levels were
measured by ELISA, and values normalised to total amount of cellular protein. Each bar represents means ±
SEM from triplicate determinants of at least 3 independent experiments. Student t-test was used for the
analysis,
#,+
p value <0.05, **
,##
p<0.01,
###,+++
p<0.001 and ****
,####,++++
p<0.0001 (
*
indicates the difference
between unstimulated and IL-1ß-induced samples within the same cell line,
#
is the difference between
unstimulated normal and CF cells,
+
is the difference between IL-1ß-induced normal and CF cells).
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y> ?ǁĂƐĐŽŶƐƚŝƚƵƚŝǀĞůǇĞǆƉƌĞƐƐĞĚŝŶďŽƚŚŶŽƌŵĂůĂŝƌǁĂǇĞƉŝƚŚĞůŝĂůĐĞůůůŝŶĞƐ ?/> ? ?ɴ
stimulation resulted in an induction of CXCL8 secretion in a time and concentration
dependent manner. Both CF cell lines produced statistically significantly higher
basal levels of CXCL8 (p<0.05): a fourfold increase in CFBE41o- CF and seven fold
increase in IB3-1 CF cells compared to the corresponding normal cells (Figure 4-3).
Likewise, IL-1ß stimulation resulted in greater CXCL8 production in CFTR-deficient
than normal cell lines (six fold increase in CFBE41o- CF versus seven fold increase in
IB3-1 CF cells) in comparison to the analogous normal cells (p<0.05) (Figure 4-3).
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A
B
&ŝŐƵƌĞ  ? ? ? ? /> ? ?ɴ ?ŝŶĚƵĐĞĚ y> ? ƐĞĐƌĞƚŝŽŶ ŝŶ ŶŽƌŵĂů ĂŶĚ & ĂŝƌǁĂǇ ĞƉŝƚŚĞůŝĂů ĐĞůůƐ ?CFBE41o- normal and
CFBE41o- CF (A) and IB3-1 normal and IB3-1 CF (B) cell lines, confluent and growth-arrested 24 hours prior an
experiment, were incubated with 1ng/mL of IL-1ß for 24 hours. CXCL8 protein levels were measured by ELISA,
and values normalised to total amount of cellular protein. Each bar represents means ± SEM from triplicate
determinants of at least 3 independent experiments. Data were analysed using Student t-test, *p value <0.05,
**p<0.01, ***p<0.001 were considered as significant (
*
indicates the difference between normal and CF cells).
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4.4.2 IL-1ß induces increased CXCL8 mRNA expression in CF airway
epithelial cells
To identify the effects of IL-1ß on CXCL8 mRNA expression in normal and CF airway
epithelial cells, time course experiments were carried out. Total RNA was collected
at 0, 2, 4, 6, 8, and 24 hours from cells treated with and without 1ng/mL IL-1ß and
then reverse transcribed. qPCR was performed on the resulting cDNA.
Representative graphs are shown due to variability in the relative expression levels
across individual experiments (Figure 4-4).
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B
&ŝŐƵƌĞ  ? ? ? ?dŚĞĞĨĨĞĐƚŽĨ /> ? ?ɴŽŶy> ?ŵZEĞǆƉƌĞƐƐŝŽŶ ?CFBE41o- normal and CFBE41o- CF (A) and IB3-1
normal and IB3-1 CF (B) cell lines were growth arrested for 24 hours and incubated in media with or without
1ng/mL IL-1ß for the stated times. Isolated total RNA was reverse transcribed and resulting cDNA was analysed
by qPCR; the data were normalised to ß2-microglobulin which was used as a housekeeping gene. The graphs
shown are the representative of analogous results obtained in three independent experiments.
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EŽƌŵĂů ĐĞůůƐ ƐŚŽǁĞĚ ĂŶ ŝŶĐƌĞĂƐĞ ŝŶ ƚŚĞ ŵZE ůĞǀĞůƐ ĂĨƚĞƌ ƐƚŝŵƵůĂƚŝŽŶ ǁŝƚŚ /> ? ?ɴ ?
Both CFBE41o- CF and IB3-1 CF cell lines had higher basal levels of CXCL8 mRNA in
comparison to corresponding normal cells: nearly five fold increase in both CF cell
lines compared to normal cells. IL-1ß stimulation increased CXCL8 mRNA expression
ŝŶ ďŽƚŚ & ĐĞůů ůŝŶĞƐ ? ŽƚŚ & ĐĞůů ůŝŶĞƐ ĞǆƉƌĞƐƐĞĚ ŚŝŐŚĞƌ /> ? ?ɴ ?ƐƚŝŵƵůĂƚĞĚ ůĞǀĞůƐ
compared to the matched controls: 400 fold increase in CFBE41o- CF versus 200
fold increase in IB3-1 CF cell lines (Figure 4-5).
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A
B
&ŝŐƵƌĞ ? ? ? ?ŽŵƉĂƌŝƐŽŶŽĨƚŚĞĞĨĨĞĐƚŽĨ/> ? ?ɴŽŶy> ?ŵZEĞǆƉƌĞƐƐŝŽŶŝŶŶŽƌŵĂůĂŶĚ&ĂŝƌǁĂǇĞƉŝƚŚĞůŝĂů
cells. CFBE41o- normal and CFBE41o- CF (A) and IB3-1 normal and IB3-1 CF (B) cell lines were growth arrested
for 24 hours and incubated with 1ng/mL IL-1ß for 2 hours. Isolated total RNA was reverse transcribed and
quantified by qPCR; the data were normalised to ß2-microglobulin which used as a housekeeping gene. The
graphs shown are the representative of comparable results obtained in three independent experiments.
Overall, the data demonstrated that IL-1ß-induced CXCL8 mRNA expression with a
peak at 2 hours followed by a decline (Figure 4-4). The 2 hour time point was,
therefore, chosen for future experiments (Figure 4-5).
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4.4.3 The effect of transcription inhibitor Actinomycin D on basal
CXCL8 mRNA expression
Experiments using a trancriptional inhibitor Actinomycin D were performed to
assess possible alterations of CXCL8 mRNA stability in CF cells. All four cell lines
were grown to confluence and serum starved 24 hours before experiments. Cells
were incubated with 5µg/mL Actinomycin D for 0, 1, 2, 4, 8 and 24 hours, and the
extracted mRNA underwent qPCR analysis. We chose to analyse mRNA breakdown
levels under basal conditions as large basal differences in CXCL8 protein production
were seen between CF and normal cells. The four fold difference between normal
ĂŶĚ & ĐĞůůƐ ŽďƐĞƌǀĞĚ ďĂƐĂůůǇ ǁĂƐ ŶŽƚ ŝŶĐƌĞĂƐĞĚ ĨƵƌƚŚĞƌ ďǇ /> ? ?ɴ ƐƵŐŐĞƐƚŝŶŐ ƚŚĂƚ
basal changes in CXCL8 production may be driving the induced release.
There was no difference in the rate of decay in mRNA levels between CF and
normal cell lines suggesting that greater mRNA stability was not responsible for the
increase in CXCL8 in CF cells (Figure 4-6). The differences in the CXCL8 expression
levels are, therefore, more likely to be due to altered transcriptional regulation and
this is addressed in the next chapter.
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Figure 4-6. mRNA stability in normal and CF airway epithelial cells. Confluent and growth arrested CFBE41o-
normal and CFBE41o- CF (A) and IB3-1 normal and IB3-1 CF (B) cell lines were incubated with 5µg/mL
Actinomycin D for the stated time points. Isolated total RNA was assayed for CXCL8 mRNA via qPCR; the data
were normalised to ß2-microglobulin which was used as a housekeeping gene. Each bar represents mean ± SE of
at least 3 independent experiments.
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4.5 Discussion
The principal findings of the experiments in this chapter are that CFTR-deficient
airway epithelial cells express significantly higher levels of CXCL8 protein and mRNA
transcripts both constitutively and in response to IL-1ß stimulation. We also showed
that IL-1ß induces increased CXCL8 secretion in a concentration- and time-
dependent manner.
The principal aim of this chapter was to measure the production of CXCL8 protein
from normal and CF cells and to determine any differences in the expression. We
showed that CF cells had greater levels of CXCL8 protein as compared to normal
cells under basal conditions, and this was the same in both CF and matched normal
cell lines used. Stimulation with IL-1ß resulted in a significant increase in CXCL8
production in all four cell lines. IL-1ß-induced CXCL8 expression was significantly
higher in CF cells as compared to the corresponding normal cell lines.
We chose to study two published CF and corresponding normal cell lines to
determine whether the difference between normal and CF cells is consistently seen.
The fact that we obtained similar results in both cell lines suggests, that the
difference between normal and CF cells is real. The IB3-1 normal and IB3-1 CF cell
lines were used at different passage numbers (15 and 41 respectively), and we
considered that altered passage number might have affected the results. However,
the CFBE41o- normal and CFBE41o- CF cells were used at a similar passage number
(21 and 22 respectively) and had similar findings to the IB3-1 cells, suggesting that
the difference between normal and CF cells is not an artefact produced by
differences in passage number.
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Our data in airway epithelial cells confirm the findings of other studies conducted in
macrophages derived from CF patients (Khan et al., 1995b, Conese et al., 2009) and
airway epithelial cells (Saadane et al., 2011) showing that CF cells secrete greater
levels of CXCL8 compared to healthy subjects (Khan et al., 1995b, Saadane et al.,
2011). BAL fluid of infants with CF has been reported to have significantly higher
levels of CXCL8 even though culture for common bacterial pathogens is negative
(Khan et al., 1995b, Nixon et al., 2002). Collectively, these observations suggest that
CF cells have altered CXCL8 release as a result of a fundemental abnormality of the
cells themselves rather than as a result of an altered airway environment.
In contrast to our studies, Massengale et al using normal human bronchial (HBE4-
E6/E7-C1) and airway epithelial (CF/T43), CFTR-deficient (CFT1, CFT1-LC3) and
CFTR-corrected (CFT1-LCFSN) cell lines showed lower secretion of CXCL8 protein
from CF cells compared to the control cell lines under basal conditions and
following induction with IL-1ß (Massengale et al., 1999). Differences in the results
between this study and our findings are unclear, but partially reflect differences in
the cell lines used and the lower concentration of IL-1ß used (100pg/mL) versus
1ng/mL used in our study.
Consistent with the protein results we found that CXCL8 mRNA levels were
increased in both CF cell lines compared to the normal cells basally and after
induction with IL-1ß. These findings suggest that overexpression of CXCL8 in CF cells
might be due to upregulated transcription of CXCL8 mRNA or, conversely, a reduced
breakdown of mRNA through an increase in its stability.
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To examine whether changes in mRNA expression were due to altered post-
transcriptional mechanisms, we analysed CXCL8 mRNA stability by performing
experiments using transcriptional inhibitor Actinomycin D. Our results showed no
increase in mRNA stability in CF cells basally, suggesting, that the mechanism of
increased CXCL8 production was probably transcriptional, which we address further
in the next chapter. In retrospect, we should, perhaps, have also studied mRNA
stability after IL-1ß treatment, but our observations of higher basal CXCL8 protein
secretion and mRNA levels, and the similar four fold increase between normal and
CF cells both basally and upon IL-1ß stimulation suggested, that altered basal
expression may be more important. Previous studies on CXCL8 mRNA stability show
conflicting results with a study showing no alteration like ours and another showing
an increase in mRNA stability in CF (Balakathiresan et al., 2009, Bhattacharyya et al.,
2010). Again, the variability may reflect the differences between the cell lines used
in their experiments and ours.
Collectively, our findings suggest that the enhanced CXCL8 production in CF cells is
likely to be due to an increase in mRNA levels possibly reflecting altered
transcriptional regulation. We decided to use IB3-1 normal and IB3-1 CF cells for
further studies due to the stronger signal. In the next chapter, we studied CXCL8
trancription using CXCL8 promoter luciferase reporter assays.
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5 E& ?Ů ?W ? ?E ?WƘdZE^Z/Wd/KE&dKZ^Z
INVOLVED IN CXCL8 EXPRESSION IN CF AIRWAY EPITHELIAL
CELLS
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5.1 Introduction
In the studies in Chapter 4, we showed that CF cells express greater levels of both
CXCL8 protein and mRNA basally and following IL-1ß stimulation as compared to
normal cells. In this chapter we performed mechanistic studies looking at the
potential transcriptional mechanisms involved in CXCL8 upregulation in CF.
Transcriptional regulation of CXCL8 expression is tightly controlled by a range of
transcription factors (TFs) through their coordinated binding to cis-acting DNA
elements in the promoter region. The nucleotide sequence from -1 to -133 within
the 5-flanking region of the CXCL8 gene containing CCAAT/enhancer binding
ƉƌŽƚĞŝŶ  ? ?W Zɴ ? ŶƵĐůĞĂƌ ĨĂĐƚŽƌ  ?E& Z ?Ů ? ĂĐƚŝǀĂƚŽƌ ƉƌŽƚĞŝŶ  ?W Z ? ? ? ĂŶĚ ŽĐƚĂŵĞƌ
(Oct)-1 binding sites is crucial for the transcriptional regulation of the gene
(Mukaida et al., 1994, John et al., 2009) particularly for IL-1ß-induced CXCL8
expression (Mukaida et al., 1990, Carroll et al., 2005). Studies performed in gastric
cancer cells (Yasumoto et al., 1992) and fibrosarcoma cell lines (Mukaida et al.,
 ? ? ? ? Z ŚĂǀĞ ƌĞƉŽƌƚĞĚ ? ƚŚĂƚ ǁŚŝůĞ /> ? ?ɴ Žƌ dE& ?ɲ ?ŝŶĚƵĐĞĚ y> ? ƚƌĂŶƐĐƌŝƉƚŝŽŶ ŝƐ
ŝŶŝƚŝĂůůǇE& ?Ů ?ĚƌŝǀĞŶ ?ƐǇŶĐŚƌŽŶŝƐĞĚďŝŶĚŝŶŐŽĨE& ?Ů W ? ? ?ĂŶĚ ?WƘŝƐƌĞƋƵŝƌĞĚ
for maximum activation of CXCL8 transcription (Verhaeghe et al., 2007b, Li et al.,
2002, Holtmann et al., 1999, Hoffmann et al., 2002).
Although the mechanisms involved in transcriptional activation of CXCL8 in
response to inflammatory stimuli have been well characterised, the mechanisms
regulating basal CXCL8 production have not been studied in as much detail.
Sequence analysis suggested that the presence of the negative regulatory element
 ?EZ ZƉĂƌƚŝĂůůǇŽǀĞƌůĂƉƉŝŶŐǁŝƚŚE& ?ʃƌĞƐƉŽŶƐĞĞůĞŵ ŶƚĂƚƚŚĞy> ?ƉƌŽŵŽƚĞƌŝŶ
ĐŽŵďŝŶĂƚŝŽŶ ǁŝƚŚ E& ?Ů ?ƌĞƉƌĞƐƐŝŶŐ ĨĂĐƚŽƌ  ?EZ& Z ƉƌŽƚĞŝŶ ďŽƵŶĚ ƚŽ ƚŚĞ E& ?Ů ƐŝƚĞ
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results in transcriptional repression of the CXCL8 promoter in unstimulated cells
(Hoffmann et al., 2002, O'Dea and Hoffmann, 2010). Collectively, these findings
suggest that basal CXCL8 transcription is closely controlled via a complex and
multilevel hierarchical system.
The mechanisms implicated in the altered CXCL8 transcription in CF cells have not
ďĞĞŶ ĨƵůůǇ ĐŚĂƌĂĐƚĞƌŝƐĞĚ P ƚŚĞ ĂǀĂŝůĂďůĞ ĞǀŝĚĞŶĐĞ ŝŵƉůŝĐĂƚĞƐ ďŽƚŚ E& ?Ů ĂŶĚ W ? ?
(Hoffmann et al., 2002). In this chapter we characterised the TFs involved in basal
and IL-1ß-induced CXCL8 expression in normal and CF cells to determine if there
were any differences.
5.2 Aims
The aims of this chapter were:
- to determine the TFs involved in CXCL8 transcription in normal and CF
airway epithelial cells basally and after IL-1ß stimulation using CXCL8 promoter
reporter constructs with mutated TF binding sites;
- to characterise IL-1ß-induced activation and binding of TFs to the
corresponding cis-elements in the CXCL8 promoter in normal and CF airway
epithelial cells.
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5.3 Methods
Transient transfections
To identify the TFs involved in CXCL8 expression and determine the effect of IL-1ß
on their activity, dual luciferase reporter assays were performed as described in 3.5
of Chapter 3 Materials and Methods. Normal and CF cells were transiently
transfected with vectors encoding the wild type (wt)CXCL8 promoter (-162/+44),
ƐŝƚĞ ŵƵƚĂƚŝŽŶƐ ŽĨ ŽŶĞ ŽĨ ƚŚĞ ďŝŶĚŝŶŐ ƐŝƚĞƐ  ?E& ?ʃ ?W ? ? ? ĂŶĚ  ?Wɴ Z ǁŝƚŚŝŶ ƚŚĞ
CXCL8 promoter as well as control luciferase reporter pRL-TK. Vectors were a
generous gift of Dr. A. R. Braiser (Department of Medicine, Sealy Center for
Molecular Science, Galveston, TX).
Chromatin immunoprecipitation
To identify the TFs binding to the CXCL8 promoter region, chromatin
immunoprecipitation (ChIP) was performed as described in 3.7 of Chapter 3
Materials and Methods. Binding of TFs was measured in normal and CF cells basally
ĂŶĚĨŽůůŽǁŝŶŐ/> ? ?ɴƐƚŝŵƵůĂƚŝŽŶĨŽƌƵƉƚŽ ?ŚŽƵƌƐ ?
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5.4 Results
5.4.1 /> ? ?ɴ ?ŝŶĚƵĐĞĚ y> ? ƉƌŽŵŽƚĞƌ ĂĐƚŝǀĂƚŝŽŶ ƌĞƋƵŝƌĞƐ  ?WƘ ?
E& ?ŮĂŶĚW ? ?ƚƌĂŶƐĐƌŝƉƚŝŽŶĨĂĐƚŽƌƐ
5.4.1.1 Basal and IL-1ß-induced stimulation of the wild type
CXCL8 promoter
Unstimulated CF cells transfected with wild type (wt)CXCL8 promoter reporter
expressed significantly lower levels (three fold decrease) of luciferase activity
ĐŽŵƉĂƌĞĚ ƚŽ ŶŽƌŵĂů ĐĞůůƐ ? /> ? ?ɴ ƐƚŝŵƵůĂƚŝŽŶ ƌĞƐƵůƚĞĚ ŝŶ Ă ƐŝŐŶŝĨŝĐĂŶƚ ŝŶĐƌĞĂƐĞ ŝŶ
luciferase activity in both normal (eight fold increase) and CF cells (nearly 15 fold
increase) with no significant difference between these two cell lines (Figure 5-1).
Figure 5-1. The effect of IL-1ß on the CXCL8 promoter luciferase reporter activity. IB3-1 normal and IB3-1 CF
cells were growth arrested 16 hours prior to an experiment, were transiently transfected with (wt)CXCL8 firefly
vectors along with pRL-TK renilla luciferase reporter plasmid DNA at 1:2 ratio with LF2000 for 3 hours. This was
ĨŽůůŽǁĞĚďǇŝŶĐƵďĂƚŝŽŶĨŽƌĂŶŽƚŚĞƌ ?ŚŽƵƌƐŝŶƚŚĞƉƌĞƐĞŶĐĞŽƌĂďƐĞŶĐĞŽĨ ?ŶŐ ?ŵ>/> ? ?ɴ ?ĐƚŝǀŝƚŝĞƐŽĨĨŝƌĞĨůǇĂŶĚ
renilla luciferase reporters were measured using an Omega Fluostar luminometer; data were normalised by
dividing firefly readings by renilla expressed as relative luciferase activity (fold change over control). Each
column represents means ± SEM from at least triplicate determinants of at least 3 independent experiments.
Student t-test was used for the analysis; **p value<0.01, ***p<0.001 and ****p<0.0001.
117
5.4.1.2 DƵƚĂƚŝŽŶŽĨƚŚĞE& ?ŮďŝŶĚŝŶŐƐŝƚĞ
DƵƚĂƚŝŽŶ ŽĨ ƚŚĞ E& ?Ů ƐŝƚĞ ƌĞĚƵĐĞĚ ďĂƐĂů ĂŶĚ /> ? ?Ƙ ?ŝŶĚƵĐĞĚ ůƵĐŝĨĞƌĂƐĞ ĂĐƚŝǀŝƚǇ ŝŶ
both normal and CF cell lines compared to (wt)CXCL8 promoter transfections
(Figure 5-2).
&ŝŐƵƌĞ ? ? ? ?dŚĞĞĨĨĞĐƚŽĨ/> ? ?ƘŽŶƚŚĞE& ?ʃŵƵƚĂŶƚy> ?ůƵĐŝĨĞƌĂƐĞƌĞƉŽƌƚĞƌĂĐƚŝǀŝƚǇ ?IB3-1 normal and IB3-1
CF cells were growth arrested 16 hours prior to an experiment, were transiently transfected with a CXCL8
ƉƌŽŵŽƚĞƌ ĨŝƌĞĨůǇ ůƵĐŝĨĞƌĂƐĞ ƌĞƉŽƌƚĞƌ ĐŽŶƚĂŝŶŝŶŐ Ă ŵƵƚĂƚĞĚ E& ?Ů ƐŝƚĞ ĂůŽŶŐ ǁŝƚŚ ƉZ> ?d< ƌĞŶŝůůĂ ůƵĐŝĨĞƌĂƐĞ
reporter plasmid DNA at 1:2 ratio with LF2000 for 3 hours. This was followed by incubation for another 3 hours
ŝŶƚŚĞƉƌĞƐĞŶĐĞŽƌĂďƐĞŶĐĞŽĨ ?ŶŐ ?ŵ>/> ? ?ɴ ?ĐƚŝǀŝƚŝĞƐŽĨĨŝƌĞĨůǇĂŶĚƌĞŶŝůůĂůƵĐŝĨĞƌĂƐĞƌĞƉŽƌƚĞƌƐǁĞƌĞŵĞĂƐƵƌĞĚ
using an Omega Fluostar luminometer; data were normalised by dividing firefly readings by renilla expressed as
relative luciferase activity (fold over control). Each column represents means ± SEM from at least triplicate
determinants of at least 3 independent experiments. Student t-test was used for the analysis; *p value <0.05,
**p<0.01, ***p<0.001 and ****p<0.0001.
5.4.1.3 Mutation of the C/EBPß binding site
DƵƚĂƚŝŽŶŽĨƚŚĞ ?WɴďŝŶĚŝŶŐƐŝƚĞĂůƐŽƌĞĚƵĐĞĚůƵĐŝĨĞƌĂƐĞĂĐƚŝǀŝƚǇŝŶďŽƚŚŶŽƌŵĂů
and CF cells compared to the transfections with (wt)CXCL8 promoter basally and
after IL-1ß stimulation (Figure 5-3).
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Figure 5-3. The effect of IL-1ß on the C/EBPß mutant CXCL8 luciferase reporter activity. IB3-1 normal and IB3-1
CF cells were growth arrested 16 hours prior to an experiment, were transiently transfected with a CXCL8
ƉƌŽŵŽƚĞƌ ĨŝƌĞĨůǇ ůƵĐŝĨĞƌĂƐĞ ƌĞƉŽƌƚĞƌ ĐŽŶƚĂŝŶŝŶŐ Ă ŵƵƚĂƚĞĚ  ?Wɴ ƐŝƚĞ ĂůŽŶŐ ǁŝƚŚ ƉZ> ?d< ƌĞŶŝůůĂ ůƵĐŝĨĞƌĂƐĞ
reporter plasmid DNA at 1:2 ratio with LF2000 for 3 hours. This was followed by incubation for another 3 hours
ŝŶƚŚĞƉƌĞƐĞŶĐĞŽƌĂďƐĞŶĐĞŽĨ ?ŶŐ ?ŵ>/> ? ?ɴ ?ĐƚŝǀŝƚŝĞƐŽĨĨŝƌĞĨůǇĂŶĚƌĞŶŝůůĂůƵĐŝĨĞƌĂƐĞƌĞƉŽƌƚĞƌƐǁĞƌĞŵĞĂƐƵƌĞĚ
using an Omega Fluostar luminometer; data were normalised by dividing firefly readings by renilla expressed as
relative luciferase activity (fold over control). Each column represents means ± SEM from at least triplicate
determinants of at least 3 independent experiments. Student t-test was used for the analysis; *p value <0.05,
**p<0.01, ***p<0.001 and ****p<0.0001.
5.4.1.4 Mutation of the AP-1 binding site
Mutation of the AP-1 binding site reduced luciferase reporter activity in normal and
CF cells under both basal and IL-1ß stimulated conditions (Figure 5-4).
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Figure 5-4. The effect of IL-1ß on the AP-1 mutant CXCL8 luciferase reporter activity. IB3-1 normal and IB3-1
CF cells were growth arrested 16 hours prior to an experiment, were transiently transfected with a CXCL8
promoter firefly luciferase reporter containing a mutated AP-1 site along with pRL-TK renilla luciferase reporter
plasmid DNA at 1:2 ratio with LF2000 for 3 hours. This was followed by incubation for another 3 hours in the
ƉƌĞƐĞŶĐĞŽƌĂďƐĞŶĐĞŽĨ ?ŶŐ ?ŵ>/> ? ?ɴ ?ĐƚŝǀŝƚŝĞƐŽĨĨŝƌĞĨůǇĂŶĚƌĞŶŝůůĂůƵĐŝĨĞƌĂƐĞƌĞƉŽƌƚĞƌƐǁĞƌĞŵĞĂƐƵƌĞĚƵƐŝŶŐ
an Omega Fluostar luminometer; data were normalised by dividing firefly readings by renilla expressed as
relative luciferase activity (fold over control). Each column represents means ± SEM from at least triplicate
determinants of at least 3 independent experiments. Student t-test was used for the analysis; *p value <0.05,
**p<0.01, ***p<0.001 and ****p<0.0001.
ŽůůĞĐƚŝǀĞůǇƚŚĞƐĞƐƚƵĚŝĞƐƐƵŐŐĞƐƚƚŚĂƚĂůůƚŚƌĞĞd&ƐĂƌĞŝŶǀŽůǀĞĚŝŶďĂƐĂůĂŶĚ/> ? ?ɴ ?
induced release of CXCL8 in both normal and CF cells. The fact, that CF cells did not
show an increase in the (wt)CXCL8 promoter luciferase activity compared to normal
cells was surprising considering the results of the previous chapter showing greater
levels of CXCL8 protein production and mRNA expression in CF cells as compared to
the normal cells. However, the reporter assays do not measure binding of a TF to a
gene in the chromatin environment - a key regulator of TF access. Thus,
hypothesising, that abnormal CXCL8 production could be due to increased binding
of TFs to the CXCL8 promoter as a result of an altered chromatin environment
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facilitating TF binding, we went on to perform ChIP which have the advantage of
studying TF binding in the chromatin environment.
5.4.2 /ŶĐƌĞĂƐĞĚ ďĂƐĂů ďŝŶĚŝŶŐ ŽĨ E& ?ʃ Ɖ ? ? ƚƌĂŶƐĐƌŝƉƚŝŽŶĨĂĐƚŽƌ ƚŽ
the CXCL8 promoter
& ĐĞůůƐ ĚŝƐƉůĂǇĞĚ ŐƌĞĂƚĞƌ ůĞǀĞůƐ ŽĨ E& ?Ů Ɖ ? ? ĂƐƐŽĐŝĂƚĞĚ ďĂƐĂůůǇ ǁŝƚŚ ƚŚĞ y> ?
promoter compared to normal cells. Whilst IL-1ß stimulation resulted in an increase
ŝŶE& ?ŮƉ ? ?ďŝŶĚŝŶŐŝŶŶŽƌŵĂůĐĞůůƐ ?&ĐĞůůƐĚŝĚŶŽƚƐŚŽǁĂŶǇĨƵƌƚŚĞƌƌŝƐĞŝŶE& ?Ů
Ɖ ? ?ďŝŶĚŝŶŐůĞǀĞůƐŽǀĞƌƚŚĞĂůƌĞĂĚǇĞůĞǀĂƚĞĚďĂƐĂůĞǀĞůƐ ?,ŽǁĞǀĞƌ ?ůĞǀĞůƐŽĨE& ?Ů
p65 association with the CXCL8 promoter were greater in CF compared to normal
cells both basally and following IL-1ß stimulation (Figure 5-5).
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A
B
&ŝŐƵƌĞ ? ? ? ?E& ?ŮƉ ? ?ďŝŶĚŝŶŐƚŽƚŚĞŚƵŵĂŶy> ?ƉƌŽŵŽƚĞƌ ?Confluent and growth arrested IB3-1 normal and
IB3-1 CF cells were incubated without (A) or with 1ng/mL IL-1ß (B) for 0, 0.5, 1 and 2 hours. Chromatin,
ĞǆƚƌĂĐƚĞĚĨƌŽŵĐĞůůƐ ?ǁĂƐƐŚĞĂƌĞĚĂŶĚŝŶĐƵďĂƚĞĚǁŝƚŚĂŶƚŝ ?E& ?ŮƉ ? ?ĂŶƚŝďŽĚǇ ?ƚŚĞďŝŶĚŝŶŐůĞǀĞůƐǁĞƌĞĂƐƐĞƐƐĞĚ
through the analysis of isolated DNA by qPCR using CXCL8 promoter-specific primers. DNA, resulting from
chromatin immunoprecipitation using normal rabbit IgG, was used as a negative control. Data are expressed as
fold change relative to the 0h mean of normal cells first normalised to Input DNA. Each column represents
means ± SEM from at least 3 independent experiments.
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/ŶƐƵŵŵĂƌǇ ?ƚŚĞŐƌĞĂƚĞƌďŝŶĚŝŶŐŽĨE& ?ʃƉ ? ?ƚŽƚŚĞy> ?ƉƌŽŵŽƚĞƌƵŶĚĞƌďĂƐĂů
conditions might in part explain the increased basal CXCL8 transcription in CF cells.
There was no difference in basal C/EBPß binding to the CXCL8 promoter between
normal and CF cells. IL-1ß caused a rapid increase in C/EBPß binding greatest at 0.5
hour (four fold increase) that was not different between CF and normal cells (Figure
5-6).
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A
B
Figure 5-6. C/EBPß binding to the human CXCL8 promoter. IB3-1 normal and IB3-1 CF cells, confluent and
growth arrested, were incubated without (A) or with 1ng/mL IL-1ß (B) for 0, 0.5, 1 and 2 hours. Extracted
ĐŚƌŽŵĂƚŝŶǁĂƐƐŚĞĂƌĞĚĂŶĚŝŵŵƵŶŽƉƌĞĐŝƉŝƚĂƚĞĚǁŝƚŚĂŶƚŝďŽĚǇĂŐĂŝŶƐƚ ?Wɴ ?ďŝŶĚŝŶŐŽĨ ?WɴƚƌĂŶƐĐƌŝƉƚ ŽŶ
factor was assessed through the analysis of isolated DNA by qPCR using CXCL8 promoter-specific primers.
Samples, immunoprecipitated with normal rabbit IgG, were used as a negative control. Data are expressed as
fold change relative to the 0h mean of normal cells first normalised to Input DNA. Each column represents
means ± SEM from at least 3 independent experiments.
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Finally, ChIP analysis of AP-1 binding to the CXCL8 promoter was performed.
Unfortunately, numerous attempts to measure binding of AP-1 to the CXCL8
promoter were unsuccessful due to technical difficulties in obtaining a single
product during qPCR.
5.5 Discussion
dŚĞŬĞǇĨŝŶĚŝŶŐƐŝŶƚŚŝƐĐŚĂƉƚĞƌĂƌĞƚŚĂƚE& ?Ů ? ?WƘĂŶĚW ? ?d&ƐĂƌĞŝŶǀŽůǀĞĚŝŶ
basal and IL-1ß-induced CXCL8 expression in both normal and CF cells and that
ďĂƐĂůďŝŶĚŝŶŐŽĨE& ?ŮƚŽƚŚĞy> ?ƌĞƉŽƌƚĞƌǁĂƐŝŶĐƌĞĂƐĞĚŝŶ&ĐĞůůƐ ?
Our promoter mutation transfection studies showed that under both basal and IL-
1ß stimulated conditions all three TFs were required for optimum CXCL8 expression
both in normal and CF cells. In contrast to the increased CXCL8 protein and mRNA
levels in CF cells described in the previous chapter, there was no increase in
(wt)CXCL8 promoter luciferase activity in CF versus normal cells. The studies
showing involvement of all three TFs in CXCL8 transcription are consistent with
other studies in the literature performed in several cell types and suggesting, that
all three TFs are necessary for the full activation of the CXCL8 promoter both basally
and following IL-1ß stimulation (John et al., 2009, Holtmann et al., 1999, Cloutier et
al., 2009).
A disadvantage of transient transfections is that the plasmid is not incorporated
into the genome and, therefore, epigenetic chromatin-based regulatory
mechanisms do not influence plasmid expression. In previous studies carried out in
our department in idiopathic pulmonary fibrosis (IPF) and bronchial asthma (Clarke
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et al., 2010, John et al., 2010), our group showed that whilst promoter mutation
experiments are effective for identifying the TFs involved in a target gene
regulation, they can give misleading results when compared with ChIP assays in
terms of alterations in disease-related binding of TFs.
In view of the discrepancy in our transfection study results, we performed ChIP
assays to look at binding of TFs to the CXCL8 promoter in the chromatin
environment. The latter is influenced by histone modifications and/or DNA
methylation which alter DNA structure and TFs access. In contrast to our
ƚƌĂŶƐĨĞĐƚŝŽŶƐƚƵĚŝĞƐ ?Ś/WĂŶĂůǇƐŝƐƐŚŽǁĞĚŚŝŐŚĞƌE& ?ŮƉ ? ?ďŝŶĚŝŶŐďĂƐĂůůǇďƵƚŶŽ
difference in C/EBPß binding to the CXCL8 promoter in unstimulated CF cells
ĐŽŵƉĂƌĞĚƚŽŶŽƌŵĂůĐĞůůƐ ?dŚŝƐƐƵŐŐĞƐƚƐƚŚĂƚŐƌĞĂƚĞƌE& ?ŮƉ ? ?ĂƐƐŽĐŝĂƚŝŽŶǁŝƚŚƚŚĞ
CXCL8 promoter in CF cells may be responsible for the increased CXCL8 production
in CF under basal conditions.
KƵƌ ĚĂƚĂ ĂƌĞ ĐŽŶƐŝƐƚĞŶƚ ǁŝƚŚ ƐƚƵĚŝĞƐ ƌĞƉŽƌƚŝŶŐ ŐƌĞĂƚĞƌ ůĞǀĞůƐ ŽĨ E& ?Ů ? ďƵƚ ŶŽƚ
C/EBPß in the nucleus of unstimulated CF human bronchial epithelial cells as
compared to normal cell lines (DiMango et al., 1998, Chan et al., 2006, Joseph et al.,
 ? ? ? ? Z ? KƚŚĞƌ ƐƚƵĚŝĞƐ ŚĂǀĞ ƌĞƉŽƌƚĞĚ ŝŶĐƌĞĂƐĞĚ ďĂƐĂůE& ?ʃ ĂĐƚŝǀŝƚǇ ĂŶĚ ŚŝŐŚĞƌ
nuclear localisation in CF nasal epithelial cells as compared to non-CF cells
(Carrabino et al., 2006, Raia V et al., 2005). However, we did not find any increase in
ƚŚĞ ďŝŶĚŝŶŐ ůĞǀĞůƐ ŽĨ E& ?ʃ ŝŶ & ĐĞůůƐ ĂĨƚĞƌ ŝŶĚƵĐƚŝŽŶ ǁŝƚŚ /> ? ?Ƙ ŝŶ ĐŽŶƚƌĂƐƚ ƚŽ
ƐƚƵĚŝĞƐ ƚŚĂƚ ŚĂǀĞ ŝĚĞŶƚŝĨŝĞĚ ŐƌĞĂƚĞƌ ůĞǀĞůƐ ŽĨ E& ?ʃ ŝŶ ƚŚĞ ŶƵĐůĞƵƐ ĨŽůůŽǁŝŶŐ
ƐƚŝŵƵůĂƚŝŽŶ ǁŝƚŚ /> ? ?ɴ Žƌ WK ? ŽĨP. aeruginosa in CF cell lines (DiMango et al.,
1998, Joseph et al., 2005). The difference in findings could be a result of failure of
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different cell lines to respond to the cytokine challenge due to impairment in the
ďĂƐĂůŶƵĐůĞĂƌE& ?ʃĂĐƚŝǀŝƚǇĂŶĚ ?ŽƌĚĞƉůĞƚĞĚĂďŝůŝƚǇŽĨĐĞůůƐƚŽƐǇŶƚŚĞƚŝƐĞy> ? ?
/Ŷ ĐŽŶƚƌĂƐƚ ƚŽ E& ?Ů ? ƚŚĞƌĞ ǁĂƐ ŶŽ ĚŝĨĨĞƌĞŶĐĞ ŝŶ ďŝŶĚŝŶŐ ŽĨ  ?Wɴ ƚŽ ƚŚĞ y> ?
ƉƌŽŵŽƚĞƌ ŝŶ & ĐĞůůƐ ĐŽŵƉĂƌĞĚ ƚŽ ŶŽƌŵĂů ĐĞůůƐ ƵŶĚĞƌ ďĂƐĂů ĂŶĚ ?Žƌ /> ? ?ɴ ?ŝŶĚƵĐĞĚ
ĐŽŶĚŝƚŝŽŶƐ ? KƚŚĞƌ ƐƚƵĚŝĞƐ ŝŶ ŚƵŵĂŶ ďƌŽŶĐŚŝĂů ĞƉŝƚŚĞůŝĂů ĐĞůůƐ ƐŚŽǁĞĚ ƚŚĂƚ  ?Wɴ
was not involved in basal regulation of CXCL8 transcription, yet, stimulation with IL-
 ?ɴ ?dE& ?ɲĂŶĚ ?ŽƌP. aeruginosaƌĞƐƵůƚĞĚŝŶƚŚĞĂĐƚŝǀĂƚŝŽŶŽĨ ?Wɴ ?ŝDĂŶŐŽĞƚĂů ? ?
1998, Hoffmann et al., 2002) suggesting an important role of this TF in CXCL8
regulation. No other studies have investigated the role of C/EBPß in the regulation
of CXCL8 in CF.
We were unable to reliably detect AP-1 binding to the CXCL8 promoter and so
cannot comment as to whether it is abnormal in CF cells. The inability to identify a
single product during qPCR might be due to a difference in the primers covering
different regions of the CXCL8 promoter. In future, it would be interesting to carry
out a more detailed ChIP analysis of AP-1 binding to identify the presence of this
protein at the CXCL8 promoter, its role in the enhanced CXCL8 transcription and
the interaction between AP-1 and other proteins in CF airway epithelial cells.
In summary, our data suggest that CF cells have increased CXCL8 protein and mRNA
ůĞǀĞůƐĚƵĞƚŽĞŶŚĂŶĐĞĚy> ?ƚƌĂŶƐĐƌŝƉƚŝŽŶŝŶǀŽůǀŝŶŐŝŶĐƌĞĂƐĞĚďŝŶĚŝŶŐŽĨE& ?ʃ ?Ɛ
the enhanced binding of this TF was observed in ChIP experiments which have the
contribution of a chromatin environment, we hypothesised that other chromatin-
based mechanisms such as histone acetylation and/or DNA methylation might
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potentially play a key role in CXCL8 expression in CF. This is addressed in the next
chapter.
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6 E& ?ʃ ?,/^dKEdz>d/KE ?Dd,z>d/KEEE
METHYLATION AT THE CXCL8 PROMOTER IN CF AIRWAY
EPITHELIAL CELLS
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6.1 Introduction
The studies in chapter 2 and 3 suggest that enhanced CXCL8 expression in CF cells is
ĐĂƵƐĞĚďǇĂďŶŽƌŵĂůƚƌĂŶƐĐƌŝƉƚŝŽŶƚŚƌŽƵŐŚŝŶĐƌĞĂƐĞĚďŝŶĚŝŶŐŽĨE& ?ŮǁŚŝĐŚŝƐŽŶůǇ
observed in the chromatin environment. The possible mechanisms responsible for
the chromatin-dependent increase in CXCL8 transcription including altered histone
modifications and/or DNA methylation have not been identified and are the focus
of this chapter.
Gene expression is influenced by several covalent modifications of histone proteins
or DNA itself. Acetylation, methylation, phosphorylation, and ubiquitination of
lysine (K) residues and/or core domains of histones can alter chromatin structure
and/or binding of non-histone proteins to chromatin. Histone methylation can be a
marker of both active and inactive chromatin (Plath et al., 2003, Lachner and
Jenuwein, 2002). Di- and trimethylation of histone H3 at K4 is generally associated
with transcriptional activation, whereas di- and trimethylation of histone H3 at K9
and K27 as well as trimethylation of histone H4 at K20 are linked to transcriptional
repression (Rice et al., 2003).
Another histone modification, histone acetylation, is a hallmark of a
transcriptionally active chromatin. Studies in different mammalian cells have
demonstrated that actively transcribed chromatin has more acetylated sites on
histones in comparison to inactive chromatin that is mostly hypoacetylated (Barnes
et al., 2005, Tsaprouni et al., 2011). Studies in yeast and mammalian cells have
demonstrated that K9 and K14 acetylation on histone H3 as well as pan-acetylation
of histone H4 are conserved hallmarks of transcriptionally active promoters
(Pokholok et al., 2005, Bernstein et al., 2005).
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Increased histone acetylation enables access of transcription factors (TFs) to the
DNA facilitating active transcription through structural changes in the nucleosomes
(Lee et al., 1993, Adcock et al., 2006). Acetylation of K residues on histones directly
influences gene transcription levels (Mizuguchi et al., 2001) serving as binding sites
for special domains and co-activators through creation of a platform recognised by
other proteins and, consequently, facilitating downstream signalling (Strahl and
Allis, 2000). Histones are acetylated by histone acetyltransferases (HATs) and
deacetylated by histone deacetylases (HDACs). HATs can also directly acetylate TFs
ƚŽ ŝŶĨůƵĞŶĐĞ ƚĂƌŐĞƚ ŐĞŶĞ ƚƌĂŶƐĐƌŝƉƚŝŽŶ ? dŚĞƌĞ ŝƐ ƐŽŵĞ ĞǀŝĚĞŶĐĞ ƚŚĂƚ Ɖ ? ? E& ?ʃ
acetylation can regulate CXCL8 expression. Cigarette smoke exposure in
ŵĂĐƌŽƉŚĂŐĞƐ ĂŶĚ ƌĂƚ ůƵŶŐƐ ƌĞƐƵůƚƐ ŝŶ Ɖ ? ? E& ?ʃ ĂĐĞƚǇůĂƚŝŽŶ ĂŶĚ ĞŶŚĂŶĐĞĚ y> ?
ƚƌĂŶƐĐƌŝƉƚŝŽŶ  ?zĂŶŐ Ğƚ Ăů ? ?  ? ? ? ? Z ? ^ƚƵĚŝĞƐ ŚĂǀĞ ƐŚŽǁŶ ƚ Ăƚ E& ?Ů ?ŵĞĚŝĂƚĞĚ y> ?
release is influenced by reversible acetylation of p65 at K310 (Chen et al., 2002,
Yeung et al., 2004, Huang et al., 2009). Finally, DNA methylation also affects gene
transcription. Studies in human cancer cells have shown that the presence of
unmethylated CGI regions (CpG islands) initiates active gene transcription, while
methylation of the same sites represses promoter activity (Herman and Baylin,
2003).
DNA methylation and histone modifications are tightly controlled events in
eukaryotes and often interlinked (Cheng and Blumenthal, 2010). The potential
mechanism involves binding of methyl-CpG-binding domain proteins to the
methylated CpG islands at the target gene promoter with further recruitment of
HDACs resulting in histone deacetylation and consequently leading to nucleosome
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condensation and structural changes followed by inhibition of gene expression
(Urnov and Wolffe, 2001).
There are few studies looking at the epigenetic modifications affecting the CXCL8
promoter in CF cells. A recent study has reported that increased acetylation of
histone H4, caused by existing oxidative stress in CF, might be responsible for the
dysregulated transcription of several inflammatory genes such as CXCL8, IL-6,
CXCL1, CXCL2, and CXCL3 in airway epithelial cells (Bartling, 2009), although the
exact mechanism was not probed in depth. To the best of our knowledge, there are
no studies addressing the effect of histone methylation on CXCL8 expression in CF.
Furthermore, there are no studies exploring the role of DNA methylation in the
increased expression of CXCL8 in airway cells in CF, although a study in buccal
epithelial cells has shown hypermethylation of the CXCL8 gene promoter in CF
patients with periodontitis (Andia et al., 2010).
In summary, histone modifications, TF acetylation and DNA methylation can all
modify gene transcription. In this chapter we studied whether any of these
alterations are responsible for the increased CXCL8 transcription in CF epithelial
cells.
6.2 Aims
The aims of this chapter were:
 to measure the H3K4 methylation status of the CXCL8 promoter in normal
ĂŶĚ&ĂŝƌǁĂǇĞƉŝƚŚĞůŝĂůĐĞůůƐďĂƐĂůůǇĂŶĚĂĨƚĞƌ/> ? ?ɴƐƚŝŵƵůĂƚŝŽŶ ?
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 to measure histone acetylation levels at the CXCL8 promoter in normal and
&ĂŝƌǁĂǇĞƉŝƚŚĞůŝĂůĐĞůůƐďĂƐĂůůǇĂŶĚĂĨƚĞƌ/> ? ?ɴƐƚŝŵƵůĂƚŝŽŶ ?
 ƚŽŵĞĂƐƵƌĞE& ?ŮĂĐĞƚǇůĂƚŝŽŶůĞǀĞůƐĂƚƚŚĞy> ?ƉƌŽŵŽƚĞƌŝŶŶŽƌŵĂůĂŶĚ&
ĂŝƌǁĂǇĞƉŝƚŚĞůŝĂůĐĞůůƐďĂƐĂůůǇĂŶĚĂĨƚĞƌ/> ? ?ɴƐƚŝŵƵůĂƚŝŽŶ ?
 to measure the methylation status of CpG sites within the CXCL8 promoter
ŝŶŶŽƌŵĂůĂŶĚ&ĐĞůůƐďĂƐĂůůǇĂŶĚĂĨƚĞƌ/> ? ?ɴƐƚŝŵƵůĂƚŝŽŶĂŶĚ ?ƚŚĞƌĞďǇ ?ƚŽĚĞƚĞƌŵŝŶĞ
whether altered DNA methylation contributes to aberrant CXCL8 transcription in CF
cells.
6.3 Methods
Chromatin immunoprecipitation (ChIP)
dŽ ŝĚĞŶƚŝĨǇ, ?< ?ŵĞƚŚǇůĂƚŝŽŶ ?ŚŝƐƚŽŶĞ, ?ĂŶĚ, ?ĂĐĞƚǇůĂƚŝŽŶĂŶĚE& ?ʃƉ ? ?< ? ? ?
acetylation at the CXCL8 promoter, ChIP was performed as described in 3.7 of
Chapter 3 Materials and Methods.
Bisulphite sequencing
To identify the methylation status of CpG sites within the CXCL8 promoter,
bisulphite sequencing was performed as described in 3.9 of Chapter 3 Materials and
Methods.
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6.4 Results
6.4.1 Increased histone H3 lysine 4 trimethylation (H3K4me3) at
the CXCL8 promoter in CF airway epithelial cells
Unstimulated normal cells had low basal levels of H3K4 trimethylation which was
ĚŽƵďůĞĚ ĨŽůůŽǁŝŶŐ /> ? ?ɴ ƐƚŝŵƵůĂƚŝŽŶ ? & ĐĞůůƐ ŚĂĚ ŚŝŐ Ğƌ ďĂƐĂů ůĞǀĞůƐ ŽĨ
trimethylated H3K4 at the CXCL8 promoter compared to normal cell lines; no
ĨƵƌƚŚĞƌŝŶĐƌĞĂƐĞǁĂƐŽďƐĞƌǀĞĚĂĨƚĞƌ/> ? ?ɴƐƚŝŵƵůĂƚŝŽŶ ?&ŝŐƵƌĞ ? ? ? Z ?
Figure 6-1. H3 lysine 4 trimethylation (H3K4me3) at the human CXCL8 promoter. Association of trimethylated
lysine 4 on histone 3 (H3K4me3) was measured in confluent and growth arrested IB3-1 normal and IB3-1 CF
cells. Cells were incubated with/without 1ng/mL IL-1ß for 0 and 1 hour. Extracted chromatin was sheared and
immunoprecipitated with 4µg of antibody against H3K4me3 or rabbit IgG used as a negative control. Isolated
DNA underwent qPCR analysis with CXCL8 promoter-specific primers. Data are expressed as fold change relative
to the 0h mean of IB3-1 normal cells first normalised to the Input DNA. Each column represents means ± SEM
from at least 3 independent experiments.
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6.4.2 Histone acetylation at the CXCL8 promoter in CF airway
epithelial cells
No difference between acetylated histone H3 and IgG negative control levels was
ŝĚĞŶƚŝĨŝĞĚ ŝŶ ĞŝƚŚĞƌ ŶŽƌŵĂů Žƌ & ĐĞůů ůŝŶĞƐ ďĂƐĂůůǇ Žƌ ĨŽůůŽǁŝŶŐ /> ? ?ɴ ƐƚŝŵƵůĂƚŝŽŶ
(Figure 6-2).
Figure 6-2. Histone H3 acetylation (H3ac) at the human CXCL8 promoter (a representative graph). Association
of acetylated histone H3 with the CXCL8 promoter was determined in confluent and growth arrested IB3-1
normal and IB3-1 CF cells. Cells were incubated with/without 1ng/mL IL-1ß for 0 and 1 hour. Extracted
chromatin was sheared and immunoprecipitated with 4µg of antibody against pan-acetylated H3 or rabbit IgG
used as a negative control. Isolated DNA underwent qPCR analysis with CXCL8 promoter-specific primers. Data
are expressed as fold change relative to the 0h mean of IB3-1 normal cells first normalised to the Input DNA.
The graph is a representative of three independent experiments.
Normal cells showed a 56 fold increase in acetylated histone H4 association
following IL-1ß induction, whilst there was no difference between acetylated
histone H4 and IgG negative control levels at the CXCL8 promoter in CF cells both
ďĂƐĂůůǇĂŶĚĂĨƚĞƌ/> ? ?ɴƐƚŝŵƵůĂƚŝŽŶ ?&ŝŐƵƌĞ ? ? ? Z ?
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Figure 6-3. Histone H4 acetylation (H4ac) at the human CXCL8 promoter (a representative graph). Association
of acetylated H4 with the CXCL8 promoter was analysed in confluent and growth arrested IB3-1 normal and IB3-
1 CF cells. Cells were incubated with/without 1ng/mL IL-1ß for 0 and 1 hour. Extracted chromatin was sheared
and immunoprecipitated with 4µg of antibody against pan-acetylated H4 or rabbit IgG used as a negative
control. Isolated DNA underwent qPCR analysis with CXCL8 promoter-specific primers. Data are expressed as
fold change relative to the 0h mean of IB3-1 normal cells first normalised to the Input DNA. The graph is a
representative of three independent experiments.
Collectively, these findings suggest that neither increased histone H3 nor H4
acetylation at the CXCL8 promoter explain the differences in CXCL8 release
between normal and CF cell lines.
6.4.3 E& ?ʃ ĂĐĞƚǇůĂƚŝŽŶ Ăƚ ƚŚĞ y> ? ƉƌŽŵŽƚĞƌ ŝŶ & ĂŝƌǁĂǇ
epithelial cells
Little p65 K310 acetylation was measured over IgG control in either normal or CF
ĐĞůůƐ ƵŶĚĞƌďĂƐĂůŽƌ /> ? ?ɴ ƐƚŝŵƵůĂƚĞĚ ĐŽŶĚŝƚŝŽŶƐ ? EŽĚŝĨĨĞƌĞŶĐĞ ŝŶďĂƐĂůE& ?ʃ Ɖ ? ?
K310 acetylation levels was observed between normal and CF cells. IL-1ß
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ƐƚŝŵƵůĂƚŝŽŶ ĚŝĚ ŶŽƚ ƌĞƐƵůƚ ŝŶ ĂŶǇ ŝŶĐƌĞĂƐĞ ŝŶ E& ?ʃ Ɖ ? ? < ? ? ? ĂĐĞƚǇůĂƚŝŽŶ ůĞǀĞůƐ ŝŶ
either cell line (Figure 6-4).
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&ŝŐƵƌĞ  ? ? ? ?E& ?ŮƉ ? ?< ? ? ?ĂĐĞƚǇůĂƚŝŽŶ  ?Ɖ ? ?< ? ? ? ?ĂƚƚŚĞŚƵŵ Ŷy> ?ƉƌŽŵŽƚĞƌ ?Association of acetylated
E& ?ŮƉ ? ?< ? ? ?ǁŝƚŚƚŚĞy> ?ƉƌŽŵŽƚĞƌǁĂƐĂŶĂůǇƐĞĚŝŶĐŽŶĨůƵĞŶƚĂŶĚŐƌŽǁƚŚĂƌƌĞƐƚĞĚ/ ? ? ?ŶŽƌŵĂůĂŶĚ/ ? ?
1 CF cells. Cells were incubated with/without 1ng/mL IL-1ß for 0 and 1 hour. Extracted chromatin was sheared
ĂŶĚ ŝŵŵƵŶŽƉƌĞĐŝƉŝƚĂƚĞĚ ǁŝƚŚ  ?A?Ő ŽĨ ĂŶƚŝďŽĚǇ ĂŐĂŝŶƐƚ ĂŶƚŝ ?E& ?Ů Ɖ ? ? ĂĐĞƚǇů ?< ? ? ? Žƌ ƌĂďďŝƚ /Ő' ƵƐĞĚ ĂƐ Ă
negative control. Isolated DNA underwent qPCR analysis with CXCL8 promoter-specific primers. Data are
expressed as fold change relative to the 0h mean of IB3-1 normal cells first normalised to the Input DNA. Each
column represents means ± SEM from at least 3 independent experiments.
dŚĞƐĞ ĨŝŶĚŝŶŐƐ ƐƵŐŐĞƐƚ ƚŚĂƚ ĂůƚĞƌĞĚ ĂĐĞƚǇůĂƚŝŽŶ ŽĨ E& ?ʃ Ɖ ? ? Ăƚ < ? ? ? ŝƐ ŶŽƚ
responsible for the increased CXCL8 production in CF cells.
6.4.4 P300 binding to the CXCL8 promoter in CF airway epithelial
cells
ůƚŚŽƵŐŚ ǁĞ ĨĂŝůĞĚ ƚŽ ƐŚŽǁ ĞŝƚŚĞƌŚŝƐƚŽŶĞ , ? ?, ? Žƌ E& ?ŮƉ ? ? < ? ? ? ĂĐĞƚǇůĂƚŝŽŶ ?
we considered the fact that HATs can sometimes have transcriptional co-activator
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properties that are independent of their HAT activities (Clarke et al., 2010). We
looked at the recruitment and binding of HATs that potentially could be involved in
the altered CXCL8 expression in CF cells. No binding of p300 above IgG control
levels was obtained in either cell line under any condition (Figure 6-5).
Figure 6-5. p300 binding to the human CXCL8 promoter (a representative graph). Association of p300 with the
CXCL8 promoter was analysed in confluent and growth arrested IB3-1 normal and IB3-1 CF cells. Cells were
incubated with/without 1ng/mL IL-1ß for 0 and 1 hour. Extracted chromatin was sheared and
immunoprecipitated with 1µg of antibody against p300 or rabbit IgG used as a negative control. Isolated DNA
underwent qPCR analysis with CXCL8 promoter-specific primers. Data are expressed as fold change relative to
the 0h mean of IB3-1 normal cells first normalised to the Input DNA. A representative graph of two independent
experiments is shown.
This suggests that there was no increased p300 binding to the CXCL8 promoter that
could explain the abnormal CXCL8 expression in CF cells.
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6.4.5 DNA methylation at the CXCL8 promoter in CF airway
epithelial cells
Finally, we examined methylation patterns of CpG sites within the CXCL8 promoter
as well as global DNA methylation.
The CXCL8 promoter is not a classic "CpG island" promoter as it contains sparse CpG
dinucleotide sequences. Although, the four CpG sites located within close proximity
of the promoter do not form a distinctive "CpG island", they still represent potential
targets for methylation. The CpG sites are situated within -136 to +43 region of the
CXCL8 promoter, namely at -7, -83, -158 and -168; two more sites are positioned at
-1241 and - 1311 upstream of the TATA box. This region contains sequences of four
ĐŝƐ ?ĞůĞŵĞŶƚƐŽĨE& ?Ů  ? ? ? ?ƚŽ  ? ? ? Z ? ?W  ? ? ? ?ƚŽ  ? ?  Z ĂŶĚW ? ?ƉƌŽƚĞŝŶ  ? ? ? ? ?ƚŽ  W
120) binding sites. The fourth cis-regulator element is activated by Oct-1 factor
down regulating CXCL8 transcription and is located between -90 and -83. Location
of the CpG sites near TATA and CCAAT boxes suggests that they might play a crucial
role in transcription initiation (De Larco et al., 2003).
Figure 6-6. A schematic diagram of the CXCL8 gene showing the approximate location of CpG sites 1, 2, 3, and
4 within CXCL8 gene.
CXCL8
CpG site 1 CpG site 4 CpG site 2CpG site 3
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Considering the close proximity of the CpG sites and primer sequences designed by
PyroMark Assay Design SW 2.0 software, CpG sites were clustered as follows: CpG
site 1 containing CpG clusters 1.1 and 1.2 (blue triangles,
Figure 6-6), CpG site 4 encompassing CpG clusters 3.1, CpG 3.2 and CpG 3.3 (green
triangles,
Figure 6-6) and CpG site 2 including CpG clusters 2.1 and 2.2 (orange triangles,
Figure 6-6).
Data analysis showed that unstimulated normal cells were severely methylated at
CpG clusters 1.1, 1.2 and less methylated at 2.1, 2.2, 2.3, 3.1, 3.2 and 3.3. Similarly,
untreated CF cells were methylated at CpG sites 1.1, 1.2, 2.2, 3.3 and highly
methylated at CpG site 3.1 with DNA methylation levels being slightly lower at CpG
sites 1.1, 1.2, 3.3 and 3.1 as compared to normal cells. This suggests that altered
methylation of CpG 1.1, 1.2, 2.2, 3.1 and 3.3 might contribute to the abnormal
CXCL8 production in CF cells under basal conditions. IL-1ß stimulation resulted in a
decrease in methylation levels of CpG clusters 2.2, 2.3 and 3.1 in normal cells and at
CpG clusters 1.2, 2.3, 3.3 but not 3.1 in CF cells consistent with it activating
transcription. Global DNA methylation (LINE-1 assay) was no different between
ŶŽƌŵĂů ĂŶĚ & ĐĞůůƐ ďŽƚŚ ƵŶĚĞƌ ďĂƐĂů ĐŽŶĚŝƚŝŽŶƐ ĂŶĚ ĨŽůůŽǁŝŶŐ /> ? ?ɴ ƐƚŝŵƵůĂƚŝŽŶ
(Figure 6-7).
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Figure 6-7. Methylation status of CpG sites within the CXCL8 promoter. Methylation levels of CpG sites 1 (A,
B), 2 (C, D), 3 (E), and 4 (F, G, H) as well as global DNA methylation (LINE-1 assay) (I) in IB3-1 normal and IB3-1
CF cells were analysed. 2µg of genomic DNA was subjected to bisulphite conversion and purified DNA
underwent PCR analysis using specific primers to amplify DNA regions containing CpG sites and to identify
global DNA methylation pattern. PCR products were run on 2% agarose gel to identify the correct band size.
Data are expressed as a percentage of methylated CpG sites; each column represents means ± SEM from at
least 2 or 3 independent experiments.
Collectively, the DNA methylation data suggests that the CXCL8 promoter is slightly
hypomethylated in CF cells in comparison to the normal cells.
6.5 Discussion
The major findings in this chapter are increased histone H3K4 trimethylation and
hypomethylation of CpG site 3.1 under basal conditions at the CXCL8 promoter in
CF cells compared to normal cells. IL-1ß stimulation did not result in any changes in
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H3K4me3 levels but caused hypomethylation of CpG sites in both normal and CF
ĐĞůůůŝŶĞƐ ?dŚĞƌĞǁĂƐŶŽĚŝĨĨĞƌĞŶĐĞŝŶŚŝƐƚŽŶĞ, ? ?, ?ŽƌE& ?ʃƉ ? ?< ? ? ?ĂĐĞƚǇůĂƚŝŽŶ
ĂƚƚŚĞƉƌŽŵŽƚĞƌĞŝƚŚĞƌďĂƐĂůůǇŽƌĨŽůůŽǁŝŶŐ/> ? ?ɴƐƚŝŵƵůĂƚŝŽŶ ?
Our study showed that CF cells had greater levels of trimethylated H3K4 under
ďĂƐĂůĐŽŶĚŝƚŝŽŶƐĂƐĐŽŵƉĂƌĞĚƚŽŶŽƌŵĂůĐĞůůƐ ?Ɛ/> ? ?ɴƐƚŝŵƵůĂƚŝŽŶĨĂŝůĞĚƚŽŝŶĚƵĐĞ
any increase in H3K4me3 levels in CF cell line, it is less likely that H3K4me3 is
ƌĞƐƉŽŶƐŝďůĞ ĨŽƌ ĂůƚĞƌĞĚ /> ? ?ɴ ?ŝŶĚƵĐĞĚ y> ? ĞǆƉƌĞƐƐŝŽŶ ŝŶ & ĐĞůůƐ ? ,ŽǁĞǀĞƌ ? ƚŚĞ
basal increase in trimethylated H3K4 together with the increased association of NF-
ʃ Ɖ ? ? ǁŝƚŚ ƚŚĞ y> ? ƉƌŽŵŽƚĞƌ ƌĞƉŽƌƚĞĚ ŝŶ ƚŚĞ ƉƌĞǀŝŽƵƐ ĐŚĂƉƚĞƌ ƐƵŐŐĞƐƚƐ ƚŚĞ
existence of a hyperactive transcription complex associated with the CXCL8
promoter basally in CF cells.
Previous work has shown a strong correlation between H3K4 trimethylation levels
and gene transcription activity (Pokholok et al., 2005). This epigenetic modification
can function as an initiating point for the increased recruitment of chromatin
specific remodelling complexes/enzymes such as p300 HAT followed by further
histone hyperacetylation and enhanced gene transcription (Li et al., 2007). There is
a positive correlation between H3K4 trimethylation and transcriptional activity of
E& ?ʃ ?ŝŶĚƵĐĞĚ ŐĞŶĞƐ  ?^ĂĐĐĂŶŝ Ğƚ Ăů ? ?  ? ? ? ? Z ? dŚŽƵŐŚƚŚŝƐ ŵŽĚŝĨŝĐĂƚŝŽŶ ŝƐ ǁĞůů
described in other cells, our study is the first to show altered H3K4me3 at the
CXCL8 promoter in CF airway epithelial cells.
Several studies have shown increased levels of histone H3 and/or H4 acetylation
alongside increased H3K4me3 levels at the promoters of transcriptionally active NF-
ʃ ?ƌĞŐƵůĂƚĞĚŐĞŶĞƐ  ?^ĂĐĐĂŶŝĞƚĂů ? ?  ? ? ? ? ?EĂƚŽůŝ ?  ? ? ? ? Z ? /ŶĐŽŶƚƌĂƐƚ ?ǁĞƐŚŽǁĞĚŶŽ
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difference in histone H3 or H4 acetylation levels at the CXCL8 promoter between
ŶŽƌŵĂů ĂŶĚ & ĐĞůůƐ ĞŝƚŚĞƌ ďĂƐĂůůǇ Žƌ ĂĨƚĞƌ /> ? ?ɴ ƐƚŝŵƵůĂƚŝŽŶ ? KŶĞ ƉƌĞǀŝŽƵƐ ƐƚƵĚǇ
measured the acetylation status of the CXCL8 promoter in CF epithelial cells and in
ĐŽŶƚƌĂƐƚ ƚŽ ŽƵƌ ŽďƐĞƌǀĂƚŝŽŶƐ ƌĞƉŽƌƚĞĚ ŝŶĐƌĞĂƐĞĚ ŚŝƐƚŽŶĞ , ? ĂĐĞƚǇůĂƚŝŽŶ Ăƚ E& ?Ů
binding sites at the CXCL8 promoter (Bartling, 2009). The disagreement between
our findings and results reported by Bartling et al could potentially be due to the
difference in the cell lines used and variance in their properties. However, only one
out of three CF cell lines and corresponding controls used in Bartlings study
showed increased histone H4 acetylation at the CXCL8 promoter. Variations in the
experimental design might also be an influential factor: cells were stimulated with a
ĐŽŵďŝŶĂƚŝŽŶŽĨƉŽƚĞŶƚƉƌŽ ?ŝŶĨůĂŵŵĂƚŽƌǇĐǇƚŽŬŝŶĞƐ ? ?ŶŐ ?ŵ>dE&ɲĂŶĚ ? ? ?ŶŐ ?ŵ>/> ?
 ?ɴ Z ĨŽƌ  ? ŚŽƵƌƐ ǀĞƌƐƵƐ Ă ƐŝŶŐůĞ ƐƚŝŵƵůƵƐ  ? ?ŶŐ ?ŵ> /> ? ?ɴ Z ĂŶĚĂĚŝĨĨĞƌĞŶƚ ƚŝŵĞƉŽŝŶƚ
used in our study (1 hour). Furthermore, the inconsistency in the results might be
partly explained by a greater CXCL8 promoter coverage of the PCR primers used in
the study conducted by Bartling as compared to the ones used in our study. Finally,
the presence of other specific epigenetic modifications involved in the control of
CXCL8 expression, that either of the studies investigated, might possibly influence
the CXCL8 release from CF cells.
tĞ ĨŽƵŶĚ ŶŽ ĚŝĨĨĞƌĞŶĐĞ ŝŶ ƚŚĞ ĂĐĞƚǇůĂƚŝŽŶ ůĞǀĞůƐ ŽĨ ƚŚĞ Ɖ ? ? ƐƵďƵŶŝƚ ŽĨ E& ?ʃ Ăƚ
< ? ? ? ďĞƚǁĞĞŶ ŶŽƌŵĂů ĂŶĚ & ĐĞůůƐ ? dŚƵƐ ? E& ?Ů Ɖ ? ? < ? ĂĐĞƚǇůĂƚŝŽŶ ŝƐ ŶŽƚ
responsible for the increased CXCL8 expression in CF cells. Likewise, we found no
increase in the recruitment of p300 to the CXCL8 promoter suggesting that
increased recruitment of this HAT is not implicated in CF epithelial cells. In future, it
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would be interesting to determine any changes in the levels of other HATs recruited
to the CXCL8 promoter in CF epithelial cells.
Lastly, DNA methylation showed hypomethylation of CpG site 3.1 at the CXCL8
promoter under basal conditions, suggesting that this may contribute to the
increased basal transcription in CF cells. There was a further reduction in
methylation levels of several CpG sites after stimulation with IL-1ß which was
greater in CF cells, suggesting that this might contribute to IL-1ß-induced activation
of CXCL8. There was no difference in global DNA methylation levels between
normal and CF cells, suggesting, that any changes are likely to be promoter-specific.
This is the first time that the methylation status of CpG sites within the CXCL8
promoter has been described in CF cells.
Almost 50% of all CpG sites within the genome overlap transcription initiation sites
and commonly lack DNA methylation (Clifford et al., 2013, Illingworth et al., 2010).
DNA methylation in the regulatory region results in gene silencing via prevention of
TFs access to the gene promoter (Deng et al., 2001). Recent genome-scale analysis
has shown that DNA methylation also negatively correlates with H3K4 methylation
levels at the target gene promoter (Cheng and Blumenthal, 2010, Laurent et al.,
2010). These findings are consistent with our findings of both H3K4
hypermethylation and DNA hypomethylation under basal conditions at the CXCL8
promoter in CF cells.
To conclude, the results in this chapter showed increased H3K4 trimethylation in CF
ĐĞůůƐ ƵŶĚĞƌ ďĂƐĂů ĐŽŶĚŝƚŝŽŶƐ ? ďƵƚ ŶŽ ĂůƚĞƌĂƚŝŽŶ ŝŶŚŝƐƚŽŶĞ , ? ? , ? Žƌ E& ?Ů
acetylation or p300 recruitment. Furthermore, there was hypomethylation of CpG
145
sites at the CXCL8 promoter in CF cells compared to normal cell lines that were
further hypomethylated by IL-1ß. Collectively, these abnormalities are likely to
contribute to the altered CXCL8 transcription in CF epithelial cells. The next chapter
will focus on identifying potential co-factors recruited to the CXCL8 promoter in CF
cells as well as studying drugs which modify epigenetic signatures of CXCL8
secretion.
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7 BET PROTEIN INHIBITORS ABOLISH CXCL8 EXPRESSION IN
CF AIRWAY EPITHELIAL CELLS
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7.1 Introduction
In Chapter 6 we showed that enhanced CXCL8 release from CF airway epithelial
cells might be due to increased H3K4 trimethylation and hypomethylation of CpG
site 3.1 at the CXCL8 promoter further hypomethylated following IL-1ß stimulation.
This chapter will aim to identify co-factors recruited to the CXCL8 promoter as well
as to study compounds influencing CXCL8 secretion in CF airway epithelial cells.
Epigenetic alterations such as DNA methylation and/or histone modifications affect
gene expression not only through a direct effect on protein-protein interactions,
but via recruitment of regulatory molecules targeting gene transcription. Recently,
bromodomain and extra-terminal (BET) proteins (BRD2, 3, 4 and BRD-T) have been
shown to play an important role in gene activation. Studies in animal models have
shown that deletion of either BRD2 or BRD4 in mice is lethal: BRD4-deficient mice
develop severe developmental defects (Houzelstein et al., 2002, Shang et al., 2009).
BRD2 and BRD3 are associated with increased acetylation of histone H3 at K14 and
histone H4 at K5 and K12 respectively. These BET proteins have been reported to
activate RNA Pol II-driven transcription of target genes (LeRoy et al., 2008). BRD3
has been implicated in the activation and interaction with acetylated TF GATA1
targeting it to chromatin (Gamsjaeger et al., 2011). BRD4 has been involved in basal
E& ?ʃĂĐƚŝǀĂƚŝŽŶŝŶĐĂŶĐĞƌƐƵŐŐĞƐƚŝŶŐĂŶŝŶƚĞƌĂĐƚŝŽŶďĞƚǁĞĞŶĂĐĞƚǇůĂƚĞĚE& ?ʃĂŶĚ
BRD4 at the promoter of target genes (Zou et al., 2014).
Bromodomains (BRDs) are also present in some chromatin-remodelling nuclear
proteins such as HATs (Nagy and Tora, 2007a), methyltransferases (Malik and
Bhaumik, 2010) and transcriptional activators (Brès et al., 2008). Studies in LPS- or
IL-1ß-stimulated macrophages (Nicodeme et al., 2010, Hargreaves et al., 2009) and
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different cancer cell lines (Filippakopoulos et al., 2010) have reported BRD2 and
BRD4 to control target genes via recruitment of protein interaction and activator
molecules including positive transcription elongation factor complex (P-TEFb)
(Muller et al., 2011a, Nicodeme et al., 2010).
Recently, BET protein inhibitors have been shown to have a potential role in the
treatment of several cancers. Treatment of midline carcinoma cells with selective
BET protein inhibitors JQ1 or PFI-1 resulted in substantial cell growth arrest and
apoptosis alongside with substantial reduction in tumour growth (Barbieri I et al.,
2013). Treatment with JQ1 resulted in a reduced cell viability and osteoblastic
differentiation via transcriptional silencing of MYC and RUNX2 genes in both in vitro
and in vivo models (Lamoureux et al., 2014). Another inhibitor, I-BET-151, was
effective in pre-clinical models of multiple myeloma (Chaidos et al., 2014). I-BET762
is being evaluated in a phase I clinical trial for treatment of human testis midline
carcinoma (Zhao et al., 2013).
BET proteins may also be a target in inflammatory diseases, although this has been
ƐƚƵĚŝĞĚ ƚŽ Ă ůĞƐƐĞƌ ĞǆƚĞŶƚ ? / ?d ? ? ? ? ŝŶŚŝďŝƚƐ ƚƌĂŶƐĐƌŝƉƚŝŽŶ ŽĨ E& ?ʃ ?ŵĞĚŝĂƚĞĚ
inflammatory genes and reduces production of IL-6 and CXCL8 via downregulation
ŽĨ E& ?ʃ Ɖ ? ? ? ?Ɖ ? ? ŝŶƚĞƌĂĐƚŝŽŶ  ?'ĂůůĂŐŚĞƌ Ğƚ Ăů ? ?  ? ? ? ? Z  ^ŝŵŝůĂƌ ƌĞƐƵůƚƐ ŚĂǀĞ ďĞĞŶ
observed in mouse macrophages following treatment with JQ1. Furthermore, JQ1
ĂŶĚW&/ ? ? ŝŶŚŝďŝƚE& ?Ů ?ĚƌŝǀĞŶƚƌĂŶƐĐƌŝƉƚŝŽŶŽĨ /> ? ?ĂŶĚy> ?ĐǇƚŽŬŝŶĞƐ ŝŶƉƌŝŵĂƌǇ
and immortalised airway epithelial cells. BRD4 deficiency and/or treatment with
JQ1 results in the ubiquitination and degradation of the active nuclear form of NF-
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ʃƉ ? ?  ?<ŚĂŶĞƚĂů ? ?  ? ? ? ? Z ?ƐƵŐŐĞƐƚŝŶŐ ?ƚŚĂƚdƉƌŽƚĞŝŶƐƉůĂǇĂŶ ŝŵƉŽƌƚĂŶƚƌŽůĞ ŝŶ
ƚŚĞƚƌĂŶƐĐƌŝƉƚŝŽŶŽĨŝŶĚŝǀŝĚƵĂůE& ?Ů ?ŵĞĚŝĂƚĞĚŐĞŶĞƐ ?ĞůŬŝŶĂĞƚĂů ? ? ? ? ? ?ď Z ?
As the role of BET protein inhibitors in regulating CXCL8 in CF airway epithelial cells
is unknown, the present chapter examines this.
7.2 Aims
The aims of this chapter were:
 to determine the effect of BET protein inhibitors on CXCL8 release from
normal and CF airway epithelial cells basally and after IL-1ß stimulation;
 to measure binding of BET proteins to the CXCL8 promoter in normal and CF
airway epithelial cells basally and after IL-1ß stimulation;
 to study the interaction between BET proteins and TFs at the CXCL8
ƉƌŽŵŽƚĞƌ ŝŶ ŶŽƌŵĂů ĂŶĚ & ĂŝƌǁĂǇ ĞƉŝƚŚĞůŝĂů ĐĞůůƐ ďĂƐĂůůǇ ĂŶĚ ĂĨƚĞƌ /> ? ?ɴ
stimulation.
7.3 Methods
Inhibitor studies
To identify the effect of BET protein inhibitors on CXCL8 protein secretion in normal
and CF cells, confluent and growth arrested cells were pre-treated with 10-5, 10-6,
10-7M of PFI-1, 10-6, 10-7, 10-8M of JQ1 or DMSO used as a vehicle control for 30 min
and stimulated with 1ng/mL IL-1ß for 24 hours. Supernatants were collected and
assayed for CXCL8 by ELISA as described in 3.2 of Chapter 3 Materials and Methods.
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Cell viability (MTT) assay
To measure the toxicity of drug compounds used during the study, cell viability
assay was performed as described in 3.6 of Chapter 3 Materials and Methods.
Chromatin immunoprecipitation (ChIP)
To measure binding of BRD2, BRD3 and BRD4 to the CXCL8 promoter and the effect
of BET protein inhibitors on their binding, ChIP assay was performed as described in
3.7 of Chapter 3 Materials and Methods.
Nuclear Co-Immunoprecipitation (Co-IP)
dŽ ƐƚƵĚǇ ƚŚĞ ŝŶƚĞƌĂĐƚŝŽŶ ďĞƚǁĞĞŶ E& ?Ů Ɖ ? ? ĂŶĚ Z ? ? ĐŽ ?ŝŵŵƵŶŽƉƌĞĐŝƉŝƚĂƚŝŽŶ
(Co-IP) assay followed by western blotting analysis was performed as described in
3.8 of Chapter 3 Materials and Methods.
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7.4 Results
7.4.1 BET protein inhibitors PFI-1 and JQ1 reduce CXCL8 protein
release from normal and CF airway epithelial cells
ŽƚŚ W&/ ? ? ĂŶĚ :Y ? ƌĞĚƵĐĞĚ ďĂƐĂů y> ? ĂŶĚ /> ? ?ɴ ?ŝŶĚƵĐĞĚ y> ? ƉƌŽĚƵĐƚŝŽŶ ŝŶ
both normal and CF cells in a concentration dependent manner (Figure 7-8).
A B
Figure 7-8. The effect of BET protein inhibitors, PFI-1 and JQ1, on CXCL8 protein release from normal and CF
cells. IB3-1 normal and IB3-1 CF cells, confluent and growth arrested 24 hours prior to an experiment, were pre-
incubated for 30 min with stated concentrations of PFI-1 (A) and (+)/- JQ1 (B) followed by stimulation with or
ǁŝƚŚŽƵƚ  ?ŶŐ ?ŵ> /> ? ?ɴ ?^ƵƉĞƌŶĂƚĂŶƚƐǁĞƌĞĂƐƐĂǇĞĚĨŽƌy> ?ƉƌŽƚĞŝŶďǇ>/^ ?ƚŚĞƌĂǁĚĂƚĂǁĞƌĞŶŽƌŵĂůŝƐĞĚ
against total cellular protein. Each bar represents means ± SEM from triplicate determinants of at least 3
independent experiments. Student t-test was used for the analysis, *p value <0.05 compared to corresponding
cells without PFI-1 or JQ1 treatment was considered as significant.
No toxicity was observed under any experimental condition (see 9.1 of Appendix for
the cytotoxicity data). As both compounds had similar effects, we used JQ1 in
further experiments.
Our results suggest that BET proteins and/or BRD containing regulatory proteins
might be involved in the CXCL8 dysregulation in CF.
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7.4.2 Increased binding of BRD3 and BRD4 to the CXCL8 promoter
in CF airway epithelial cells
Next, binding levels of BET proteins to the CXCL8 promoter were determined by
ChIP.
There was no difference in basal BRD2 binding to the CXCL8 promoter between
normal and CF cells. Stimulation with IL-1ß resulted in a slight or no increase in
BRD2 binding levels in both cell lines (Figure 7-9, A, B). BRD3 binding levels were
higher in unstimulated CF cells under basal conditions compared to normal cells
 ?ŶĞĂƌůǇ ƚǁŽ ĂŶĚ ŚĂůĨ ĨŽůĚ ĚŝĨĨĞƌĞŶĐĞ Z ? /> ? ?ɴ ƐƚŝŵƵůĂƚŝŽŶ ĚŝĚ ŶŽƚ ĂůƚĞƌ ƚŚĞ ďŝŶĚŝŶŐ
levels (Figure 7-9, C, D). There was a two fold increase in basal BRD4 binding to the
y> ? ƉƌŽŵŽƚĞƌ ŝŶ ƵŶƐƚŝŵƵůĂƚĞĚ & ĐĞůůƐ ĐŽŵƉĂƌĞĚ ƚŽ ŶŽƌŵĂů ĐĞůůƐ ? /> ? ?ɴ
stimulation resulted in a fourfold increase in bound BRD4 levels after 2 hours upon
IL-1ß stimulation (Figure 7-9, E, F).
153
A B
C D
BR
D3
0h
IgG
0h
BR
D3
1h
IgG
1h
BR
D3
2h
IgG
2h
BR
D3
0h
IgG
0h
BR
D3
1h
IgG
1h
BR
D3
2h
IgG
2h
R
e
la
t
iv
e
a
s
s
o
c
ia
ti
o
n
o
f
B
R
D
3
w
it
h
-1
2
1
to
+
6
1
o
f
C
X
C
L
8
p
r
o
m
o
te
r
E F
BR
D4
0h
IgG
0h
BR
D4
1h
IgG
1h
BR
D4
2h
IgG
2h
R
e
la
ti
v
e
a
s
s
o
c
ia
ti
o
n
o
f
B
R
D
4
w
it
h
-
1
2
1
to
+
6
1
o
f
C
X
C
L
8
p
r
o
m
o
te
r
Figure 7-9. Association of BRD2, BRD3, and BRD4 with the human CXCL8 promoter in normal and CF airway
epithelial cells. Confluent and growth arrested IB3-1 normal and IB3-1 CF cells, serum starved 24 hour prior to
an experiment, were incubated without (A, C, E) or with 1ng/mL IL-1ß (B, D, F) for 0, 1 and 2 hour. Extracted
chromatin was sheared and immunoprecipitated with 3µg of BRD2 (A, B), BRD3 (C, D) and BRD4 (E, F) or IgG
used as a negative control. Isolated DNA underwent qPCR analysis with the CXCL8 promoter-specific primers.
Data are expressed as fold change relative to the 0h mean of IB3-1 normal cells first normalised to the Input
DNA. Each column represents means ± SEM from at least 3 independent experiments.
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Collectively, these results suggest that BRD3 and BRD4 are both important for basal
y> ?ĞǆƉƌĞƐƐŝŽŶŝŶ& ?ďƵƚZ ?ŝƐŝŶǀŽůǀĞĚŝŶ/> ? ?ɴ ?ŝŶĚƵĐĞĚy> ?ƐĞĐƌĞƚŝŽŶŝŶ&
cells. Thus, further studies in this chapter were concentrated on BRD4.
7.4.3 dŚĞ ĞĨĨĞĐƚ ŽĨ :Y ? ŽŶ E& ?ʃ ƌĞĐƌƵŝƚŵĞŶƚ ƚŽ ƚŚĞ y> ?
promoter in CF airway epithelial cells
dŚĞ ĞĨĨĞĐƚ ŽĨ :Y ? ŽŶE& ?ʃ Ɖ ? ? ďŝŶĚŝŶŐ ƚŽ ƚŚĞy> ? ƉƌŽŵŽƚĞƌ ŝŶŶŽƌŵĂů ĂŶĚ &
cells was determined by ChIP.
dŚĞƌĞ ǁĂƐ ŵŽĚĞƐƚ ďŝŶĚŝŶŐ ŽĨ E& ?ʃ Ɖ ? ? ƚŽ ƚŚĞ y> ?ƉƌŽŵŽƚĞƌ ŝŶ ƵŶƐƚŝŵƵůĂƚĞĚ
ŶŽƌŵĂů ĐĞůůƐ ǁŝƚŚ ŶŽ ƌĞĚƵĐƚŝŽŶ ĨŽůůŽǁŝŶŐ ƚƌĞĂƚŵĞŶƚ ǁŝƚŚ :Y ? ? /> ? ?ɴ ƐƚŝŵƵůĂƚŝŽŶ
ŝŶĐƌĞĂƐĞĚ E& ?ʃ Ɖ ? ? ďŝŶĚŝŶŐ Ăƚ  ? ŚŽƵƌƐ ? ďƵƚ :Y ? ĚŝĚ ŶŽƚ ĐĂƵƐĞ ĂŶǇ ĚĞĐƌĞĂƐĞ ŝŶ
ďŝŶĚŝŶŐ ůĞǀĞůƐ  ?&ŝŐƵƌĞ  ? ? ? ? Z ? :Y ? ƌĞƐƵůƚĞĚ ŝŶ ƌĞĚƵĐĞĚ E& ?ʃ Ɖ ? ? ůĞǀĞůƐ ŝŶ
ƵŶƐƚŝŵƵůĂƚĞĚ&ĐĞůůƐĂƚ ?ŚŽƵƌ ?^ƚŝŵƵůĂƚŝŽŶǁŝƚŚ/> ? ?ƘŝŶĐƌĞĂƐĞĚE& ?ʃƉ ? ?ďŝŶĚŝŶŐ
at 2 hours, but JQ1 did not reduce the binding levels (Figure 7-10).
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&ŝŐƵƌĞ ? ? ? ? ?dŚĞĞĨĨĞĐƚŽĨ:Y ?ŽŶE& ?ʃƉ ? ?ƌĞĐƌƵŝƚŵĞŶƚ ŽƚŚĞŚƵŵĂŶy> ?ƉƌŽŵŽƚĞƌŝŶŶŽƌŵĂůĂŶĚ&ĐĞůůƐ ?
Confluent and growth arrested IB3-1 normal and IB3-1 CF airway epithelial cells were serum starved 24 hour
prior to an experiment, pre-incubated with 10
-6
M of JQ1 for 30 min and incubated with/without 1ng/mL IL-1ß
for 1 (A) and 2 (B)ŚŽƵƌƐ ?ǆƚƌĂĐƚĞĚĐŚƌŽŵĂƚŝŶǁĂƐƐŚĞĂƌĞĚĂŶĚŝŵŵƵŶŽƉƌĞĐŝƉŝƚĂƚĞĚǁŝƚŚ ?A?ŐŽĨE& ?ʃƉ ? ?Žƌ
IgG used as a negative control. Isolated DNA underwent qPCR analysis with the CXCL8 promoter-specific
primers. Data are expressed as fold change relative to the 0h mean of IB3-1 normal cells first normalised to the
Input DNA. Each column represents means ± SEM from at least four independent experiments.
dŚĞƐĞƌĞƐƵůƚƐĚŝĚŶŽƚŝĚĞŶƚŝĨǇĂŶǇŵĂũŽƌĞĨĨĞĐƚŽĨ:Y ?ŽŶE& ?ŮƉ ? ?ĂƐƐŽĐŝĂƚŝŽŶǁŝƚŚ
the CXCL8 promoter in CF cells.
7.4.4 The effect of TPCA-1 on BRD4 recruitment to the CXCL8
promoter in CF airway epithelial cells
dŽĚĞƚĞƌŵŝŶĞƚŚĞĞĨĨĞĐƚŽĨdW ? ? ?ĂƐĞůĞĐƚŝǀĞ/ȾȾ ? ŝŶŚŝďŝƚŽƌ ?ŽŶƚŚĞZ ?ďŝŶĚŝŶŐ
to the CXCL8 promoter, ChIP assays were performed.
There was insignificant binding of BRD4 to the CXCL8 promoter in unstimulated
normal cells with no reduction in cells following TPCA-1 treatment. IL-1ß
stimulation increased BRD4 binding at 2 hours, but TPCA-1 did not have any effect
on binding levels (Figure 7-11). TPCA-1 reduced bound BRD4 levels in unstimulated
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&ĐĞůůƐĂƚ ?ŚŽƵƌ ?/> ? ?ɴƐƚŝŵƵůĂƚŝŽŶůĞĚƚŽĂŶŝŶĐƌĞĂƐĞŝŶƚŚĞďŝŶĚŝŶŐůĞǀĞůƐŽĨZ ?
at 2 hours, and TPCA-1 reduced binding levels of BRD4 to the CXCL8 promoter at 1
hour (Figure 7-11).
A B
DM
SO
2h
BR
D4
DM
SO
2h
IgG
TP
CA
-
1 2
h B
RD
4
TP
CA
-
1 2
h I
gG
DM
SO
2h
BR
D4
DM
SO
2h
IgG
TP
CA
-
1 2
h B
RD
4
TP
CA
-
1 2
h I
gG
Figure 7-11. The effect of TPCA-1 on BRD4 recruitment to the human CXCL8 promoter in normal and CF cells.
Confluent and growth arrested IB3-1 normal and IB3-1 CF cells were serum starved 24 hour prior to an
experiment, pre-incubated with 10
-5
M of TPCA-1 for 30 min and then incubated with/without 1ng/mL IL-1ß for
1 (A) and 2 (B) hours. Extracted chromatin was sheared and immunoprecipitated with 3µg of BRD4 or IgG used
as a negative control. Isolated DNA underwent qPCR analysis with the CXCL8 promoter-specific primers. Data
are expressed as fold change relative to the 0h mean of IB3-1 normal cells first normalised to the Input DNA.
Each column represents means ± SEM from at least 3 independent experiments.
Collectively, our findings showed an effect of TPCA-1 on BRD4 association with
y> ?ƉƌŽŵŽƚĞƌŝŶ&ĐĞůůƐďŽƚŚďĂƐĂůůǇĂŶĚĨŽůůŽǁŝŶŐ/> ? ?ɴƐƚŝŵƵůĂƚŝŽŶƐƵŐŐĞƐƚŝŶŐ
ĂŶŝŶƚĞƌĂĐƚŝŽŶďĞƚǁĞĞŶZ ?ĂŶĚE& ?ʃ ?
7.4.5 ŝƌĞĐƚ ƉƌŽƚĞŝŶ ŝŶƚĞƌĂĐƚŝŽŶ ďĞƚǁĞĞŶ E& ?ʃ Ɖ ? ? ĂŶĚ Z ? ŝŶ
CF airway epithelial cells
dŽĚĞƚĞƌŵŝŶĞƚŚĞƉƌĞƐĞŶĐĞŽĨĂƉƌŽƚĞŝŶĐŽŵƉůĞǆĐŽŶƚĂŝŶŝŶŐZ ?ĂŶĚE& ?ʃƉ ? ? ?
we performed co-immunoprecipitation (Co-IP) assays on nuclear extracts of
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ƵŶƐƚŝŵƵůĂƚĞĚ ĂŶĚ /> ? ?ɴ ?ƐƚŝŵƵůĂƚĞĚ / ? ? ? ŶŽƌŵĂů ĂŶĚ/ ? ? ? & ĐĞůůƐ  ? ? ?  ? ĂŶĚ  ?
hours).
/ŶŝƚŝĂů ŝŵŵƵŶŽƉƌĞĐŝƉŝƚĂƚŝŽŶ ǁĂƐ ƉĞƌĨŽƌŵĞĚ ǁŝƚŚ ĂŶ ĂŶƚŝ ?E& ?Ů Ɖ ? ? ĂŶƚŝďŽĚǇ
followed by immunoblotting with BRD4 (Figure 7-12). We did not identify any
difference between bands of Co-IP and IgG samples at the expected molecular
weight for BRD4. No protein was present in the loading samples in both cell lines
either basally or following IL-1ß stimulation.
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&ŝŐƵƌĞ ? ? ? ? ?dŚĞĞĨĨĞĐƚŽĨ/> ? ?ƘŽŶĂƐƐŽĐŝĂƚŝŽŶŽĨE& ?ʃƉ ? ?ĂŶĚZ ?ŝŶŶŽƌŵĂůĂŶĚ&ĐĞůůƐ ?Confluent and
growth arrested IB3-1 normal and IB3-1 CF cells were serum starved 24 hour prior to an experiment and
incubated with/without 1ng/mL IL-1ß for 0, 1 and 2 hours. Nuclear extracts were co-immunoprecipitated with
ŵĂŐŶĞƚŝĐ/Ő'ďĞĂĚƐŝŶƚŚĞƉƌĞƐĞŶĐĞŽĨE& ?ʃƉ ? ?Žƌ/Ő'ĐŽŶƚƌŽůĂŶƚŝďŽĚǇ ? ? ?A?ŐŽĨƚŽƚĂůĐĞůůƉƌŽƚĞŝŶƉƌŝŽƌƚŽĐŽ ?
immunoprecipitation was loaded and used as a loading control (Input). The complexes were then separated by
SDS-PAGE and immunoblotted for BRD4. The figure shown is a representative image of two independent
experiments.
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dŽ ĨƵƌƚŚĞƌ ŝŶǀĞƐƚŝŐĂƚĞ ǁŚĞƚŚĞƌ Ă ŶƵĐůĞĂƌ E& ?ʃ Ɖ ? ?ĂƐƐŽĐŝĂƚŝŽŶ ǁŝƚŚ Z ? ǁĂƐ
present, the Co-IP assay was repeated in reverse: nuclear extract protein was co-
ŝŵŵƵŶŽƉƌĞĐŝƉŝƚĂƚĞĚ ǁŝƚŚ Z ? ĂŶĚ ŝŵŵƵŶŽďůŽƚƚĞĚ ǁŝƚŚ ĂŶ ĂŶƚŝ ?E& ?Ů Ɖ ? ?
antibody.
We did not observe any obvious difference between bands of Co-IP and IgG
ƐĂŵƉůĞƐ Ăƚ ƚŚĞ ĞǆƉĞĐƚĞĚ ŵŽůĞĐƵůĂƌ ǁĞŝŐŚƚ ĨŽƌ E& ?ŮƉ ? ? ŝŶ ďŽƚŚ ŶŽƌŵĂů ĂŶĚ &
ĐĞůůƐ ? ůƚŚŽƵŐŚ E& ?ʃ Ɖ ? ? ƉƌŽƚĞŝŶ ǁĂƐ ƉƌĞƐĞŶƚ ŝŶ ƐĂŵƉůĞƐ ƉƌŝŽƌ ƚŽ
immunoprecipitation, however, loading was not equal between the samples (see
Input protein bands, Figure 7-13).
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&ŝŐƵƌĞ ? ? ? ? ?dŚĞĞĨĨĞĐƚŽĨ/> ? ?ƘŽŶĂƐƐŽĐŝĂƚŝŽŶŽĨE& ?ʃƉ ? ?ĂŶĚZ ?ŝŶŶŽƌŵĂůĂŶĚ&ĐĞůůƐ ?Confluent and
growth arrested IB3-1 normal and IB3-1 CF cells were serum starved 24 hour prior to an experiment and
incubated with/without 1ng/mL IL-1ß for 0, 1 and 2 hours. Nuclear extracts were co-immunoprecipitated with
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Due to technical difficulties, at this stage we cannot conclusively state whether a
ƉƌŽƚĞŝŶ ĐŽŵƉůĞǆ ĐŽŶƚĂŝŶŝŶŐ ĂƐƐŽĐŝĂƚĞĚ E& ?ʃ  ? ? ĂŶĚZ ? ƉƌŽƚĞŝŶƐ ĞǆŝƐƚƐ ƵŶĚĞƌ
basal or IL-1ß-induced conditions in normal or CF cells that could explain increased
CXCL8 transcription.
7.5 Discussion
The main findings of this chapter are that BET protein inhibitors JQ1 and PFI-1
reduce CXCL8 protein release from CF airway epithelial cells both basally and
following IL-1ß stimulation. We also identified increased binding of BRD4 and BRD3
ƚŽƚŚĞy> ?ƉƌŽŵŽƚĞƌƵŶĚĞƌďĂƐĂůĂŶĚ/> ? ?ɴ ?ŝŶĚƵĐĞĚĐŽŶĚŝƚŝŽŶƐŝŶ&ĐĞůůƐ ?
We found, that BET protein inhibitors, JQ1 and PFI-1, reduced basal and IL-1ß-
induced CXCL8 release from normal and CF cells in a concentration dependent
manner. No previous studies have explored the effect of BET protein inhibitors on
CXCL8 secretion in CF airway epithelial cells, although our findings are similar to a
recent study showing that JQ1 and PFI-1 inhibit CXCL8 production in BEAS-2B cells
(Khan et al., 2014). Likewise, treatment of bone marrow-derived macrophages with
I-BET-151 following LPS stimulation results in the downregulation of several pro-
ŝŶĨůĂŵŵĂƚŽƌǇ ĐǇƚŽŬŝŶĞƐ ƐƵĐŚ ĂƐ /> ? ? ? /> ? ?ɴ ? ĂŶĚ /&E ?ɶ  ?EŝĐŽĚĞŵĞ Ğƚ Ăů ? ?  ? ? ? ? Z ?
Similar observations have been made in cancer: application of JQ1 in glioblastoma
cells of different backgrounds leads to significant cell growth arrest and apoptosis
due to displacement of individual BET proteins from their targets resulting in
altered gene expression of p21CIP1/WAF1, hTERT, Bcl-2 and Bcl-xL (Cheng et al.,
2013).
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Subsequently, we performed ChIP and showed that BRD3 and BRD4, but not BRD2
are important for basal CXCL8 expression, but it is only BRD4 that is involved in IL-
 ?ɴ ?ŝŶĚƵĐĞĚ y> ? ĞǆƉƌĞƐƐŝŽŶ & ĐĞůůƐ ? dĂŬĞŶ ĂůŽŶŐƐŝĚĞ ƚŚĞ ŝŶŚŝďŝƚŽƌ ƐƚƵĚŝĞƐ ? ŽƵƌ
data suggest that BRD4 plays an essential role in CXCL8 transcription in CF airway
epithelial cells. Similar observations have been made in BEAS-2B cells where
ŬŶŽĐŬĚŽǁŶ ŽĨ Z ? ? ďƵƚ ŶŽƚ Z ? ? ƌĞƐƵůƚĞĚ ŝŶ ŝŶŚŝďŝƚŝŽŶ ŽĨ /> ? ?ɴ ?,2O2-induced
secretion of CXCL8 (Khan et al., 2014).
dŚĞƐƚƵĚŝĞƐŝŶŚĂƉƚĞƌ ?ƐŚŽǁĞĚŝŶĐƌĞĂƐĞĚďĂƐĂůďŝŶĚŝŶŐŽĨE& ?ʃƉ ? ?ƚŽƚŚĞy> ?
ƉƌŽŵŽƚĞƌŝŶ&ĐĞůůƐ ?ƚŚƵƐ ?ǁĞůŽŽŬĞĚĂƚƚŚĞŝŶƚĞƌĂĐƚŝŽŶďĞƚǁĞĞŶZ ?ĂŶĚE& ?ʃĂƚ
the CXCL8 promoter using selective inhibitors of each protein and ChIP. We found
ƚŚĂƚƐĞůĞĐƚŝǀĞŝŶŚŝďŝƚŝŽŶŽĨE& ?ʃƉ ? ?ĚŝĚŶŽƚĂĨĨĞĐƚZ ?ďŝŶĚŝŶŐƵŶĚĞƌďĂƐĂůŽƌ/> ?
 ?ɴ ?ŝŶĚƵĐĞĚĐŽŶĚŝƚŝŽŶƐŝŶ&ĐĞůůƐ ?,ŽǁĞǀĞƌ ?ƚƌĞĂƚŵĞŶƚǁŝƚŚ:Y ?ƌĞĚƵĐĞĚE& ?ʃƉ ? ?
ďŝŶĚŝŶŐ ƚŽ ƚŚĞ y> ? ƉƌŽŵŽƚĞƌ ďĂƐĂůůǇ ĂŶĚ ĨŽůůŽǁŝŶŐ /> ? ?ɴ ƐƚŝŵƵůĂƚŝŽŶ ŝŶ & ĐĞůůƐ ?
This suggests that both proteins are present at the promoter complex, and
inhibition of one of them alters the binding of the other one. Although our results
ƐŚŽǁĞĚĂƌĞĚƵĐƚŝŽŶŝŶďŝŶĚŝŶŐůĞǀĞůƐŽĨE& ?ʃƉ ? ?ŝŶ&ĐĞůůƐ ?ƚŚĞƌĞǁĂƐĂǀĂƌŝĂďŝůŝƚǇ
observed throughout all experiments. This could also suggest that the effect of BET
ƉƌŽƚĞŝŶ ŝŶŚŝďŝƚŽƌƐ ŽŶ y> ? ƐĞĐƌĞƚŝŽŶ ŝƐ ŶŽƚ ŵĞĚŝĂƚĞĚ ďǇ ĂůƚĞƌĂƚŝŽŶ ŽĨ E& ?ʃ
properties, but by an effect on BRDs.
Next, to decisively confirm our data, we went to look at a complex formation
ďĞƚǁĞĞŶ E& ?Ů Ɖ ? ? ĂŶĚ Z ? ďǇ ƉĞƌĨŽƌŵŝŶŐ Ž ?/W ? ,ŽǁĞǀĞƌ ? ĚƵĞ ƚŽ ƚĞĐŚŶŝĐĂů
ƉƌŽďůĞŵƐǁĞǁĞƌĞƵŶĂďůĞƚŽĐŽŶĨŝƌŵĂĚŝƌĞĐƚĂƐƐŽĐŝĂƚŝŽŶďĞƚǁĞĞŶZ ?ĂŶĚE& ?Ů
Ɖ ? ? ŝŶ ŶƵĐůĞĂƌ ƉƌŽƚĞŝŶ ĞǆƚƌĂĐƚƐ ŝŶ ƵŶƐƚŝŵƵůĂƚĞĚ ĂŶĚ /> ? ?ɴ ?ŝŶĚƵĐĞĚ & ĐĞůůƐ ? KƵƌ
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results differ from those reported by Khan et alŝŶ^ ? ?ĐĞůůƐƐŚŽǁŝŶŐƚŚĂƚ/> ? ?ɴ
ŝŶĐƌĞĂƐĞƐ ƌĞĐƌƵŝƚŵĞŶƚ ŽĨ E& ?ʃ ĂŶĚ Z ? ƚŽ ƚŚĞ y> ? ƉƌŽŵŽƚĞƌ ŝŶ ĂŝƌǁĂǇ
epithelial cells (Khan et al., 2014).
We have considered reasons that could explain the contradiction between our
results and Khans study findings. Technically challenging, Co-IP is not designed to
determine weak and transient interactions such as IL-1ß-induced association
ďĞƚǁĞĞŶE& ?ŮƉ ? ?ĂŶĚZ ? ?ŶŽƚŚĞƌŵĂũŽƌůŝŵŝƚĂƚŝŽŶ ƐƚŚĂƚĂŶƚŝďŽĚŝĞƐƵƐĞĚĨŽƌ
the Co-IP can cross-react with other nuclear proteins affecting the results. Although
we started to optimise the Co-IP method, the results might be influenced by low
levels of immunoprecipitated protein in samples. Another disadvantage of this
technique is that although it shows the interaction between proteins within the cell,
it does not allow speculations about where the interaction occurs and whether it is
direct or not. In our studies we used polyclonal rabbit IgG as a negative control.
Presence of both heavy and light chains increases the cross-reactivity with other
immunoglobulins and antigens of similar weight present in the sample. Using
monoclonal light chain of native IgG antibody possessing higher purity and better
specificity in future experiments could significantly improve detection of protein-
protein interaction by Co-IP. However, data in previous chapters as well as findings
ƌĞƉŽƌƚĞĚŝŶƚŚĞĐƵƌƌĞŶƚĐŚĂƉƚĞƌƐƵŐŐĞƐƚƚŚĂƚďŽƚŚZ ?ĂŶĚE& ?ʃƉ ? ?ĂƌĞƌĞƋƵŝƌĞĚ
for transcriptional activation of CXCL8 in CF airway epithelial cells.
In summary, the results in this chapter suggest that BRD4 is involved in the
increased CXCL8 transcription in CF epithelial cells and targetting BET proteins may
have therapeutic potential in CF.
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8 GENERAL DISCUSSION, CONCLUSIONS AND FUTURE
DIRECTIONS
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The main findings of this thesis are that there is increased recruitment of BRD3 and
Z ? ĂƐƐŽĐŝĂƚĞĚ ǁŝƚŚ ĞŶŚĂŶĐĞĚ ďŝŶĚŝŶŐ ŽĨ E& ?ʃ ƚŽ ƚŚĞ y> ? ƉƌŽŵŽƚĞƌ ĚƵĞ ƚŽ
ŝŶĐƌĞĂƐĞĚ, ?< ?ŵĞ ?ĂŶĚEŚǇƉŽŵĞƚŚǇůĂƚŝŽŶŝŶ&ĐĞůůƐďĂƐĂůůǇ ?/> ? ?ɴƐƚŝŵƵůĂƚŝŽŶ
leads to a further increase in BRD4 binding and DNA hypomethylation resulting in
the formation of an active complex responsible for the upregulation of CXCL8
transcription in CF airway epithelial cells.
A B
Unstimulated normal cell /> ? ?ɴ ?ŝŶĚƵĐĞĚŶŽƌŵĂůĐĞůů
v
C D
Unstimulated CF cell /> ? ?ɴ ?ŝŶĚƵĐĞĚ&ĐĞůů
Figure 8-14. Overview of a proposed molecular mechanism of basal CXCL8 transcription in normal and CF
airway epithelial cells.E& ?Ů ?W ? ?ĂŶĚ ?WƘĂƌĞŝŶǀŽůǀĞĚŝŶƚŚĞy> ?ƚƌĂŶƐĐƌŝƉƚŝŽŶŝŶďŽƚŚŶŽƌŵĂůĂŶĚ&
ĐĞůůƐ ?ŶĂĐƚŝǀĞƚƌĂŶƐĐƌŝƉƚŝŽŶĐŽŵƉůĞǆĂƐƐŽĐŝĂƚĞĚǁŝƚŚƚŚĞŶŽƌŵĂůy> ?ƉƌŽŵŽƚĞƌĐŽŶƚĂŝŶƐůŽǁůĞǀĞůƐŽĨE& ?Ů
p65, BRD3 and BRD4 accompanied by insignificant levels of H3K4 trimethylation and DNA methylation basally
(A) ?/> ? ?ɴƐƚŝŵƵůĂƚŝŽŶƌĞƐƵůƚƐŝŶĂŶŝŶĐƌĞĂƐĞĚďŝŶĚŝŶŐŽĨ ?Wɴ ?E& ?ʃĂŶĚĨƵƌƚŚĞƌ, ?< ?ƚƌŝŵĞƚŚǇůĂƚŝŽŶĂŶĚ E
hypomethylation of the CXCL8 promoter (B). In contrast, the CXCL8 promoter in CF cells contains a
ƚƌĂŶƐĐƌŝƉƚŝŽŶĂůůǇĂĐƚŝǀĞĐŽŵƉůĞǆĐŽŶƚĂŝŶŝŶŐŝŶĐƌĞĂƐĞĚůĞǀĞůƐŽĨE& ?ŮƉ ? ? ?Z ?ĂŶĚZ ?ĂůŽŶŐǁŝƚŚŝŶĐƌĞĂƐĞĚ
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H3K4me3 and DNA hypomethylation at CpG site 3.1 (C) ?^ƚŝŵƵůĂƚŝŽŶǁŝƚŚ/> ? ?ɴƌĞƐƵůƚƐŝŶĂŶŝŶĐƌĞĂƐĞĚďŝŶĚŝŶŐŽĨ
BRD4 and further DNA hypomethylation of the CXCL8 promoter in CF cells (D).
The initial work in this thesis was largely confirmatory to make sure that we were
able to see the same increase in CXCL8 in CF that others had described and to study
the TFs regulating CXCL8 expression in our cells. We confirmed that CF cells
expressed higher levels of CXCL8 than normal cells and that the TFs regulating
y> ?ƌĞůĞĂƐĞƵŶĚĞƌďŽƚŚďĂƐĂůĂŶĚ/> ? ?ďĞƚĂƐƚŝŵƵůĂƚĞĚĐŽŶĚŝƚŝŽŶƐŶĂŵĞůǇ ?E& ?Ů ?
AP-1 and C/EBP, were similar to those reported in a number of other studies in a
range of cell types (Verhaeghe et al., 2007b, Li et al., 2002, Hoffmann et al., 2002,
John et al., 2009).
We used ChIP assays to analyse any alteration in the binding of TFs to the CXCL8
promoter in CF cells in the chromatin environment and found enhanced binding of
E& ?ʃƉ ? ? ?ďƵƚŶŽƚ ?WɴƚŽƚŚĞy> ?ƉƌŽŵŽƚĞƌŝŶ&ĐĞůůƐƵŶĚĞƌďĂƐĂůĐŽŶĚŝƚŝŽŶƐ
ƚŚĂƚ ǁĂƐ ŶŽƚ ĨƵƌƚŚĞƌ ŝŶĐƌĞĂƐĞĚ ĨŽůůŽǁŝŶŐ /> ? ?ɴ ƐƚŝŵƵůĂƚŝŽŶ ? ůƚŚŽƵŐŚ ŽƵƌ
transfection studies showed a role for AP-1 in CXCL8 transcription, we failed to
detect c-jun binding to the CXCL8 promoter either in normal or CF cells. In future, it
ǁŽƵůĚďĞŝŶƚĞƌĞƐƚŝŶŐƚŽĨƵƌƚŚĞƌĞǆƉůŽƌĞƚŚĞƌŽůĞŽĨW ? ?ŝŶďĂƐĂůĂŶĚ/> ? ?ɴ ?ŝŶĚƵĐĞĚ
transcription of CXCL8 possibly by designing region-specific primers and further
optimising the ChIP technique used. Future studies could also look at the
involvement and interaction between other TFs at the CXCL8 promoter as well as
identification of other signalling pathways involved.
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We found an increase in basal H3K4 trimethylation that was not further increased
ďǇ /> ? ?ɴ ƐƚŝŵƵůĂƚŝŽŶ ? tĞ ĂůƐŽ ĚŝĚ ŶŽƚ ŝĚĞŶƚŝĨǇ ĂŶǇĂůƚĞƌĂƚŝŽŶ ŝŶ ŚŝƐƚŽŶĞ , ? Žƌ , ?
acetylation at the CXCL8 promoter in CF airway epithelial cells. It would be
interesting in future studies to look at other histone modifications such as
acetylation of specific lysines including H3K14, H3K18 and H4K5 (Heintzman et al.,
2007, Barrera and Ren, 2006, Strahl and Allis, 2000) and other methylation sites
such as H3K9me1, H3K27me1, H4K20me1, H3K4me1,2 and H3K36me3. An
interesting area for further research might also be to explore the presence and
effect of other post-translational modifications, such as phosphorylation,
ubiquitination and sumoylation, on the transcriptional regulation of CXCL8 in CF.
We did not study the enzymes responsible for regulating H3K4 trimethylation in our
studies and identification of the methyltransferases and demethylases regulating
this mark at the CXCL8 promoter might potentially provide novel molecular targets
for future theraputic strategies.
In our experiments we showed no alteration in the recruitment of p300 HAT to the
CXCL8 promoter. However, we did not investigate other HATs that could be
involved in CXCL8 transcription in CF cells. In future, it would be interesting to look
at the changes in the activity and function of CBP, PCAF and other chromatin-
remodelling enzymes that have been reported to affect CXCL8 transcription (Huang
and McCance, 2002).
Our study showed hypomethylation of a CpG site within the CXCL8 promoter in
ƵŶƐƚŝŵƵůĂƚĞĚ & ĐĞůůƐ ǁŚŝĐŚ ǁĂƐ ĨƵƌƚŚĞƌ ŚǇƉŽŵĞƚŚǇůĂƚĞĚ ƵƉŽŶ /> ?ɴ ƐƚŝŵƵůĂƚŝŽŶ ?
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Future studies could look at the DNA methyltransferases regulating CpG site 3.1 in
the promoter and whether these are abnormal in CF.
We did not study ways in which the changes in DNA methylation and the histone
modifications might be linked. Studies in cancer cells and fibroblasts have identified
an inverse correlation between DNA methylation and levels of H3K4me3 at the
promoters of target genes (Balasubramanian et al., 2012). H3K4me3 can influence
DNA methylation via recruitment of the Dnmt3-associated protein Dnmt3L that
specifically interacts with unmodified H3K4 (Ooi et al., 2007). The presence of
H3K4me3 also results in the association of RNA Pol II with the promoters of target
genes via facilitation of global recruitment of TFIID (Lauberth et al., 2013,
Vermeulen et al., 2007) acting as a platform for H3K4me3 lysine methyltransferase
complexes (Horton et al., 2010). Furthermore, H3K9me3 and H3K4me3 can interact
leading to the recruitment of DNA methylases and altered TFs binding to the
promoters of associated genes (Przybilla et al., 2013). Future studies using
optimised sequencing and ChIP-on-chip/ChIP-seq analysis might be helpful to
explore the distribution of histone modifications and their localisation at the CXCL8
promoter as well as to investigate DNA/histone protein interactions on a genome
wide basis.
Our data suggests that BET protein inhibitors might reduce airway inflammation in
CF by reducing CXCL8 secretion. A number of pharmaceutical companies are
developing these agents for the treatment of inflammatory and neoplastic diseases,
and it would be useful to test them in mouse models of CF inflammation and if
suitable, perhaps, as agents in clinical trials. The mechanistic studies in Chapter 6
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ƐƵŐŐĞƐƚ Ă ƉŽƐƐŝďůĞ ŝŶƚĞƌĂĐƚŝŽŶ ďĞƚǁĞĞŶ Z ? ĂŶĚ E& ?Ů Ɖ ? ? Ăƚ ƚŚĞ y> ?
promoter. Although we found that BET protein inhibitors seemed to have no
ŽďǀŝŽƵƐĞĨĨĞĐƚŽŶƚŚĞďŝŶĚŝŶŐůĞǀĞůƐŽĨE& ?ʃƉ ? ?ƚŽƚŚĞy> ?ƉƌŽŵŽƚĞƌ ?ŝƚǁŽƵůĚ
be interesting to further explore the effects of BET protein inhibitors and determine
if they alter the binding of any other TFs to the CXCL8 promoter in CF cells using
ChIP assays. Further optimisation of the Co-IP technique as well as application of
sensitive and accurate methods such as Re-ChIP, tandem affinity purification and
pull down assays detecting protein in the correct cellular and chromatin
ĞŶǀŝƌŽŶŵĞŶƚĐŽƵůĚĚĞĐŝƐŝǀĞůǇĐŽŶĨŝƌŵĂĚŝƌĞĐƚŝŶƚĞƌĂĐƚŝŽŶďĞƚǁĞĞŶE& ?ŮĂŶĚZ ?
in CF cells. Furthermore, other techniques including crosslinking protein interaction
and label transfer protein interaction analysis designed to identify transient and
weak interactions could be used for future studies.
Our studies used immortalised cell lines. In future it would be interesting to
strengthen and confirm the CXCL8 data by using primary cells and BAL fluid
obtained from CF patients as this would more reflect the environment in the
airways of CF patients.
/Ŷ ŽƵƌ ƐƚƵĚǇ ǁĞ ŝŶǀĞƐƚŝŐĂƚĞĚ ƚŚĞ ĞĨĨĞĐƚ ŽĨ ŽŶĞ ĐǇƚŽŬŝŶĞ ? /> ? ?ɴ ? ŽŶ ƚŚĞ ƌĞůĞĂƐĞ ŽĨ
y> ?ĨƌŽŵ&ĂŝƌǁĂǇĞƉŝƚŚĞůŝĂůĐĞůůƐ ?>W^ ?dE& ?ɲĂŶĚ/&E ?ɶŚĂǀĞďĞĞŶƐŚŽǁŶƚŽďĞ
present in abundance in the CF airways and stimulate CXCL8 expression in different
cells including epithelial cells, endothelial cells, neutrophils, fibroblasts, smooth
muscle cells and others (Conese et al., 2009, Carrabino et al., 2006, Stecenko et al.,
2001). Future experiments could determine the effect of these stimuli on CXCL8
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production from CF airway epithelial cells as well as identify other signal
transduction pathways involved in the secretion of CXCL8 in CF.
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9 APPENDIX
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9.1 PFI-1 and JQ1 MTT (cell viability) assay
A B
&ŝŐƵƌĞ ? ? ? ?dŚĞƚŽǆŝĐŝƚǇŽĨW&/ ? ?ĂŶĚ:Y ?ĐŽŵƉŽƵŶĚƐŝŶƵŶƐƚŝŵƵůĂƚĞĚĂŶĚ/> ? ?ɴ ?ŝŶĚƵĐĞĚŶŽƌŵĂůĂŶĚ&ĂŝƌǁĂǇ
epithelial cells. Confluent and growth arrested IB3-1 normal and IB3-1 CF cells were pre-treated with stated
concentrations of PFI-1 (A) and JQ1 (B) ĂŶĚ ƐƚŝŵƵůĂƚĞĚ ǁŝƚŚ  ?ŶŐ ?ŵ> /> ?ɴ ĨŽƌ  ? ? ŚŽƵƌƐ ? ƚ ƚŚĞ ĞŶĚ ŽĨ ƚŚĞ
experiment, MTT assay was performed as described in 3.6 of Chapter 3 Materials and Methods. Each bar
represents mean ± SEM of at least three independent experiments.
9.2 Additional figures
A B
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C
Figure 9-2. Histone H3 acetylation (H3ac) at the human CXCL8 promoter. Association of acetylated histone H3
with the CXCL8 promoter was determined in confluent and growth arrested IB3-1 normal and IB3-1 CF cells.
Cells were incubated with/without 1ng/mL IL-1ß for 0, 1 and 2 hours. Extracted chromatin was sheared and
immunoprecipitated with 4µg of antibody against pan-acetylated H3 or rabbit IgG used as a negative control.
Isolated DNA underwent qPCR analysis with CXCL8 promoter-specific primers. Data are expressed as fold
change relative to the 0h mean of IB3-1 normal cells first normalised to the Input DNA.
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C
Figure 9-3. Histone H4 acetylation (H4ac) at the human CXCL8 promoter. Association of acetylated H4 with the
CXCL8 promoter was analysed in confluent and growth arrested IB3-1 normal and IB3-1 CF cells. Cells were
incubated with/without 1ng/mL IL-1ß for 0, 1 and 2 hours. Extracted chromatin was sheared and
immunoprecipitated with 4µg of antibody against pan-acetylated H4 or rabbit IgG used as a negative control.
Isolated DNA underwent qPCR analysis with CXCL8 promoter-specific primers. Data are expressed as fold
change relative to the 0h mean of IB3-1 normal cells first normalised to the Input DNA.
A B
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Usntimulated IL-1 -induced
&ŝŐƵƌĞ  ? ? ? ?E& ?ŮƉ ? ?< ? ? ?ĂĐĞƚǇůĂƚŝŽŶ  ?Ɖ ? ?< ? ? ? ?ĂƚƚŚĞŚƵŵ Ŷy> ?ƉƌŽŵŽƚĞƌ ?Association of acetylated
E& ?ŮƉ ? ?< ? ? ?ǁŝƚŚƚŚĞy> ?ƉƌŽŵŽƚĞƌǁĂƐĂŶĂůǇƐĞĚŝŶĐŽŶĨůƵĞŶƚĂŶĚŐƌŽǁƚŚĂƌƌĞƐƚĞĚ/ ? ? ?ŶŽƌŵĂůĂŶĚ/ ? ?
1 CF cells. Cells were incubated with/without 1ng/mL IL-1ß for 0, 1 and 2 hours. Extracted chromatin was
ƐŚĞĂƌĞĚĂŶĚŝŵŵƵŶŽƉƌĞĐŝƉŝƚĂƚĞĚǁŝƚŚ ?A?ŐŽĨĂŶƚŝďŽĚǇĂŐĂŝŶƐƚĂŶƚŝ ?E& ?ŮƉ ? ?ĂĐĞƚǇů ?< ? ? ?ŽƌƌĂďďŝƚ/Ő'ƵƐĞĚĂƐ
a negative control. Isolated DNA underwent qPCR analysis with CXCL8 promoter-specific primers. Data are
expressed as fold change relative to the 0h mean of IB3-1 normal cells first normalised to the Input DNA.
A B
Figure 9-5. p300 binding to the human CXCL8 promoter. Association of acetylated p300 with the CXCL8
promoter was analysed in confluent and growth arrested IB3-1 normal and IB3-1 CF cells. Cells were incubated
with/without 1ng/mL IL-1ß for 0, 1 and 2 hours. Extracted chromatin was sheared and immunoprecipitated with
1µg of antibody against p300 or rabbit IgG used as a negative control. Isolated DNA underwent qPCR analysis
with CXCL8 promoter-specific primers. Data are expressed as fold change relative to the 0h mean of IB3-1
normal cells first normalised to the Input DNA.
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9.3 List of reagents
9.3.1 Antibodies
Anti-acetyl-Histone H3 antibody, 100µg/mL Millipore, UK
Anti-acetyl-Histone H4 antibody, 100µg/mL Millipore, UK
Ŷƚŝ ?E& ?ʃƉ ? ? ?ĂĐĞƚǇůŬ ? ? ? ZĂŶƚŝďŽĚǇ ?
ChIP Grade, 100µg/mL Abcam Biochemicals, UK
Ŷƚŝ ?E& ?ʃƉ ? ?ĂŶƚŝďŽĚǇŚ/W ?'ƌĂĚĞ ďĐĂŵŝŽĐŚĞŵŝĐĂůƐ ?h<
Bromodomain (BRD) 2 antibody, 200µg/mL Santa Cruz Biotechnology, UK
Bromodomain (BRD) 3 antibody, 200µg/mL Santa Cruz Biotechnology, UK
Bromodomain (BRD) 4 antibody, 200µg/mL Santa Cruz Biotechnology, UK
 ?Wɴ ^ĂŶƚĂƌƵǌŝŽƚĞĐŚŶŽůŽŐǇ ?h<
C-Jun antibody, 200µg/mL Active Motif, USA
Histone H3K4me3 (pAb), 100µl Active Motif, USA
Normal rabbit IgG antibody, 200mg/0.5mL Santa Cruz Biotechnology, UK
P300 antibody Santa Cruz Biotechnology, UK
9.3.2 Kits
Bicinchoninic acid (BCA) assay kit Pierce, UK
ChIP-IT
®
Express kit Active Motif, USA
Dual-Luciferase
®
Reporter Assay System kit Promega, UK
ECL
TM
Western blotting detection kit GE Healthcare Life Sciences, UK
EpiTect
®
Bisulfite kit Qiagen, UK
Human CXCL8/IL-8 DuoSet ELISA kit R&D Systems, UK
Nuclear Complex Co-IP kit Active Motif, USA
Nuclear Extract kit
NucleoSpin RNA II kit
Active Motif, USA
Macherey-Nagel, Germany
Plasmid purification midi kit Qiagen, UK
QIAamp DNA blood mini Kit (50) Qiagen, UK
Re-ChIP-IT® kit Active Motif, USA
Nuclear Magnetic Co-IP kit Active Motif, USA
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9.3.3 Materials
Hyper film ECL
TM
GE Healthcare Life Sciences, UK
Siliconised tubes Sigma-Aldrich, UK
PVDF Immunblott
TM
membrane Bio-Rad, UK
9.3.4 Reagents
Agarose beads Qiagen, UK
Ammonium persulphate Sigma-Aldrich, UK
Amphotericin B, 2.5µg/mL Sigma-Aldrich, UK
Annealing buffer Qiagen, UK
Bisacrilamide, 30% Sigma Aldrich, UK
ß-mercaptoethanol Santa Cruz Biotechnology, UK
Binding buffer Qiagen, UK
Bovine serum albumin, powder Sigma Aldrich, UK
Bromophenol blue Sigma-Aldrich, UK
3-(4,5-dimethylthiazol-2-yl)-2,5
diphenyltetrazolium bromide Sigma-Aldrich, UK
Denaturation solution Qiagen, UK
Deoxynucleoside triphosphates (dNTPs) Promega, UK
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, UK
Ethanol, 100% Sigma-Aldrich, UK
Ethidium bromide Sigma-Aldrich, UK
Fetal calf serum (FCS),
heat-inactivated solution Sigma-Aldrich, PAA laboratories, UK
Formaldehyde Sigma-Aldrich, UK
Glycine Sigma-Aldrich, UK
Glycogen, 20mg/mL Roche Diagnostics Ltd, UK
HotStarTaq plus DNA polymerase Qiagen, UK
/ŶƚĞƌůĞƵŬŝŶĞ ?/> Z ? ?ɴ WĞƉƌŽƚĞĐŚ ?h<
LipofectamineΡ 2000 transfection reagent Invitrogen, UK
LHC-8 without gentamicin (1x) medium Gibco, Life technologies, UK
Methanol Sigma-Aldrich, UK
Minimum Essential Medium Eagle Sigma-Aldrich, UK
M-MLV RT Promega, UK
M-MLV RT buffer, 1x solution Promega, UK
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N,N,N,N-Tetramethylethylenediamine (Temed) Sigma-Aldrich, UK
Non-fat dry milk Insight Biotechnology, UK
Normal goat IgG serum Santa Cruz Biotechnology, UK
Normal rabbit serum Santa Cruz Biotechnology, UK
Nuclease-free water Ambion, UK
OligoDT primer Roche Diagnostics Ltd, UK
PBS, 10X solution Active Motif, USA
Penicillin/streptomycin, 100U/100µg/mL Sigma-Aldrich, UK
PFI-1 Cayman Chemical, USA
Phenol/Chloroform Sigma Aldrich, UK
Phosphate buffered saline (PBS), tablets Sigma-Aldrich, UK
Protein G magnetic beads Active Motif, USA
Protease Qiagen, UK
PyroMark Gold Q24 reagents Qiagen, UK
Puromycin, 10mg/mL InvivoGen, UK
(+)/-JQ1 Cayman Chemical, USA
Rainbow
TM
colored protein marker GE healthcare, UK
Ribonuclease (RNAase) inhibitor Promega, UK
Sodium dodecyl sulphate (SDS) Sigma-Aldrich, UK
Sulphuric acid (H2SO4) Sigma-Aldrich, UK
SYBR
®
Premix Ex TaqΡ Clontech Laboratories, Inc, USA
SYBR
®
Premix Ex TaqΡ II
(Tli Rnase H Plus) Clontech Laboratories, Inc, USA
Triton
TM
X-100 Sigma-Aldrich, UK
Trypsin/EDTA Sigma-Aldrich, UK
Trizma
®
base (Tris-base) Sigma-Aldrich, UK
Tween-20, 0.05% Sigma-Aldrich, UK
Wash buffer, 5x Qiagen, UK
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9.4 Buffers and recipes
Reducing loading buffer, 2x
Resolving gel, 10%
Stacking gel
Buffer 1, pH=8.8
Reagents Volume/mass
130mM Tris pH 6.8
15.74g
SDS, 4%
4g
Bromophenol blue, 0.02%
20mg
20% glycerol
20g
100mM DTT
1.525g
ddH2O 100mL
Reagents Volume/mass
Bisacrilamide, 30% 6.66mL
Buffer 1 5.2mL
dH2O 7.92mL
Ammonium persulphate, 10% 200µl
TEMED 20µl
Reagents Volume/mass
Bisacrilamide, 30% 1.3mL
Buffer 2 2.5mL
dH20 6.1mL
Ammonium persulphate, 10% 50µl
TEMED 10µl
Reagents Volume/mass
Tris base 18.5g
ddH2O 100mL
SDS, 10% 4mL
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Buffer 2, pH=6.8
TBST, 10x, pH=7.4-7.6
Running buffer, 10x
Transfer buffer, 10x
Transfer buffer, 1x
Reagents Volume/mass
Tris base 6g
ddH2O 100mL
SDS, 10% 4mL
Reagents Volume/mass
Tris base 24.2g
ddH2O 1000mL
NaCl 87.6g
Tween 20, 0.5% 10mL
Reagents Volume/mass
Tris base 24.2g
ddH2O 1000mL
Glycine 144g
SDS 10g
Reagents Volume/mass
Tris base 24.2g
ddH2O 1400mL
Methanol 400mL
Reagents Volume/mass
10x Transfer buffer 200mL
ddH2O 1000mL
Glycine
144g
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Sodium acetate, 3M, pH=5.2
Tris buffered saline, pH=7.2-7.4
9.5 PCR primers and cycling conditions
Table 9-1. Primer sequences and cycling conditions for qPCR analysis of CXCL8 mRNA expression and CXCL8
promoter (ChIP).
Reagents Volume/mass
Sodium acetate 40.8g
ddH2O 100mL
Reagents Volume/mass
Trizma base 0.242g
Sodium chloride
8.76 g
ddH2O 1000mL
Gene Primer sequence
qPCR and RT-PCR
cycling conditions
CXCL8
(cDNA)
Sense: 5-ATGACTTCCAAGCTGGCCGTGGCT3
Antisense: 5TCTCAGCCCTCTTCAAAAACTTCTC3
95°C for 30 seconds
40 cycles of:
95°C for 5 seconds
60°C for 30 seconds
72°C for 15 seconds
ɴ2-
microglobulin
 ?ɴ2-M)
Forward: 5GAG TAT GCC TGC CGT GTG3
Reverse: 5 AAT CCA AAT GCG GCA TCT3
CXCL8
(ChIP)
Forward: 5GGGCCATCAGTTGCAAATC3
Reverse: 5TTCCTTCCGGTGGTTTCTTC3
95°C for 10 seconds
45 cycles of:
95°C for 5 seconds
60°C for 30 seconds
72°C for 15 seconds
95°C for 60 seconds
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Table 9-2. Cycling conditions for bisulphite conversion of DNA
95°C for 5 minutes
60°C for 25 minutes
95°C for 5 minutes
60°C for 85 minutes
95°C for 5 minutes
60°C for 175 minutes
Table 9-3. Primers sequences and cycling conditions for PCR of bisulphite converted DNA.
CpG
site
Primer sequence
RT- PCR cycling
conditions
CpG1
CpG1.1
F: TGTTTATAGTGTGGGTAAATTTATTGT
R: ATCCTAAAAAAAAAAATCCAAAACCT
95°C for 5
minutes
45 cycles of:
94°C for 30
seconds
56°C for 30
seconds
72°C for 60
seconds
72°C for 10
minutes
CpG1.2
F: TGTTTATAGTGTGGGTAAATTTATTGT
R: ATCCTAAAAAAAAAAATCCAAAACCT
CpG2
CpG2.1 and
CpG2.2
F: GTGGAGTTTTAGTATTTTAAATGTATAT
R: ATCACACTTCCTATTTATTCCTTATCA
CpG3 CpG2.3
F: TTGAGGGGATGGGTTATTAGTT
R: ACTTATACACCCTCATCTTTTCAT
CpG4
CpG3.1
F: GTGTATAAGTTTTTTAGTAGGGTGATG
R: AATCAAAAAAACTACCAAAAAAACC
95°C for 5
minutes
45 cycles of:
94°C for 30
seconds
52.6°C for 30
seconds
72°C for 60
seconds
72°C for 10
minutes
CpG3.3
F: GTGTATAAGTTTTTTAGTAGGGTGATG
R: AATCAAAAAAACTACCAAAAAAACC
LINE-1
Primers sequence is proprietary and not provided by
QIAGEN
95°C for 5
minutes
45 cycles of:
94°C for 30
183
seconds
50°C for 30
seconds
72°C for 30
seconds
72°C for 10
minutes
Table 9-4. Primer sequences used for bisulphite pyrosequencing.
CpG
site
Primer sequence
CpG1
CpG1.1 TGGGTAAATTTATTGTTTTGT
CpG1.2 ATAAATTATGTATTTGTTTAGAAG
CpG2 CpG2.1 and CpG2.2 ACTTCCTATTTATTCCTTATCAA
CpG3 CpG2.3 GGATGGGTTATTAGTTGTA
CpG4
CpG3.1 AGGGTGATGATATAAAAAGT
CpG3.2 AGGATAAGAGTTAGGAAGA
CpG3.3 ATTGTGTGTAAATATGATTTTTAA
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